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and Outline of the Thesis
JA Schrumpf
Department of Pulmonology, Leiden University Medical Center, Leiden, 
The Netherlands
Introduction 
Vitamin D is a well-recognized for its systemic role in calcium absorption and bone 
mineralization. In the airways, vitamin D enhances airway epithelial cell 
homeostasis and is a modulator of both innate and adaptive immune responses (1). 
The airway epithelium is the front line of the lung’s host defense and its main 
function is to clear and protect the airways from hazardous inhaled substances such 
pollutants and pathogens (2). These protective airway epithelial cell functions could 
be affected by for example genetic alterations and environmental insults in early 
life and/or the long-term exposure to inhaled toxicants, such as caused by cigarette 
smoking. Consequently, this may increase the susceptibility towards infections and 
eventually lead to (chronic) inflammation and aberrant immune responses, 
epithelial remodeling and repair (3, 4). Furthermore, studies have now shown that 
the airway epithelium from patients with chronic inflammatory lung diseases may 
differ from healthy subjects, and show signs of altered epithelial differentiation and 
aberrant repair (4-6). These findings support the hypothesis that the airway 
epithelium plays a central role in the pathogenesis of chronic inflammatory lung 
diseases such as asthma and chronic obstructive pulmonary disease (COPD).  
Vitamin D deficiency was classically known to be solely associated with bone 
diseases such as rickets until it gradually became evident that vitamin D deficiency 
was also associated with many other diseases including chronic inflammatory lung 
diseases such as asthma and COPD (1, 7-9). Several in vitro studies have already 
indicated that the active form of vitamin D [1,25 dihydroxy-vitamin D (1,25(OH)2D)] 
might protect the airway epithelium against injury by promoting integrity of the 
epithelial barrier, dampening immune responses and via the induction of the 
antimicrobial peptide (AMP) hCAP18/LL-37 (1). However, the precise impact of 
1,25(OH)2D) on the airway epithelium in a chronic inflammatory environment as 
observed in chronic lung diseases remains to be defined.  
The Airway Epithelium 
The lungs are in close contact with the external environment due to the large 
volumes of air inhaled on a daily basis. The airway epithelium lines the conducting 
airways and removes and eliminates potentially harmful substances and pathogens 
to protect the alveoli, where gas exchange occurs, from injury. The epithelium that 
lines the conducting airways is composed of a pseudostratified cell layer that 
consists of several epithelial cell types of which the major cell-types are ciliated 
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cells, secretory and basal cells (10). The basal cells are regarded as the main 
progenitor cells, that are able to renew and differentiate into intermediate cells 
followed by end-stage differentiation into secretory- or ciliated cells (5, 10). The 
ciliated cell is the main cell type of the airway epithelium that transports mucus 
produced by the submucosal glands and the goblet cells of the surface epithelium 
out of the airways through highly coordinated ciliary beating, generating a wavelike 
movement across the epithelial surface (11). Activation of the transcription factor 
forkhead box J1 (FOXJ1) is involved in the formation of ciliated cells (11), whereas 
Notch-signaling and activation of SAM pointed domain–containing ETS 
transcription factor (SPDEF) are the main inducers for secretory cell differentiation 
(12, 13). The goblet- and club cells are the secretory cells of the conducting airways. 
Whereas goblet cells are more prominent in the trachea and bronchi, club cells are 
most the predominant secretory cell type in the terminal and respiratory 
bronchioles (small airways). Goblet cells predominantly secrete gel-forming mucins 
such as mucin-5AC (MUC5AC) that trap particles in the gel-matrix to be removed 
through the mucociliary escalator, which is dependent on proper mucin-hydration 
and function of ciliated cells (14). Club cells are present throughout the airways and 
are the main source of club cell protein (CC16), which has been shown to contribute 
to epithelial homeostasis and to reduce inflammation and might therefore have 
protective features against development and progression of COPD (15). 
Furthermore, club cells also secrete antimicrobial compounds, surfactant proteins 
and mucins such as mucin-5B (MUC5B), which are known regulators of respiratory 
host defense and they express cytochrome P450 (CYP) enzymes such as CYP2F2 that 
neutralize xenobiotics (5, 15-17). The fact that CYP2F2 metabolizes some toxins into 
even more harmful substances might explain why club cells are more sensitive to 
these toxins than other airway epithelial cell types (Figure 1) (18). 
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Figure 1. The airway epithelium: cells that line and constitute the physical- and humoral barrier of 
the conducting airways. Physical defenses are provided by the mucociliary clearance and cell 
junctions forming the physical epithelial barrier, whereas humoral defenses are provided by the 
secretion of host defense molecules such as interferons (type I and III), antimicrobial peptides and 
proteins, cytokines, chemokines and lipid mediators. These mediators are also involved in regulating 
both innate and adaptive immune responses by attracting and activating immune cells in the 
submucosa. 
Airway epithelial innate host defense involves a physical barrier and a humoral 
barrier (Figure 1). The physical barrier of the epithelium is maintained by its tight- 
and adherens junctions and mucociliary clearance of trapped particles and 
pathogens (3). In chronic inflammatory airway diseases such as asthma and COPD, 
both of these defenses are compromised, which contributes to increased 
susceptibility towards infections (19). Furthermore, the ability to repair damage 
upon infection or exposure to toxicants is also impaired, and it has been 
hypothesized that aberrant repair results in remodeling of the airway epithelium 
such as reduced numbers of ciliated cells, goblet cell hyperplasia or epithelial-to 
mesenchymal transition (EMT) (20). EMT is a process characterized by a 
transformation of differentiated epithelial cells into mesenchymal cells (21). 
Furthermore, airway host defense is maintained via the humoral barrier provided 
by the secretion of host defense molecules such as antimicrobial proteins and 
peptides (AMPs), secretory immunoglobulin A (sIgA) and reactive oxygen species 
(ROS) (3). Furthermore upon activation of pattern recognition receptors (PRRs), 
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interferons, cytokines, chemokines and lipid mediators are released to promote 
viral clearance and to recruit and activate innate and adaptive immune cells (22, 
23). AMPs have, in addition to their broad-spectrum antimicrobial activity, also the 
ability to modulate immune responses and to promote wound repair (24). AMPs 
are either constitutively expressed at high levels or their expression can be induced 
upon activation of PRRs, cytokine and growth factor receptors, and by other 
mediators such as 1,25(OH)2D (25). In addition to AMPs, ROS also have 
antimicrobial features and are generated in airway epithelial cells by dual oxidases 
(DUOX), which are localized on the apical plasma membranes (26, 27). Epithelial 
clearance of viruses is generally promoted via the expression and release of type I 
and III interferons, which induces expression of a range of proteins that selectively 
interfere with virus replication, protein synthesis, or protein trafficking (23). In the 
chronic inflammatory lung diseases, aberrant secretion of AMPs and impaired 
expression of interferons contributes to defective clearance of pathogens, despite 
the increased production of ROS and influx of inflammatory cells (3, 23, 25, 28).  
Chronic Obstructive Pulmonary Disease (COPD) and Exacerbations  
COPD is a progressive lung disease characterized by chronic obstruction of airflow 
that interferes with normal breathing and is not fully reversible. The primary cause 
of COPD is exposure to noxious particles or gases such as tobacco smoking and 
environmental exposures to biomass fuels or air pollution, but also host factors 
such as genetics, abnormal lung development and aging may contribute to COPD 
development  (29). COPD is a major cause of chronic morbidity and is currently the 
3rd leading cause of death in the world (29, 30).  Exacerbations of COPD are episodes 
of acute worsening of symptoms that require additional therapy, accelerate disease 
progression and are a substantial burden on health-care systems worldwide 
through their effects on morbidity and mortality (29, 31). COPD exacerbations are 
mainly associated with by respiratory viral- and bacterial infections or by air 
pollution (31). As discussed in the previous paragraph, dysfunctional epithelial 
innate defense in the lungs of COPD patients likely contributes to the increased 
susceptibility towards bacterial and viral infections, and thereby to COPD 
exacerbations. Moreover, multiple studies have now demonstrated that COPD 
patients generally have lower serum 25(OH)D-levels, which are associated with an 
increased number and more severe exacerbations (8, 32). Studying the role of 
vitamin D in COPD exacerbations and airway epithelial innate immune defenses 
might therefore provide additional insight into the potential benefit of monitoring 
1
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vitamin D status of these patients and supplementation of patients with a vitamin 
D deficiency. 
Vitamin D Deficiency 
Vitamin D is a pleiotropic hormone that is well known for its role in regulating 
calcium (Ca2+) and phosphate (PO42-) homeostasis and bone mineralization. The 
receptor for 1,25(OH)2D (VDR) is however expressed in more than 40 tissues and 
regulates a large number of genes (approximately 0.8–5% of the total genome) (33). 
As a result, 1,25(OH)2D affects several cellular processes including proliferation, 
DNA repair, differentiation, apoptosis, membrane transport, metabolism, cell 
adhesion, and oxidative stress (33, 34). Vitamin D deficiency [serum 25(OH)D < 50 
nmol/L (35)] affects more than 30% of the children and adults worldwide and is 
linked to bone diseases such as rickets and osteoporosis, but also associated with 
many other diseases including cancer, type 2 diabetes, cardiovascular diseases, 
Alzheimer’s’ disease, muscle myopathy, multiple sclerosis, inflammatory bowel 
disease (IBD), psoriasis, and chronic inflammatory lung diseases including asthma 
and chronic obstructive pulmonary disease (COPD) (1, 7-9).  
Metabolism of Vitamin D 
Vitamin D enters the body either via food intake or as a result of its synthesis in the 
skin under the influence of UV-light (Figure 2). In the intestine, vitamin D2 or vitamin 
D3 enters the circulation actively from the lumen by apical membrane transporters 
or by passive diffusion through enterocytes (36). In the skin, UVB radiation triggers 
conversion of the cutaneous reservoir of 7-dehydrocholesterol into pre-vitamin D3. 
After isomerization of pre-vitamin D3 into vitamin D3, this secosteroid is removed 
from the skin through binding to the vitamin D binding protein (VDBP) and 
transported into the circulation (37). This VDBP-bound vitamin D2 or vitamin D3, 
which has a half-life of one day, is transported to the liver where it is converted by 
vitamin D-25-hydroxylases (CYP2RI and CYP27A1) into 25-hydroxy-vitamin D 
[25(OH)D]. However, recent studies showed that also other cell types such as 
airway epithelial cells, keratinocytes, monocytes/macrophages and intestinal 
epithelial cells express CYP2RI and CYP27A1, and thus are able to (locally) convert 
vitamin D3 into 25(OH)D3 (38, 39). 25(OH)D (both 25(OH)D2 and 25(OH)D3) is the 
main circulating form of vitamin D, which has a half-life of 20 days and its levels are 
used to assess vitamin D status in the clinic (40). This inactive 25(OH)D needs to be 
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converted into the active 1,25 dihydroxy-vitamin D (1,25(OH)2D) by 25-
hydroxyvitamin D-1α-hydroxylase (CYP27B1) in the kidney, locally in tissues or in 
several types of immune cells (41-44). 1,25(OH)2D binds the nuclear vitamin D 
receptor (VDR), which heterodimerizes with the retinoic acid receptor (RXR) to 
interact with vitamin D response elements (VDREs) that are present on the 
promoter region of vitamin D target genes (33, 45). The VDR-RXR-complex needs 
additional corepressors (NCoR, SMRT) and/or co-stimulators (SRC-1, CBP, MED1) to 
silence or initiate gene transcription (46, 47). In addition to promoting or 
suppressing gene expression via binding of 1,25(OH)2D to the nuclear (nVDR) and 
RXR, 1,25(OH)2D furthermore interacts with membrane-bound VDR (mVDR), 
known as 1,25(OH)2D-membrane-associated, rapid response steroid-binding 
protein (1,25D-MARRS). mVDR is present in the caveolae and induces rapid non-
genomic responses through e.g. the generation of second messengers such as Ca2+ 
and/or activation of proteins kinases such as mitogen-activated protein kinases 
(MAPK) (48). Furthermore, 1,25(OH)2D regulates its own negative feedback by 
several mechanisms, for example via direct induction of the catabolic enzymes 25-
hydroxyvitamin D-24-hydroxylase (CYP24A1) and CYP3A4 (49, 50). CYP24A1 is 
expressed in most tissues and converts both 25(OH)D and 1,25(OH)2D into 
23,25(OH)2D or 24,25(OH)2D and 1,24,25(OH)3D respectively, which are further 
converted into inactive metabolites and excreted in the bile (49, 51). CYP3A4 is 
mainly expressed in the liver and small intestines and contributes to the metabolic 
clearance of 25(OH)D and 1,25(OH)2D by converting 25(OH)D into 4β,25(OH)2D, and 
1,25(OH)2D into 1,23R,25(OH)2D or 1,24S,25(OH)2D (50). Expression of both 
CYP27B1 and CYP24A1 in the kidneys is tightly regulated to maintain optimal Ca2+ 
and PO42--levels in the circulation. When Ca2+-levels are low, parathyroid hormone 
(PTH) is secreted by the pituitary glands, which in turn reduces Ca2+ excretion and 
reabsorption of PO42- (52). PTH further induces expression of CYP27B1 and 
represses expression of CYP24A1 in the kidneys (52). This will increase the levels of 
1,25(OH)2D in the circulation, which promotes intestinal Ca2+ and PO42- absorption 
(52). These elevated circulating Ca2+ and PO42- levels will subsequently induce 
expression of fibroblast growth factor 23 (FGF-23) in osteocytes and osteoblasts 
and impair secretion of parathyroid hormone (PTH) by the parathyroid glands (34). 
In the kidneys, FGF-23 suppresses expression of CYP27B1 and induces expression 
of CYP24A1, thereby inhibiting the synthesis and promoting degradation of 
1,25(OH)2D (34) (Figure 2).  
1
General Introduction and Outline of the Thesis
7
 
Figure 2. Endocrine vitamin D metabolism.  See text for details and references. 
Vitamin D and Chronic Inflammatory Lung Diseases  
Systemic levels of biologically active 1,25(OH)2D are tightly regulated to achieve 
sufficient Ca2+ and PO42- levels levels for optimal bone mineralization, whereas in 
mucosal tissues local 1,25(OH)2D activation or inactivation can result in 1,25(OH)2D 
levels that are elevated or decreased (7). The inflamed mucosal tissues of the 
airways in COPD and asthma patients are constantly exposed to pathogens and to 
several inflammatory mediators. However, the effects of this exposure on local 
levels of 1,25(OH)2D in mucosal tissues of the lung and gut are currently unclear. 
This may however be relevant since many diseases with chronic inflammation of 
the lung such as asthma and COPD are also associated with vitamin D deficiency (8, 
53, 54). These patients have furthermore dysregulated immune responses, altered 
microbiome composition, impaired epithelial barrier function and aberrant 
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secretion of host defense molecules thereby increasing their susceptibility towards 
infections (55-57). Since 1,25(OH)2D is involved in many of these processes, it might 
provide protection against these features. This may occur via various mechanisms 
induced by 1,25(OH)2D, including the maintenance of the integrity of the mucosal 
barrier and the promotion of killing of pathogens (e.g. via the induction of the 
antimicrobial peptide hCAP18/LL-37) (1). Mechanistic studies have furthermore 
shown that 1,25(OH)2D is an important mediator of both innate and adaptive 
immune responses, suggesting the importance of 1,25(OH)2D in various immune-
related diseases (58). COPD patients have an increased risk for vitamin D deficiency, 
which is associated with an increased number and more severe exacerbations (8, 
32). Studying the role of 1,25(OH)2D in COPD exacerbations and airway epithelial 
innate immune defenses might therefore provide additional insight into the 
potential benefit of monitoring 25(OH)D levels in these patients and 
supplementation of patients with a vitamin D deficiency. 
1
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Outline of the Thesis 
The overall aim of the studies described in this thesis is to elucidate the role of 
inflammation on the protective effects of vitamin D on respiratory host defense in 
chronic airway diseases with a specific focus on COPD. First, an introduction into 
the central role of the respiratory epithelium during homeostasis and in the 
pathogenesis of chronic inflammatory lung diseases such as COPD is provided, 
followed by a general introduction into vitamin D metabolism and vitamin D 
deficiency in COPD patients (Chapter 1). In the experimental studies that are 
described in this thesis, the effects of vitamin D (inactive 25(OH)D and active 
1,25(OH)2D) and inflammation are studied using in vitro models of primary 
bronchial epithelial cells. In these models, we will study the effects of toxic, 
inflammatory and microbial exposures such as cigarette smoke (chapter 2), 
cytokines (chapter 3 and 4), bacteria (chapter 4) and viruses (chapter 5) on airway 
epithelial host defense mechanisms with a focus on 1,25(OH)2D-mediated epithelial 
host defense mechanisms, i.e. expression of the AMP hCAP18/LL-37 (Figure 3).  
Both smokers and COPD patients are more susceptible for respiratory infections 
and various studies have shown that cigarette smoke exposure may alter airway 
epithelial cell composition. We therefore first aimed to investigate in Chapter 2 if 
chronic cigarette smoke-exposure during epithelial differentiation alters expression 
of constitutively expressed host defense molecules and host defense mechanisms 
through its effect on airway epithelial cell differentiation. Cigarette smoke exposure 
also induces expression of TGF-β1 in airway epithelial cells. This pleiotropic cytokine 
is elevated in COPD patients, and in addition to its ability to promote fibrosis, TGF-
β1 also impairs airway epithelial host defense mechanisms. Therefore, we next 
focused in Chapter 3 on investigating the effects of TGF-β1 on expression of 
constitutively expressed host defense molecules and on the expression of the 
1,25(OH)2D-induced hCAP18/LL-37. We furthermore determined mechanisms 
underlying behind the impaired effects of TGF-β1 on respiratory host defense by 
investigating direct effects of TGF-β1 on CAMP (hCAP18/LL-37) transcription, on 
vitamin D metabolism and on VDR expression. In Chapter 4, we continued to 
investigate the effects of proinflammatory cytokines (TNF-α, IL-1β, IL-17A), 
elevated in the airways of COPD and/or in steroid resistant asthma patients, on 
vitamin D-metabolism and on 25(OH)D and 1,25(OH)2D-mediated expression of 
hCAP18/LL-37. To determine if the 25(OH)D and 1,25(OH)2D-mediated respiratory 
host defense was affected by exposure to proinflammatory cytokines, we assessed 
epithelial antimicrobial activity against nontypeable Haemophilus influenzae. 
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Chapter 5 describes the immunomodulatory effects 25(OH)D and 1,25(OH)2D on 
virus-induced (Poly[I:C])-inflammatory responses in airway epithelial cells. In 
addition, the effects of Th2 inflammation -present in the airways of both allergic 
asthma and a subset of COPD patients- on vitamin D metabolism and 25(OH)D and 
1,25(OH)2D-mediated expression of hCAP18/LL-37 was investigated. To translate 
our findings to a more clinical level in Chapter 6, a study design is provided that 
describes a multicenter randomized controlled trial that aims to investigate if 
vitamin D supplementation can indeed protect against COPD exacerbations in a 
population of vitamin D deficient COPD patients. Finally, in Chapter 7 a review of 
all the current knowledge of the effects of disease-associated factors such as 
inflammation and cigarette smoke exposure on availability and signaling of 
1,25(OH)2D in the lungs of patients with COPD and other chronic lung diseases is 
provided, followed by an general overview and discussion of the results that are 
presented in this thesis in Chapter 8. 
  
Figure 3. Unknown effects of inflammation on vitamin D metabolism and epithelial host defense in 
the airways. The separate components of this figure are discussed in the various chapters of this 
thesis, as indicated by the chapter (Ch) numbers. Vitamin D receptor, VDR; Biologically active vitamin 
D, 1,25(OH)2D; 25-hydroxyvitamin D-1α-hydroxylase, CYP27B1; circulating inactive vitamin D, 
25(OH)D; 25-hydroxyvitamin D-24-hydroxylase, CYP24A1.  
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Abstract 
Research question: It is currently unknown how cigarette smoke-induced airway 
remodelling affects highly expressed respiratory epithelial defence proteins and 
thereby mucosal host defence. 
Methods: Localization of a selected set of highly expressed respiratory epithelial 
host defence proteins was assessed in well-differentiated primary bronchial 
epithelial cell (PBEC) cultures. Next, PBEC were cultured at the air-liquid interface 
and during differentiation for 2-3 weeks daily exposed to whole cigarette smoke. 
Gene expression, protein levels and epithelial cell markers were subsequently 
assessed. In addition, functional activities and persistence of the cigarette smoke-
induced effects upon cessation were determined. 
Results: Expression of pIgR, SLPI, long and short PLUNC was restricted to luminal 
cells and exposure of differentiating PBEC to cigarette smoke resulted in a selective 
reduction of the expression of these luminal cell-restricted respiratory host defence 
proteins compared to controls. This reduced expression was a consequence of 
cigarette smoke-impaired end-stage differentiation of epithelial cells, and 
accompanied by a significant decreased trans-epithelial transport of IgA and 
bacterial killing. 
Conclusions: These findings shed new light on the importance of airway epithelial 
cell differentiation in respiratory host defence and could provide an additional 








Respiratory infections and microbial colonization are a major health burden in 
smokers, and contribute to exacerbations and to the development and progression 
of chronic obstructive pulmonary disease (COPD) (reviewed by Sethi(1)). The 
mechanisms underlying this increased susceptibility of smokers with or without 
COPD are incompletely understood, but can be attributed in part to epithelial injury 
and remodelling resulting in a disrupted mucociliary clearance(2). In addition to 
mucociliary clearance, the airway epithelium contributes to host defence with a 
wide variety of additional activities(3) that include secretion of antimicrobial 
peptides that act as endogenous antibiotics or modulate important antimicrobial 
immune responses via a variety of mechanisms(4). Furthermore, the epithelium 
produces cytokines and chemokines that initiate an immune response to act against 
microbial invaders. Finally, transport of polymeric IgA and IgM to the lumen by the 
polymeric immunoglobulin receptor (pIgR) contributes to adaptive immunity in the 
lung by inhibiting adherence and facilitating clearance of pathogens, a process 
called immune exclusion(5). Several of these respiratory host defence proteins 
(HDPs) in the airways are highly expressed during homeostasis by epithelial cells, 
suggesting their importance for airway epithelial barrier function. Highly expressed 
proteins and peptides include -but are not limited to- antimicrobial peptides such 
as human beta defensin-1 (hBD-1) and lipocalin 2 (LCN2), the secretory leukocyte 
protease inhibitor (SLPI), pIgR and the epithelial sodium channel regulators short 
and long palate, lung and nasal epithelium clone protein (s/lPLUNC or 
BPIFA1/BPIFB1)(6-8). Expression of other peptides involved in airway host defence 
such as Ribonuclease 7 (RNase 7), LL-37 and human beta defensin-2 (hBD-2) is low 
during homeostasis but can be induced by e.g. inflammatory mediators, microbial 
products and upon injury of epithelial cells, and thus contribute to clearance of the 
pathogen and the resulting inflammatory process(4). The pseudostratified airway 
epithelium is composed of several cell-types, including goblet, club and ciliated cells 
that reach out toward the lumen of the airways, while basal cells do not reach this 
lumen in the intact epithelial layer(9). Based on their distinct anatomical 
positioning, it is not surprising that these different cell-types also produce different 
types of mediators. For example, expression of pIgR is restricted to the luminal cells 
of the pseudostratified airway epithelium and is therefore largely regulated by 
airway epithelial cell differentiation(10), similar to e.g. mucin production by goblet 
cells. In contrast, expression of the antimicrobial protein RNase 7 is restricted to 
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basal cells(11). Cigarette smoke is known to induce airway epithelial remodelling in 
smokers and patients with COPD, characterized by an increase in goblet cells and a 
reduction in presence of ciliated cells(2). As a result higher levels of mucus are 
produced by the epithelium, while mucus transport is impaired, thereby 
compromising mucociliary clearance activity of luminal airway epithelial cells. 
Currently it is unknown if the expression of proteins that are important for airway 
epithelial defence is polarized in the epithelium, and if so, how cigarette smoke-
induced remodelling of the airway epithelium affects their expression. We 
hypothesized that cigarette smoke-induced alterations in epithelial cell 
differentiation result in a decreased expression of proteins that contribute to 
respiratory host defence (HDPs), which may render the host more susceptible to 





Collection of cells and cell culture 
Primary bronchial epithelial cells (PBEC) were obtained from tumor-free resected 
lung tissue at the Leiden University Medical Center, Leiden, the Netherlands. For 
this, PBEC were cultured at the air-liquid interface (ALI) for 13 to 19 days (Figure 
2A). Apical washes were performed daily; medium was refreshed every other day.  
Primary bronchial epithelial cells (PBEC) were obtained from tumour-free resected 
lung tissue at the Leiden University Medical Center, Leiden, the Netherlands. For 
this, bronchial epithelial cells were isolated from a bronchial ring by enzymatic 
digestion for 2 h at 37 °C with 0.18% (w/v) proteinase type XIV (Sigma-Aldrich, St. 
Louis, MO, USA) in Ca2+/Mg2+-free Hank’s Balanced Salt Solution (Life Technologies 
Europe B.V., Bleiswijk, The Netherlands). Next, the obtained cell fraction was 
expanded in serum-free keratinocyte medium (KSFM, Life Technologies Europe 
B.V.) supplemented with 0.2 ng/ml epidermal growth factor (Gibco), 25 μg/ml 
bovine pituitary extract (Life Technologies Europe B.V.), 1 μM isoproterenol (Sigma-
Aldrich), 100 U/mL Penicillin (Lonza, Verviers, Belgium), 100 μg/ml Streptomycin 
(Lonza) and 5 µg/ml Ciproxin. Upon reaching confluence, cells were trypsinized in 
0.03% (w/v) trypsin (Difco, Detroit, USA), 0.01% (w/v) EDTA (BDH, Poole, England), 
0.1% glucose (BDH) in PBS and stored in liquid nitrogen until further use. For our 
cultures, cells were thawed in KSFM medium supplemented with the above 
mentioned supplements until near confluence, seeded on semipermeable 
transwell inserts with 0.4 μm pore size (Corning Costar, Cambridge, USA) that were 
coated with a mixture of bovine serum albumin, collagen and fibronectin and 
cultured as described (11).  
 
Fractionation of the airway epithelial cultures 
Luminal and basal cell-enriched fractions were obtained from 3-4 weeks 
differentiated ALI-PBEC cultures as described previously(11). The luminal cell 
fraction was spun down and either lysed in RNA lysis buffer or fixed with 1% 
paraformaldehyde (Millipore B.V., Amsterdam, the Netherlands) in PBS for 10 
minutes on ice and washed afterwards in ice-cold PBS. The remaining basal 
epithelial cell fractions on the transwell inserts were also either lysed in RNA lysis 
buffer (Promega) or fixed with 1% paraformaldehyde (Millipore B.V.) in PBS for 10 
minutes on ice and washed afterwards with ice-cold PBS. Next, cells were stained 
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as described in the online data supplement with antibodies described in 
supplemental (s)Table 2.   
 
Chronic cigarette smoke exposure 
When confluent, PBECs were air-exposed (day 0) by removal of medium from the 
apical side of the transwell insert and 4 h later exposed to freshly generated whole 
cigarette smoke (CS) using 3R4F reference cigarettes (University of Kentucky, 
Lexington, KY). CS exposure was repeated daily as described in(11), in the figure 
legends of figure 1 and online supplementary figure S1 and illustrated in figure 1b 
and online supplementary figure S1. Briefly, cells were exposed in modified hypoxic 
chambers for 4-5 minutes to either cigarette smoke from 1 cigarette or to room air, 
after which smoke was removed by ventilation with air during 10 minutes. and cells 
were subsequently placed back in the incubator overnight. Approximately 18-20 h 
later, ALI-PBEC were washed apically with PBS and 4 h hereafter exposed to 
cigarette smoke. This cycle was repeated every day until day 13-19. Cells were 




Figure 1. Cell culture set-up and cigarette smoke exposure of primary bronchial epithelial cells 
differentiated at the air-liquid interface (ALI-PBEC). (A) Primary bronchial epithelial cells (PBEC) were 
seeded on coated transwells and cultured in submerged conditions until confluent. At day 0, cultures 
were air-exposed and cultured for additional 13-19 days to allow mucociliary differentiation. (B) Each 
day, starting at day 0, cultures were exposed to cigarette smoke (CS) by placing them in an exposure 
chamber that was infused with either cigarette smoke or with air for 4-5 min. Next, residual smoke in 
the chamber was removed for a period of 10 min. by infusing the chambers with air derived from the 
incubator. Approximately 4 h before each CS exposure the apical surface of the cultures was washed 
to remove mucus. Basal medium was changed every other day. 
 
RNA isolation, cDNA synthesis and qPCR 
Cells were lysed using lysis buffer from Promega, Leiden, the Netherlands. Next, 
RNA was extracted using the Maxwell tissue RNA extraction kit (Promega) and 
quantified using the Nanodrop ND-1000 Spectrophotometer (Nanodrop 
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technologies, Wilmington, DE). cDNA synthesis was performed using oligo dT 
primers (Qiagen, Venlo, the Netherlands) and M-MLV Polymerase (Promega) in the 
presence of RNAsin (Promega). For qPCR analysis, diluted cDNA was mixed with 
primers (sTable 1) and iQ™ SYBR® Green Supermix (Bio-Rad, Veenendaal, the 
Netherlands). Reactions were performed in triplicate and results were corrected for 
the geometric mean of expression of 2-3 reference genes selected using the 
Genorm method. Expression values were determined by the relative gene 
expression of a standard curve as determined by CFX manager software (Bio-Rad).  
 
Confocal microscopy  
Following fixation with 1% PFA, cell culture inserts and/or cytospins containing 
luminal epithelial cells were treated with methanol for 10 min at 4 °C, washed with 
PBS and cells were permeabilized with 1% w/v BSA, 0.3% v/v Triton-X100 in PBS 
(PBT) for 30 min at 4 °C. After washing with PBS, cells were pre-treated with SFX-
signal enhancer (Life Technologies Europe B.V.) followed by incubation with 
primary antibodies in PBT for 1 h at RT (sTable 2). Next inserts were washed in PBS 
and incubated with an Alexa Fluor 488 or 568-labeled secondary antibody (Alexa 
Fluor 488 donkey-anti--mouse IgG; Alexa Fluor 568 donkey--anti-rabbit IgG, Life 
Technologies Europe B.V.) together with DAPI in PBT for 30 min at RT. Images were 
acquired using a TCS SP5 Confocal Laser Scanning Microscope (Leica Microsystems 
B.V., Eindhoven, The Netherlands) and LAS AF Lite software (Leica Microsystems 
B.V.). 
Transcytosis experiment 
Transcytosis capacity of the epithelial cultures was assessed in cultures exposed 
daily to whole cigarette smoke for 13 days, or air as a control. Dimeric IgA was 
added to the basal compartment of the cell cultures and 24 h thereafter, apical 
washes (PBS) were collected and stored at -20°C for further analysis. Apical washes 
were assessed for secretory (S-)IgA levels by sandwich ELISA(10).  
 
Antibacterial activity assay 
Direct antimicrobial activity was assessed in cultures of ALI-PBEC that were exposed 
daily to whole cigarette smoke or air controls for 13 days, followed by replacement 
with antibiotics-free cell culture medium for an additional 48 h period. Moraxella 
catarrhalis strain LUH2760 and Klebsiella pneumoniae strain LUH2754 were 
cultured in Tryptic Soy broth (TSB) while shaking overnight at 37⁰ C. Next, the 
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overnight cultures were transferred into fresh TSB medium (1/50 dilution) and 
incubated for 4 h at 37°C -while shaking- to obtain mid log-phase-growing bacteria. 
Bacterial concentrations of log-phase cultures were determined by OD600 nm 
measurements, pre-diluted in PBS and final dilution was made in antibiotics-free 
cell culture medium. Twenty µl of bacterial suspension was added on the apical 
surface of the cells at a concentration of ~6x105/ml CFU/ml for M. catarrhalis and 
~1x104 CFU/ml for K. pneumoniae and incubated at 37°C, 5% CO2 for 2 h. Hereafter, 
membranes containing the cells with bacteria were dissected from the inserts and 
placed into tubes containing sterile glass beads and 1% TSB in PBS. Next cells were 
disrupted by using a minilys personal homogenizer (Bertin Instruments, Montigny-
le-Bretonneux, France) for 2 times 30 s and kept on ice in between. Serial dilutions 
of both bacterial suspensions were plated on Tryptic Soy Sheep blood (TSS) agar 
plates (Biomerieux, Zaltbommel, The Netherlands), and incubated overnight at 
37°C to assess surviving bacteria by CFU determination. 
 
ELISA  
CXCL8/IL-8 production by ALI-PBEC was determined in the basal medium by use of 
the CXCL8/IL-8 Duoset kit from R&D (MN, U.S.A.). hBD-1 was measured in the apical 
wash and in the basal medium using the hBD-1 kit from Peprotech (London, U.K.) 
and SLPI was measured as described(46). 
 
Trans-epithelial electrical resistance  
Epithelial barrier integrity of ALI-PBEC cultures was determined during cell 
differentiation by measuring the trans-epithelial electrical resistance (TEER) using 
the MilliCell-ERS (Millipore, Bedford, MA). TEER values were shown as Ω*cm2 and 
calculated as TEER = (measured value – background value) *surface transwell insert 
in cm2.  
 
Inhibition of differentiation by DAPT 
At day 0, PBEC were air exposed by removal of the medium in the insert and culture 
medium of ALI-PBEC was refreshed with medium supplemented with either 5 µM 
DAPT (Notch signalling inhibitor, Sigma Aldrich, Zwijndrecht, The Netherlands), or 
solvent control. Every other day, basal medium was changed in a similar fashion up 
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Statistics 
Statistical analysis was conducted using GraphPad Prism 7 (GraphPad Software Inc., 
La Jolla, CA, U.S.A.). Data are shown as mean ± SEM and significance was tested 
with use of   a paired t-test or two-way ANOVA with a Bonferroni corrected post-




Respiratory host defence proteins display a polarized distribution in 
airway epithelial cell cultures 
In this study we have focussed on a set of proteins and peptides that are important 
for respiratory host defence. These host defence proteins (HDPs) were selected 
based on their constitutive and/or high expression by airway epithelial cells during 
homeostasis: i.e. SLPI, PLUNC (short/long), pIgR, hBD-1 and LCN2. We first 
investigated whether expression of these proteins was polarized in the airway 
epithelial cultures. To this end, we prepared luminal and basal epithelial cell-
enriched fractions of well-differentiated primary bronchial epithelial cells (PBEC), 
cultured at the air-liquid interface (ALI, Figure 2A). We confirmed the successful 
enrichment of fractions for luminal and basal cells by determining the gene 
expression of the typical basal cell markers TP63 and KRT5 and luminal epithelial 
cell markers FOXJ1 (ciliated cells), SCGB1A1 (club cells), MUC5AC and MUC5B (both 
goblet cells) (Figure 1A), and by immunofluorescence staining for p63 (basal cells), 
CC16 (club cells) and acetylated α-tubulin (ciliated cells) (sFigure 2). Further analysis 
of these fractions showed that the luminal cell-enriched fraction expressed 
significantly higher levels of BPIFA1 (sPLUNC), BPIFB1 (lPLUNC) and SLPI (Figure 2A). 
In contrast, LCN2 and DEFB1 expression did not differ between the luminal and 
basal cell-enriched fraction (Figure 1A). The luminal cell-specific expression of SLPI 
and sPLUNC was further confirmed using confocal imaging in which the staining of 
both proteins did not co-localize with p63+ basal cells, but was highly present at the 
apical side of the PBEC culture and in the luminal cell-enriched fraction (Figure 2B 
and online supplementary Figure S2).  
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Figure 2. Respiratory host defence proteins display a polarized distribution in air-liquid interface 
cultures of primary bronchial epithelial cells (ALI-PBEC). (A) PBEC were seeded on coated transwells 
and cultured in submerged conditions until confluent. At day 0, cultures were air-exposed and 
cultured at the air-liquid interface. After 3-4 weeks of differentiation luminal and basal cell-enriched 
fractions were separated followed by RNA isolation, cDNA synthesis and qPCR analysis. Data are 
shown as target gene expression normalized for the geometric mean expression of the reference 
genes ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide (ATP5B), β2-
microglobulin (B2M) and Ribosomal Protein L13a (RPL13A),  n=5-7 different donors. Open bars are 
basal cell-enriched fractions; grey bars are luminal cell-enriched fractions. Statistical significance was 
tested using a paired t-test. * p<0.05, ** p<0.01, *** p<0.001. (B) Confocal images to visualize 
polarized distribution of secretory leukocyte protease inhibitor (SLPI) and short palate, lung and nasal 
epithelium clone protein (sPLUNC) in differentiated ALI-PBEC cultures cells. After 3 weeks of 
differentiation, cells were fixed in 1% paraformaldehyde and stained using immunofluorescence with 
primary antibodies against p63 (basal cell marker, red) in combination with primary antibodies against 
SLPI and/or sPLUNC (both green) and DAPI for nuclear staining (blue). Z-stacks and images of the apical 
and basal side of stained cells were made by confocal imaging, scale bars equals 50 µm. Images shown 
are representative for results obtained with cells from 4 different donors. 
 
Chronic cigarette smoke exposure of airway epithelial cell cultures reduces 
expression of respiratory host defence proteins  
We next investigated if cigarette smoke-exposure affected expression of this set of 
respiratory HDPs. To this end, ALI-PBEC cultures were exposed on a daily basis 
during 2-3 weeks of differentiation to whole cigarette smoke (CS) (Figure 1 and 
28
Chapter 2
supplementary Figure S1). Gene expression analysis showed that DEFB1 (hBD-1) 
mRNA levels decreased during differentiation, but were not affected by CS 
exposure (Figure 3A). On the other hand, expression of SLPI, BPIFA1 (sPLUNC), 
BPIFB1 (lPLUNC) and PIGR strongly increased during differentiation, and this 
increase was significantly prevented by CS (Figure 3A). In contrast, gene expression 
of LCN2 (lipocalin 2) was increased by CS exposure during differentiation (Figure 
3A). These findings were further confirmed by assessment of hBD-1 and SLPI 
protein levels in the apical wash and in basal medium from the ALI-PBEC cultures 
(Figure 3B). Indeed, hBD-1 levels reduced over the time of differentiation in the 
apical wash, but were not significantly affected by chronic CS-exposure, whereas 
SLPI levels were significantly lower in chronic CS-exposed cell cultures (Figure 3B). 
We next performed immunofluorescence staining of the airway epithelial cell 
cultures and found strongly reduced presence of SLPI-, sPLUNC- and pIgR-positive 
cells in chronic CS-exposed epithelium compared to air controls (Figure 3C). These 
results confirmed selective impairment of specific respiratory HDPs by chronic CS 
exposure during airway epithelial differentiation. 
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Figure 3. Chronic cigarette smoke exposure of air-liquid interface cultures of primary bronchial 
epithelial cells (ALI-PBEC) lowers the expression of luminal cell-restricted host defence proteins. (A) 
ALI-PBEC were daily exposed to whole cigarette smoke (CS) or air as a control (AIR) during 
differentiation for 13-19 consecutive days. Cells were lysed at several points during this course of time 
and RNA was isolated followed by cDNA synthesis to assess gene expression of DEFB1 (human beta 
30
Chapter 2
defensin-1), SLPI (secretory leukocyte protease inhibitor), BPIF1A (short palate, lung and nasal 
epithelium clone protein), BPIF1B (long palate, lung and nasal epithelium clone protein), PIGR 
(polymeric immunoglobulin receptor) and LCN2 (lipocalin 2). Open circles: air-exposed controls, black 
circles: CS-exposed cell cultures; data are shown as target gene expression normalized for the 
geometric mean expression of the reference genes ATP synthase, H+ transporting, mitochondrial F1 
complex, beta polypeptide (ATP5B), β2-microglobulin (B2M) and Ribosomal Protein L13a (RPL13A); 
day 0, 7, 13 n=8 different donors and day 19 n=4 different donors. Statistical differences were 
evaluated using a two-way ANOVA and Bonferroni post-hoc test. * p<0.05, ** p<0.01, *** p<0.001, 
**** p<0.0001 between AIR and CS.  # p<0.05, ## p<0.01, ### p<0.001, #### p<0.0001 between AIR 
at day 7, 13 and 19 and unexposed cultures at day 0. (B) ELISA for hBD-1 and SLPI was performed on 
the apical wash (Apical) and basal medium (Basal) of these cultures. Open bars: air controls (AIR), 
black bars: CS-exposed cell cultures (CS); day 7 and 13, n=8 different donors and day 19: n=4 different 
donors. Statistical differences on T=7 and T=13 (not T=19) was tested using a paired two-way ANOVA 
to compare AIR and CS. * p<0.05, ** p<0.01. (C) ALI-PBEC were differentiated for 2-3 weeks in which 
they were daily exposed to CS or air as a control (AIR). Subsequently the cells were fixed in 1% 
paraformaldehyde and stained using primary antibodies against SLPI, sPLUNC and pIgR (all green 
staining) in combination with DAPI to stain the nuclei (blue staining). Scale bars are equal to 50 µm. 
Images shown are representative for results obtained with cell cultures from 4 different donors. 
 
Chronic cigarette smoke exposure reduces host defence of the airway 
epithelial cell cultures by decreasing apical release of secretory IgA and 
bacterial killing of Moraxella catarrhalis and Klebsiella pneumoniae   
Next, we assessed if the strong reduction in SLPI, BPIFA1 (sPLUNC), BPIFB1 (lPLUNC) 
and PIGR expression levels in the CS-exposed airway epithelial cultures had 
functional consequences for host defence. We selected pIgR-mediated transfer of 
dimeric (d)IgA across the epithelium as a proof-of-principle for the consequences 
on immunomodulatory host defence functions and found this to be significantly 
reduced in chronic CS-exposed cultures (Figure 4A). We furthermore analysed 
bacterial killing by chronic CS-exposed cell cultures of the Gram-negative bacteria 
Moraxella catarrhalis and Klebsiella pneumoniae, pathogens that are found to be 
increased in the lungs of patients with stable or acute exacerbations of COPD (12). 
We observed significantly higher bacterial counts (indicating lower antibacterial 
activity) in chronic CS-exposed PBEC cultures when compared to air-exposed 
cultures for both pathogens (Figure 4B). These data indicate that various host 
defence mechanisms are functionally impaired in CS-exposed epithelial cell 
cultures, which corresponds with impaired expression of respiratory defence 
proteins. 
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Figure 4. Chronic cigarette smoke exposure of air-liquid interface cultures of primary bronchial 
epithelial cells (ALI-PBEC) impairs host defence activities.  A) ALI-PBEC were daily exposed to whole 
cigarette smoke (CS) or air as a control (AIR) during differentiation for 13 consecutive days. After 13 
days of chronic CS exposure, dimeric (d)IgA transcytosis capacity of the epithelial cultures was 
assessed by determining secretory (S)-IgA levels in apical washes by ELISA (no S-IgA could be detected 
in the basal medium, as a control of the assay that does only recognize S-IgA and not d-IgA), n=10 
different donors. Open bars: air-exposed cell cultures, black bars: CS-exposed cell cultures. B) After 13 
days of chronic CS exposure, ALI-PBEC were cultured for 48 h in antibiotics-free cell culture medium 
after which they were exposed for 2 h to Moraxella catarrhalis or Klebsiella pneumoniae at the apical 
surface of the ALI-PBEC. The surviving bacteria are depicted as colony forming units (CFU)/ml,  n=8 
different donors. Significance was determined using a paired t-test. *p<0.05, **** p<0.0001. 
 
 
Cigarette smoke affects end-stage differentiation of airway epithelial cells 
Next we assessed if chronic CS exposure affected differentiation of ALI-PBEC by 
measuring gene expression of epithelial cell-specific markers. Gene expression of 
the basal cell markers cytokeratin-5 (KRT5) and TP63, and of cytokeratin-8 (KRT8) 
that is expressed by intermediate/committed progenitor epithelial cells(13), was 
not affected by CS (Figure 5A). In contrast, expression of the specialized luminal 
epithelial cell-specific genes FOXJ1 (ciliated cells), SCGB1A1 (club cells) and MUC5B 
(goblet cells) increased during differentiation, and this increase was significantly 
prevented by CS (Figure 5A). Confocal imaging confirmed the aberrant epithelial 
differentiation in CS-exposed cultures as cells positive for cilia marker acetylated α-
tubulin, the club cell marker CC16, and the goblet cell marker MUC5AC were 
reduced in chronic CS-exposed cultures, while cytokeratin-8 (CK-8)+ and p63+ cells 




Figure 5. Chronic cigarette smoke exposure of air-liquid interface cultures of primary bronchial 
epithelial cells (ALI-PBEC) changes cellular composition. (A) ALI-PBEC were exposed during 
differentiation for 13-19 consecutive days to whole CS. Cells were lysed at several time-points and 
RNA was isolated followed by cDNA synthesis, to assess gene expression of basal cell markers 
cytokeratin-5 (KRT5) and TP63, of early progenitor cell marker cytokeratin-8 (KRT8) and of specialized 
cell markers FOXJ1 (ciliated cells), SCGB1A1 (club cells) and MUC5B (goblet cells). Open circles: air-
exposed controls (AIR), black circles: CS-exposed cell cultures (CS); data are shown as target gene 
expression normalized for the geometric mean expression of the reference genes ATP synthase, H+ 
transporting, mitochondrial F1 complex, beta polypeptide (ATP5B), β2-microglobulin (B2M) and 
Ribosomal Protein L13a (RPL13A); day 0, 7, 13 n=8 donors and day 19 n=4 donors. Significance was 
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determined using a two-way ANOVA and Bonferroni post-hoc test. ** p<0.01, *** p<0.001, **** 
p<0.0001 between AIR and CS. # p<0.05, ## p<0.01, ### p<0.001, #### p<0.0001 between AIR at day 
7, 13 and 19 and unexposed cultures at time 0. (B) ALI-PBEC were differentiated for 2-3 weeks and 
daily exposed to CS. Subsequently the cells were fixed in 1% paraformaldehyde and stained using 
primary antibodies against basal cells (p63), presented as a red staining, in combination with primary 
antibodies against cytokeratin-8 (CK-8), acetylated α-tubulin (ciliated cells), CC16 (club cells) and 
MUC5AC (goblet cells), which are presented as a green staining; DAPI was used to stain the nuclei 
(blue staining). Z-stacks and images of the apical and basal side of stained cells were obtained by 
confocal imaging. Scale bars equals 50 µm. Images shown are representative for results obtained with 
cells from 4 different donors (CK-8; n=3 different donors). 
 
Reversibility of cigarette smoke-induced effects on host defence protein 
expression 
To assess the persistence of the CS-induced reduction in SLPI, BPIFA1 (sPLUNC), 
BPIFB1 (lPLUNC) and PIGR expression levels and of its effect on cellular 
composition, we allowed the cultures to recover from 13 days of CS exposure by 
culturing the cells for an additional 6 days without CS exposure. Chronic CS-exposed 
cultures were able to (partly) recover from the lack of end-stage differentiation, 
since all specialized luminal cell markers, except for SCGB1A1 (club cells), 
significantly increased in expression (Figure 6A). Furthermore, also SLPI, BPIFA1 
(sPLUNC), BPIFB1 (lPLUNC) and PIGR showed enhanced expression compared to 
day 13 (Figure 6A). In addition, KRT5 (basal cell marker), and DEFB1 and LCN2 
increased upon CS cessation, whereas TP63 and KRT8 were unaffected 
(Supplementary Figure S3A). This indicates that the inhibitory effects of cigarette 
smoke exposure on epithelial differentiation and expression of specific respiratory 
defence proteins are at least in part reversible. Furthermore, in an attempt to 
better mimic the in vivo situation and establish if the effects observed after chronic 
CS exposure also can be obtained when exposing an already partly differentiated 
epithelium to chronic CS, we performed a separate experiment. In this experiment, 
we first allowed the cultures to differentiate for 1 week, after which we started 
chronic CS exposure for an additional 12 days. Here we found similar effects of CS 
exposure on ALI-PBEC cultures regarding cell-type specific markers and HDP 
expression compared to CS exposure starting from day 0 (Figure 6B and 





Figure 6. Cigarette smoke-induced impairment of host defence proteins and differentiation markers 
are partly persistent upon cigarette smoke cessation. (A) Air-liquid interface cultures of primary 
bronchial epithelial cells (ALI-PBEC) were exposed during differentiation for 13 consecutive days to 
whole cigarette smoke (CS) after which cultures were continued for another 6 days without CS 
exposure. Cells were lysed at several points during this course of time and RNA was isolated followed 
by cDNA synthesis, to assess gene expression of the cell specific markers: FOXJ1 (ciliated cells), MUC5B 
(goblet cells) and SCGB1A1 (club cells) and of respiratory defence proteins: SLPI, BPIFA1 (sPLUNC), 
BPIFB1 (lPLUNC) and PIGR. Open bars: air-exposed controls (AIR), black bars: CS-exposed cell cultures 
(CS), grey bars: CS-exposed cultures that were cultured for an additional week without CS exposure 
(CS cessation). Data are shown as target gene expression normalized for the geometric mean 
expression of the reference genes ATP synthase, H+ transporting, mitochondrial F1 complex, beta 
polypeptide (ATP5B), β2-microglobulin (B2M) and Ribosomal Protein L13a (RPL13A). n=8 different 
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donors. Statistical differences were evaluated only for the difference between cessation and previous 
CS expression using a two-way ANOVA and Bonferroni post-hoc test. * p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001. (B) ALI-PBEC were air exposed at day 0 and cultured for 7 days under 
standard conditions. At day 7 cultures were exposed to CS for 12 consecutive days after which the 
cells were lysed and similar analysed as in (A). Grey bars (start point of culture at day 7): unexposed, 
open bars: air-exposed controls, black bars: CS-exposed cell cultures. Data are shown as target gene 
expression normalized for the geometric mean expression of the reference genes ATP5B, B2M and 
RPL13A; n=6 different donors. Statistical differences were evaluated using a two-way ANOVA and 
Bonferroni post-hoc test. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. 
 
Notch signalling inhibition impairs host defence protein expression during 
differentiation 
Our results so far showed an impaired end-stage differentiation into specialized 
luminal epithelial cells in CS-exposed cultures resulting in reduced levels of SLPI, 
sPLUNC, lPLUNC and pIgR. Previous studies have shown that Notch signalling is 
involved in airway epithelial differentiation and that the airway epithelium of 
smokers displays reduced Notch signalling(14). Therefore, we next examined if 
Notch signalling was impaired in CS exposed cultures, and if Notch signalling 
inhibition modulates HDP expression during differentiation. First, we assessed gene 
expression of components of the Notch signalling cascade and found that chronic 
CS exposure did not influence gene expression of Notch ligands, receptors or 
transcriptional co-activators in these cultures (Figure 7A). However, the Notch 
signalling target genes, HEY1 and HEY2, were significantly reduced by chronic CS 
exposure, while HES1 was not (Figure 7B), indicating that chronic CS exposure 





Figure 7. Chronic cigarette smoke exposure of air-liquid interface cultures of primary bronchial 
epithelial cells (ALI-PBEC) results in selective impairment of Notch signalling. (A) After 2 weeks of 
differentiation and daily cigarette smoke exposure, ALI-PBEC were lysed, RNA was isolated and cDNA 
synthesized. Subsequent qPCR analysis was performed on notch signalling ligands DLL1, JAG1 and 
JAG2, on Notch receptors 1-3 and on the transcriptional co-activators MAML1 and MAML3; data are 
shown as target gene expression normalized for the geometric mean expression of ATP synthase, H+ 
transporting, mitochondrial F1 complex, beta polypeptide (ATP5B), β2-microglobulin (B2M) and 
Ribosomal Protein L13a (RPL13A). Open circles: air-exposed controls (AIR), black circles: CS-exposed 
cell cultures (CS); n=8 different donors. (B) Subsequent qPCR analysis was performed on Notch 
signalling target genes HEY1, HEY2 and HES1. Data are shown as target gene expression normalized 
for the geometric mean expression of the reference genes ATP5B, B2M and RPL13A; n=8 different 
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donors. Statistical significance was tested using a two-way ANOVA and Bonferroni post-hoc test . ** 
p<0.01, *** p<0.001 between AIR and CS. 
 
To further investigate the importance of  Notch signalling in the expression of host 
defence proteins, we examined the effect of the γ–secretase inhibitor DAPT, which 
acts as an inhibitor of Notch signalling (Figure 8A). After 15 days of PBEC 
differentiation in the presence of DAPT, we measured expression of HDPs. DEFB1 
(hBD-1) and LCN2 were not affected by DAPT, while gene expression of SLPI, BPIFA1 
(sPLUNC), BPIFB1 (lPLUNC) and PIGR were strongly reduced by DAPT incubation 
(Figure 8B).  Furthermore, DAPT-exposed cultures showed a skewing of cell 
differentiation away from a secretory phenotype towards an increase in ciliated 







Figure 8. DAPT inhibits host defence protein expression in air-liquid interface cultures of primary 
bronchial epithelial cells (ALI-PBEC) (A) Mechanism of action of the Notch inhibitor DAPT, a γ-
secretase inhibitor that prevents proteolytic cleavage of the Notch intracellular domain (NCID). (B) 
PBEC were seeded on coated transwells and cultured in submerged conditions until confluent. At day 
0, cells were differentiated for an additional 15 days in the presence of 5 µM of the Notch signal 
transduction inhibitor DAPT in the basal medium or solvent as control. At day 0, 7, and 15 cells were 
lysed, RNA was isolated and cDNA synthesized. Subsequent qPCR analysis was performed to assess 
expression of respiratory defence proteins and epithelial cell-specific genes such as: DEFB1 (human 
beta defensin-1), SLPI (secretory leukocyte protease inhibitor), BPIFA1 (short palate, lung and nasal 
epithelium clone protein), BPIFB1 (long palate, lung and nasal epithelium clone protein), polymeric 
immunoglobulin receptor (PIGR) and LCN2 (lipocalin 2). Data are shown as target gene expression 
normalized for the geometric mean expression of the reference genes ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta polypeptide (ATP5B), β2-microglobulin (B2M) and Ribosomal Protein 
L13a (RPL13A); n=7 different donors. Statistical significance was tested using a two-way ANOVA and 
Bonferroni post-hoc test . ** p<0.01, *** p<0.001, **** p<0.0001 between CTRL and DAPT. (C) qPCR 
analysis was performed to assess mRNA expression of the epithelial cell markers SCGB1A1 (club cells), 
MUC5B (goblet cells), FOXJ1 (ciliated cells),  TP63 (basal cells), and cytokeratin-8 (KRT8) (intermediate 
cells) after 15 Days of differentiation with DAPT or solvent control, n=6 different donors. Statistical 
significance was tested using a paired t-test * p<0.05, ** p<0.01 between CTRL and DAPT (D) ALI-PBEC 
were differentiated for 15 Days with DAPT or solvent control. Subsequently the cells were fixed in 1% 
paraformaldehyde and stained using primary antibodies against CC16 (club cells), MUC5AC (goblet 
cells), and acetylated α-tubulin (ciliated cells), which are presented as a green staining; DAPI was used 
to stain the nuclei (blue staining). Scale bars equals 50 µm. Images shown are representative for 
results obtained with cells from 3 different donors.  
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Discussion 
Here we demonstrate that cigarette smoke negatively affects expression of the 
respiratory HDPs: pIgR, SLPI, lPLUNC and sPLUNC. Their expression was significantly 
reduced in epithelial cells daily exposed to CS during differentiation as a result of 
an impaired end-stage differentiation of specialized luminal cells. As a 
consequence, remodelling of the airway epithelium by cigarette smoke has a 
significant impact on respiratory host defence, underscored by the severely 
diminished IgA transport across the CS-exposed epithelium and impaired 
antibacterial defences against M. catarrhalis and K. pneumoniae. Our data suggest 
that increasing expression of specific respiratory HDPs (or preventing their 
decrease) could be of therapeutic interest to improve host defences in the lungs of 
COPD patients. Furthermore, this (selective) loss may also contribute to changes in 
lung microbiome composition, which is increasingly recognized as an important 
contributor to chronic inflammatory lung diseases(15, 16).  
The cellular composition of the ALI-PBEC cultures changed drastically upon chronic 
CS-exposure. While presence of intermediate CK-8+ cells (or also called early, 
intermediate or committed progenitor epithelial cells(13, 17)) was not affected by 
chronic CS exposure, the specialized luminal cell markers were reduced in chronic 
CS-exposed cultures. These results indicate that specifically end-stage 
differentiation seems impaired by CS exposure. The effects of chronic CS exposure 
were also observed when the cells were first allowed to differentiate for one week 
in absence of CS. Furthermore, upon cessation of CS exposure, gene expression of 
most luminal cell markers showed a strong recovery. In contrast, SCGB1A1 mRNA 
expression remained absent after almost 1 week of recovery, suggesting an 
exceptional detrimental effect of CS on club cell differentiation or the regulation of 
SCGB1A1 gene expression. This is underscored by a recent study showing that 
expression of the club cell-protein CC16 (SCGB1A1) is reduced in COPD patients and 
in CS-exposed mice. Loss of CC16 was correlated with increased severity of the 
disease and CS-induced pulmonary inflammation was lower in mice overexpressing 
CC16(18).  
Cytotoxicity is unlikely to have a major contribution to the CS-induced effects on 
the ALI-PBEC cultures since we detected no difference in trans-epithelial electrical 
resistance (TEER) as a measure of barrier function during the course of 
differentiation between CS and air-exposed controls. We previously observed 
transient decreases in TEER after acute single CS exposures, normalizing after 24 h 
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(11). In our chronic CS set-up we measured TEER 18-20h after the previous CS 
exposure, which may explain why we did not observe significant differences in TEER 
between air and CS-exposed cultures. Previous studies have shown decreases in 
TEER by CS, but often use cigarette smoke extract (CSE) and not whole CS (19, 20). 
CSE has a different composition and concentration than whole CS used in our study. 
In addition, in some studies CSE was added to the basal medium, resulting in 
stimulation from the basal side of the transwells  (19). This may also contribute to 
differences found in effects on TEER. Lastly, LDH release was not increased in our 
CS-exposed cultures, while cellular size appeared larger in the CS-exposed cultures 
for some donors. Finally, the CS-exposed cultures produced higher amounts of IL-8 
and displayed increased mRNA expression of the inducible antimicrobial peptides 
RNase7 and LL-37 (but not hBD-2). These results are described in the online data 
supplement and in sFigure 4 
Unexpectedly, we did not observe goblet cell hyperplasia in cultures that were 
exposed to CS, shown previously in smokers (21), guinea pigs (22), rats (23) and in 
cell lines (23, 24) or PBEC exposed to cigarette smoke extract (CSE)(19). However, 
Brekman et al. (25) also observed a decline in goblet cells markers in PBEC 
continuous exposed to CSE. Data are therefore conflicting and dependent on the 
type of cell culture used. Obviously, in our primary differentiated cultures,  whole 
CS exposure alone is insufficient to induce goblet cell hyperplasia within 19 days. 
We strongly consider that the findings in patients are more likely explained by a 
secondary effect of the CS-induced inflammation (which is obviously incompletely 
represented in our in vitro model). For example, neutrophil recruitment as a 
consequence of the CS-induced inflammation and subsequent release of proteases 
and other molecules, may help to explain goblet cell formation in patients. In 
addition, also the presence of other cell types besides neutrophils such as 
macrophages seem important for goblet cell hyperplasia. This has also been 
suggested in literature (26-29). Furthermore, several studies suggest that various 
other factors might have an important role in promoting goblet cell hyperplasia that 
are involved in COPD pathogenesis, including bacterial and viral infections (30, 31). 
Whereas previous studies have shown that CS reduces the presence of ciliated cells 
(19, 25, 32), so far CS-induced airway epithelial remodelling was not yet linked to 
changes in levels of the highly expressed respiratory HDPs, despite the fact that 
changes in expression in these proteins have been reported in smokers or patients 
with COPD. Aarbiou et al. showed that expression of SLPI was significantly reduced 
in damaged bronchial epithelium of COPD patients compared to non-COPD 
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individuals(33), and Gohy et al. showed reduced levels of pIgR in the lungs of 
patients with COPD, however not in smokers with a normal lung function compared 
to healthy controls(10). Finally, reduced levels of PLUNC were detected in bronchial 
brushes performed in current smokers compared to never smokers(34).  
We observed impaired anti-bacterial activity of the CS-exposed airway epithelial 
cultures against Moraxella catarrhalis and Klebsiella pneumoniae. We also 
evaluated direct anti-bacterial activity of the chronic CS-exposed cultures using a 
grid assay with live/dead staining of bacteria  (35, 36) and via conventional plating 
methods against Pseudomonas aeruginosa and non-typeable Haemophilus 
influenzae,, but could not detect any differences (data not shown). These data 
suggest that the observed CS-induced impairment of antimicrobial activity may be 
pathogen-specific, since it is not observed with all pathogens studied. In addition 
to impaired antibacterial host defence activities, the loss of HDP expression by the 
airway epithelium can have further negative effects for the host. For example, loss 
of SLPI expression (highly expressed in normal lung tissue) can promote 
inflammation in the lungs of patients with COPD. SLPI acts as an inhibitor of 
detrimental proteases such as neutrophil elastase, acts as an inhibitor of NFκB 
activation and it modulates macrophage functions(37-39). sPLUNC is involved in 
regulation of the epithelial sodium channel (ENaC), thereby regulating airway 
surface liquid (ASL), and reduced levels could result in lowered ASL volume and 
impaired mucociliary clearance(40).  
Since Notch signalling was previously reported to be impaired in COPD(14), we first 
analysed the effect of chronic CS exposure on components of the Notch signalling 
pathway and Notch target genes, and found that CS decreased the expression of 
selected Notch target genes. When we next used the Notch signalling inhibitor 
DAPT to inhibit airway epithelial cell differentiation, we found similar effects 
compared to CS exposure on expression of the selected set of respiratory HDPs. To 
our knowledge, this is the first study linking Notch signalling to expression of a 
range of host defence proteins that are increased upon differentiation. Whereas 
chronic CS exposure resulted in a reduction of all luminal-cell markers, DAPT-
exposed cultures showed higher levels of ciliated cells when compared to control-
treated cells, in line with previous studies(41, 42). These results suggest that 
expression of the luminal cell-restricted HDPs is confined to mature secretory 
epithelial cells, rather that the ciliated epithelium. Further studies using single cell 
RNA sequencing, may reveal whether the expression is restricted to a certain 
secretory cell phenotype. The partial similarity between the DAPT-incubated 
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cultures and the CS-exposed cultures suggests involvement of altered Notch 
signalling in the CS-induced effects. However, alterations in other signalling 
pathways might also be involved in the observed effects of CS, such as those 
involving EGFR(32), TGF-β(25) Wnt(43) and BMP(44). Most likely a more systems/-
omics approach has the potential to elucidate in detail all effects of chronic CS 
exposure on Notch and other signalling pathways(45). 
In summary, these findings shed new light on the role of dysregulated host defence 
in smokers and patients with COPD by highlighting the importance of airway 
epithelial cell differentiation in the expression of respiratory HDPs. Further 
investigations into how suppression of epithelial cell differentiation by cigarette 
smoke contributes to microbial colonization and infections of the airways are 
warranted in order to develop new therapeutics that restore airway epithelial host 
defence in patients with COPD. 
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Supplemental results 
Reduced respiratory host defence protein levels by chronic CS exposure 
are not a consequence of toxicity 
To exclude that possible toxic effects of the chronic CS exposure affected the 
observations we made, we performed a selection of additional experiments. We 
assessed trans-epithelial electrical resistance (TEER) of ALI-PBEC exposed to CS or 
air as a control: results showed that chronic CS-exposed ALI-PBEC displayed a slight 
but non-significant decrease of TEER in CS-exposed cultures in the first week of 
exposure, and a similar TEER as the air-exposed controls in the second week of 
exposure up until day 19  (sFigure 4A).  LDH levels in chronic CS-exposed cell 
cultures were not increased, but rather reduced compared to air-exposed cultures 
(sFigure 4B). Indirect evidence for absence of marked cytotoxicity was the 
observation that chronic CS exposure significantly increased secretion of the 
neutrophil-attracting chemokine IL-8 at 13 days of differentiation in CS-exposed 
cells compared to air-exposed controls (sFigure 4C). The cell size in chronic CS-
exposed cell cultures seemed bigger in some donors, but not all, compared to air-
exposed cultures, but no other morphological changes could be detected by 
microscopic inspection (an example illustrated in sFigure 4D). Together these data 
show that chronic CS-exposure-mediated loss of specific HDP expression by ALI-
PBEC is unlikely to be a result of toxicity. This conclusion is further supported by 
measurements on the expression of a selection of inducible HDPs. We previously 
reported induction of RNASE7 mRNA and protein in ALI-PBEC upon acute exposure 
to one cigarette (11), in line with these findings, chronic CS exposure also caused a 
progressive increase in RNASE7 compared to air-exposed controls (sFigure 4E). In 
addition also increased CAMP gene expression (LL-37-coding gene) was detected in 
chronic CS-exposed cultures (sFigure 4E). In contrast, we did not observe a 




sFigure 4. Chronic cigarette smoke exposure of airway epithelial cell cultures does not lead to cell 
toxicity.  Air-liquid interface cultures of primary bronchial epithelial cells (ALI-PBEC) were daily 
exposed to whole cigarette smoke (CS) or air as a control (AIR) during differentiation for 13-19 
consecutive days. (A) Each day trans-epithelial electrical resistance (TEER) measurements were 
performed ~18 h after the previous CS exposure. Data are expressed as Ω*cm2. Open circles: air-
exposed controls, black circles: CS-exposed cell cultures;  n=8 different donors. Significance was 
determined using a two-way ANOVA and Bonferroni post-hoc test. (B) At several time-points during 
differentiation apical washes were collected and assessed for LDH content. Open circles: air-exposed 
controls, black circles: CS-exposed cell cultures;  n=6 different donors. Statistical differences were 
evaluated using a two-way ANOVA and Bonferroni post-hoc test. * p<0.05, ** p<0.01 between AIR 
and CS. (C) At day 7 and Day 13 (~18 h after the last CS exposure), IL-8 protein levels were assessed 
by ELISA in the basal medium of the ALI-PBEC cultures. Open bars are air-exposed controls, grey bars 
are chronic CS-exposed cultures; n=8 different donors. Statistical differences were tested using a 
paired t-test. * p<0.05. (D) Illustrating phase contrast light microscopy images showing the increasing 
effects of 13 days of CS exposure (CS) or air as a control (AIR) on cell morphology in some donors. (E) 
At several time-points during differentiation, cells were lysed and RNA was isolated followed by cDNA 
synthesis, to assess gene expression of RNASE7, CAMP (LL-37) and DEFB4 (human beta defensin-2). 
Data are shown as target gene expression normalized for the geometric mean expression of the 
reference genes ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide (ATP5B), 
β2-microglobulin (B2M) and Ribosomal Protein L13a (RPL13A), n=8 different donors. Statistical 
differences were evaluated using a two-way ANOVA and Bonferroni post-hoc test. * p<0.05, ** 
p<0.01, *** p<0.001, **** p<0.0001 between AIR and CS. 
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sTable 1. Primer sequences. 
Gene forward sequence (5' to 3')  reverse sequence (5' to 3')  
ATP5B TCACCCAGGCTGGTTCAGA AGTGGCCAGGGTAGGCTGAT 
RPL13A AAGGTGGTGGTCGTACGCTGTG CGGGAAGGGTTGGTGTTCATCC 
B2M GACCACTTACGTTCATTGACTCC CAGGGTTTCATCATACAGCCAT 
DEFB1 ATGAGAACTTCCTACCTTCTGCT TCTGTAACAGGTGCCTTGAATTT 
SLPI CCA GGG AAG AAG AGA TGT TG CCT CCA TAT GGC AGG AAT C 
BPIFA1 CTTGGCCTTGTGCAGAGC CAACAGACTTGCACCGACC 
BPIFB1 CAGTGCCATGCGGGAAAAG GCTGGAGGATGTTAGCTGTGA 
PIGR CTCTCTGGAGGACCACCGT CAGCCGTGACATTCCCTG 
LCN2 CCTCAGACCTGATCCCAGC CAGGACGGAGGTGACATTGTA 
KRT5 AGGAGTTGGACCAGTCAACAT TGGAGTAGTAGCTTCCACTGC 
TP63 CCACCTGGACGTATTCCACTG TCGAATCAAATGACTAGGAGGGG 
KRT8 TCCTCAGGCAGCTATATGAAGAG GGTTGGCAATATCCTCGTACTGT 
FOXJ1        GGAGGGGACGTAAATCCCTA TTGGTCCCAGTAGTTCCAGC 
SCGB1A1 ACATGAGGGAGGCAGGGGCTC ACTCAAAGCATGGCAGCGGCA 
MUC5B GGGCTTTGACAAGAGAGT AGGATGGTCGTGTTGATGCG 
MUC5AC CCTTCGACGGACAGAGCTAC TCTCGGTGACAACACGAAAG 
JAG2 TGGGACTGGGACAACGATAC AGTGGCGCTGTAGTAGTTCTC 
DLL1 GACGAACACTACTACGGAGAGG AGCCAGGGTTGCACACTTT 
NOTCH1 GAGGCGTGGCAGACTATGC CTTGTACTCCGTCAGCGTGA 
NOTCH2 CCTTCCACTGTGAGTGTCTGA AGGTAGCATCATTCTGGCAGG 
NOTCH3 CGTGGCTTCTTTCTACTGTGC CGTTCACCGGATTTGTGTCAC 
NOTCH4 GATGGGCTGGACACCTACAC CACACGCAGTGAAAGCTACCA 
HES1 CCTGTCATCCCCGTCTACAC CACATGGAGTCCGCCGTAA 
HEY1 ATCTGCTAAGCTAGAAAAAGCCG GTGCGCGTCAAAGTAACCT 
JAG1 GCCGAGGTCCTATACGTTGC CCGAGTGAGAAGCCTTTTCAA 
MAML1 CCCCAGTGAGTCATTTCCTCT GAGGTTGCTTTGCGATATGGA 
MAML3 CTTAGGACCTCCCTCTAGTCCA GTTTTGGTTGTTAAAGGCTTGGG 
RNASE7 CCAAGGGCATGACCTCATCAC ACCGTTTTGTGTGCTTGTTAATG 
DEFB4 ATCAGCCATGAGGGTCTTG GCAGCATTTTGTTCCAGG 





sTable 2. Antibodies used for confocal imaging 
Antibody Supplier Catalog # Species   Antibody 
dilution 
CK-8               Novus 
Biologicals 
NBP2-34266 mouse  1/100 
pIgR R&D Systems MAB27171 mouse  1/100 
p63 Abcam  ab124762 rabbit  1/100 
sPLUNC  Hycult Biotech HM2314                 mouse  1/100 
SLPI   Hycult Biotech HM2037                 mouse  1/100 
Mucin 5AC     Labvision 
Neomarkers 
MS-145-P1 mouse  1/1000 
CC16 Hycult Biotech HM2178                 mouse 1/50 
Acetylated  
α-Tubulin    
Sigma Aldrich T6793 mouse 1/100 
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sFigure 1. Details of the cigarette smoke exposure design and procedure. Approximately 4 h before 
the cigarette smoke exposure, the apical surface of the cell cultures were washed with PBS and every 
other day the basal medium was replaced. Next, the cells were placed in the exposure chamber and 
the lid was removed. The closed exposure chamber was then infused with cigarette smoke from 1 
cigarette for 4-5 min, or normal air in the control chamber. Hereafter, the tubing from the cigarette is 
clamped and vents on the exposure chamber connecting to the space in the incubator are opened 
and the air is refreshed with air from the incubator for an additional 10 min. The smoke-containing air 
is removed via separate tubing outside the incubator into a fume hood. After the exposure and 
refreshing, the chamber is opened, the lid placed back on the cells and the cells are placed back in a 





sFigure 2. Expression of respiratory host defence proteins in the luminal cell fraction of air-liquid 
interface-differentiated primary bronchial epithelial cells (PBEC). PBEC were seeded on coated 
transwells and cultured in submerged conditions until confluent. At day 0, cultures were air-exposed 
and cultured at the air-liquid interface (ALI). After 3 weeks of differentiation, luminal and basal cell 
fractions were separated. Cells were fixed in 1% paraformaldehyde and cytospins were prepared of 
the luminal cell enriched fraction. Luminal cell cytospins and the basal cell enriched fraction located 
on the transwell inserts were subsequently stained using immunofluorescence with primary 
antibodies against p63 (basal cell marker, red) in combination with primary antibodies against SLPI, 
sPLUNC, CC16 and acetylated α-tubulin (all green) and DAPI for nuclear staining (blue). Scale bars 
equal 50 µm. Images shown are representative for results obtained with cells from 3 different donors. 
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sFigure 3. Persistence of cigarette smoke-induced changes in airway epithelial HDP expression and 
cellular composition. (A) Primary bronchial epithelial cells (PBEC) were cultured at the air-liquid 
interface (ALI) and exposed during differentiation for 13 consecutive days to whole CS after which 
cultures were continued for another 6 days without CS exposure. Cells were lysed at several points 
during this course of time and RNA was isolated followed by cDNA synthesis, to assess gene expression 
of the cell specific markers: TP63, KRT5 (basal cells) and KRT8 (intermediate cells), the HDPs: DEFB1 
(human beta-defensin 1) and LCN2 (lipocalin 2). Open bars: air-exposed controls (AIR), black bars: CS-
exposed cell cultures (CS), grey bars: CS-exposed cultures that were cultured for an additional week 
without CS exposure (CS cessation). Data are shown as target gene expression normalized for the 
geometric mean expression of the reference genes ATP synthase, H+ transporting, mitochondrial F1 
complex, beta polypeptide (ATP5B), β2-microglobulin (B2M) and Ribosomal Protein L13a (RPL13A); 
n=8 different donors. Statistical differences were evaluated using a two-way ANOVA and Bonferroni 
post-hoc test. * p<0.05, **** p<0.0001. (B) ALI-PBEC were air exposed at day 0 and cultured for 7 days 
under standard conditions. At day 7 cultures were exposed to CS for 12 consecutive days after which 
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the cells were lysed and similar analyzed as in (A). Grey bars: T=0 (day 7), open bars: air-exposed 
controls (AIR), black bars: CS-exposed cell cultures (CS). Data are shown as target gene expression 
normalized for the geometric mean expression of the reference genes ATP5B, B2M and RPL13A. n=6 
different donors. Statistical differences were evaluated using a two-way ANOVA and Bonferroni post-
hoc test. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.  
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The airway epithelium is an important site for local vitamin D (VD) metabolism and 
this can be negatively affected by inflammatory mediators. VD is an important 
regulator of respiratory host defence e.g. by increasing expression of hCAP18/LL-
37. TGF-β1 is increased in COPD (chronic obstructive pulmonary disease) and 
known to decrease expression of constitutive host defence mediators such as 
secretory leukocyte protease inhibitor (SLPI) and polymeric immunoglobulin 
receptor (pIgR). VD has been shown to affect TGF-β1-signalling by inhibiting TGF-
β1-induced epithelial-to-mesenchymal transition. However, interactions between 
VD and TGF-β1, relevant for understanding host defence in COPD, are incompletely 
understood. Therefore, the aim of the present study was to investigate combined 
effects of VD and TGF-β1 on airway epithelial cell host defence mechanisms. 
Exposure to TGF-β1 reduced both baseline and VD-induced expression of 
hCAP18/LL-37, partly by increasing expression of the VD-degrading enzyme 
CYP24A1. TGF-β1 alone decreased the number of secretory club- and goblet cells 
and reduced expression of the constitutive host defence mediators SLPI, s/lPLUNC 
and pIgR, effects that were not modulated by VD. These results suggest that TGF-
β1 may decrease respiratory host defence both directly by reducing expression of 
host defence mediators, and indirectly by affecting VD-mediated effects such as 





Patients with chronic obstructive pulmonary disease (COPD) suffer more frequently 
from respiratory infections than ex- or non-smokers and this may contribute to 
exacerbations and to further progression of the disease (1, 2). This increased 
susceptibility to infections can be explained by impaired mucociliary clearance and 
decreased host defence (3), that may in part result from persistent exposure to 
cigarette smoke (CS) or to other noxious gases (4-6). The airway epithelium serves 
as the front line in the lung’s host defence by preventing microbes to enter the 
tissue and bloodstream. Its contribution to this important function is mediated by 
a combination of mechanisms including (but not limited to) the maintenance of a 
physical barrier supported by its tight- and adherens junctions, mucociliary 
clearance, and secretion of both inducible and constitutively expressed host 
defence peptides and proteins (HDPs), reactive oxygen- and nitrogen species, 
interferons, chemokines and cytokines (7). In addition to broad-spectrum 
antimicrobial activity, HDPs also have the ability to modulate immune responses 
and promote wound repair (8). Under homeostasis, inducible HDPs such as human 
β-defensin-2 and hCAP18/LL-37 are expressed at low levels and their expression 
can be increased upon e.g. activation of pattern recognition receptors (9), cytokine 
and growth factor receptors, and by other mediators such as vitamin D (VD), 
whereas constitutively expressed HDPs do not require such stimuli for their 
expression (9-11).  
Whereas VD is classically known for its function in the regulation of calcium 
homeostasis and bone metabolism, multiple studies have shown that it also acts as 
an important regulator of host defence and immunity, including respiratory host 
defence (12, 13). This was supported by two clinical trials that showed that VD 
supplementation reduces the exacerbation rate in VD-deficient COPD patients (14, 
15) and a recent meta-analysis that demonstrated that VD supplementation 
protects against acute respiratory tract infections (16). Various mechanisms may 
contribute to this protective effect of VD, including direct effects such as VD-
mediated increases of hCAP18/LL-37, and/or indirect effects via promotion of CFTR 
expression or its ability to reduce oxidative stress (11, 17-19). In the airway 
epithelium, the main circulating form of VD (25(OH)D3) is hydroxylated to generate 
the active form of VD (1,25(OH)2D3) by α1-hydroxylase (CYP27B1) (20). Next, 
1,25(OH)2D3 binds the nuclear VD receptor (VDR) and heterodimerizes with the 
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retinoic acid receptor to interact with VD response elements to initiate gene 
expression of more than 900 genes, including CYP24A1, which converts both 
25(OH)D3 and 1,25(OH)2D3 into inactive metabolites (12, 21). The airway epithelium 
is an important site of local VD metabolism and we and others have shown that the 
expression or the activity of CYP27B1, CYP24A1 and VDR can be modulated by 
several inflammatory mediators such as TNF-α/IL-1β, IL-17A, nontypeable 
Haemophilus influenzae (NTHi), IL-13, the viral analogue poly(I:C) and CS, which all 
have been implicated in the pathogenesis of chronic inflammatory lung diseases (5, 
20, 22, 23).  
Studies in prostate cancer- and stromal cells and hepatocytes suggest that the 
positive effects of VD might be modulated by TGF-β1 (24, 25). This may be relevant 
for COPD, since elevated levels of TGF-β1 expression were found in the airways of 
COPD patients (26-28), although this was not shown by all studies (29). TGF-β1 is a 
multifunctional cytokine that is produced and activated upon injury, through CS-
exposure or by inflammation (30-33). When this injury persists, continued release 
of TGF-β1 contributes to tissue remodelling, a process that may be driven in part 
by epithelial-to-mesenchymal transition (EMT) (34). Several studies have shown 
that VD might counteract TGF-β1-mediated effects on fibrosis, as demonstrated by 
its ability to inhibit TGF-β1-induced EMT in both mouse models of asthma and 
fibrosis and in airway epithelial cell lines (17, 35-37). In addition to its role in fibrosis 
and EMT, TGF-β1 affects respiratory host defence by impairing anti-viral interferon 
type I and III responses, but also by restricting expression of constitutively 
expressed host defence mediators such as SLPI and pIgR (31, 32, 38, 39).  
Despite this insight into the role of TGF-β1 in the pathogenesis of COPD and other 
chronic inflammatory lung disease, it is not known whether exposure to TGF-β1 also 
affects respiratory host defence by affecting VD-metabolism and VD-mediated 
expression of the HDP hCAP18/LL-37. Moreover, it is currently unknown whether 
VD modulates TGF-β1-mediated repression of constitutively expressed HDPs. We 
therefore aimed to study the interaction between VD and TGF-β1 on airway 
epithelial cell host defence mechanisms. To this end, we first investigated the 
effects and underlying mechanisms of TGF-β1 on VD-metabolism and on VD-
mediated hCAP18/LL-37 expression. Next, we studied effects of VD on TGF-β1-
induced changes in epithelial composition and on expression of a group of 
constitutively expressed host defence mediators, as well as on antibacterial activity. 
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Materials and Methods 
 
Primary bronchial epithelial cell (PBEC) culture 
PBEC were obtained from tumour free bronchial lung tissue from anonymous 
donors that was collected during lung resection surgery for lung cancer at LUMC. 
Cells were cultured as previously described with some adaptations (5, 40). Briefly, 
cultures of bronchial epithelial cells (passage 1) were first expanded in T75 culture 
flasks, pre-coated with a mixture of 30 μg/ml Purecol (Advanced BioMatrix, San 
Diego, CA), 5 μg/ml stabilized fibronectin (Alfa Aesar, Thermo Fisher scientific, 
Landsmeer, The Netherlands) and 10 μg/ml BSA (Sigma Aldrich, Zwijndrecht, The 
Netherlands). Next, cells were seeded at a density of 5000 cells per well for 
submerged cultures of (S)-PBEC or 40,000 cells per insert (passage 2) on pre-coated 
24-well plates (Corning Costar, Cambridge, MA) and on semi-permeable Transwell 
inserts respectively (12 mm, 0.4 μm pore-size, Corning Costar). The cells were 
cultured in BEpiCM-b:DMEM (B/D)-medium (1:1) (ScienCell Research Laboratories, 
Uden, The Netherlands and STEMCELL technologies, Kӧln, Germany respectively), 
supplemented with Bronchial Epithelial Cell Growth Supplement (ScienCell 
Research Laboratories), and additional 1 nM EC-23 (Tocris, Bio-techne Ltd, 
Abington, UK) (for the submerged phase of PBEC cultures on inserts only), 25 mM 
HEPES (Cayman Chemical, Hamburg, Germany), 100 U/ml penicillin and 100 µg/ml 
streptomycin (ScienCell Research Laboratories). After cells growing on inserts had 
reached confluence (after 5-7 days), apical medium was removed and the cells were 
cultured at the air-liquid interface (ALI) and medium was changed 3 times a week 
with (B/D)-medium supplemented with Bronchial Epithelial Cell Growth 
Supplement and additional 50 nM EC-23. During refreshment, the apical surface 
was washed with PBS to remove mucus. After 14 days of air-exposed culture, the 
cells produced mucus and had developed cilia, and cultures were used for 
experiments. S-PBEC were cultured until they reached 50-70% confluence after 4-5 
days and next cultured for 24 h in B/D-medium supplemented with Bronchial 
Epithelial Cell Growth Supplement without BSA, BPE, EGF and hydrocortisone 
before stimulation (B/D-starvation medium). 
Experimental design  
PBEC that had been differentiated for 14 days at the ALI, were exposed to various 
concentrations of TGF-β1 (0.2, 1 and 5 ng/ml) and 100 nM 25(OH)D3 and/or 
1,25(OH)2D3 (Millipore B.V., Amsterdam, The Netherlands) for 24 h to assess 
3
TGF-β1 impairs vitamin D-induced and constitutive airway epithelial host defence mechanisms
61
changes in gene expression, or for 48 h to assess SLPI levels in apical washes, airway 
epithelial antibacterial activity and hCAP18/LL-37 release by Western blot or 
immunofluorescence. S-PBEC cultures were used to elucidate the mechanism of 
action of TGF-β1-reduced expression of hCAP18/LL-37. To assess the role of TGF-
β1-mediated induction of CYP24A1 or canonical TGF-β1-Smad signalling, S-PBEC 
were treated with 5 ng/ml TGF-β1 and 100 nM 1,25(OH)2D3 in presence or absence 
of 10 μM TGF-β1-Smad signalling inhibitor SB431542 (Sigma-Aldrich) or 10 μM of 
the antifungal ketoconazole (KTZ) that acts as an inhibitor of cytochrome P-450 
(CYP) (Sigma-Aldrich) for 24 h. 
Silencing of C/EBP-α using siRNA transfection  
S-PBEC were used to determine if the TGF-β1-reduced expression of hCAP18/LL-37 
was mediated by the transcription factor CCAAT/enhancer-binding protein-α 
(C/EBP-α). S-PBEC were refreshed with B/D-starvation medium containing 5 ng/ml 
TGF-β1 and 100 nM 1,25(OH)2D3 and transfected using 3 μl/well RNAiMAX 
SilentFect tranfection reagent (Thermo Fisher scientific) containing 20 mM CEBPA- 
or negative control- siRNA (Ambion, Thermo Fisher scientific) and incubated for 24 
h.  
RNA Isolation, reverse transcription (RT) and quantitative (q)PCR   
Cells were lysed in RNA lysis buffer (Promega Benelux B.V., Leiden, The 
Netherlands). Total RNA was robotically extracted using the Maxwell tissue RNA 
extraction kit (Promega) and quantified using the Nanodrop ND-1000 UV-Vis 
Spectrophotometer (Nanodrop technologies, Wilmington, DE). For cDNA synthesis, 
1 µg of total RNA was reverse transcribed using oligo dT primers (Qiagen Benelux 
B.V., Venlo, The Netherlands) and M-MLV Polymerase (Thermo Fisher scientific) at 
42° C. All qPCR reactions were performed in triplicate on a CFX-384 Real-Time PCR 
detection system (Bio-Rad Laboratories, Veenendaal, The Netherlands), using 
primers shown in table I and IQ SYBRGreen supermix (Bio-Rad). The relative 
standard curve method was used to calculate arbitrary gene expression using CFX-
manager software (Bio-Rad). Two reference genes, selected using the “Genorm 
method” (Genorm, Primer design, Southampton, UK), were included to calculate 





Table I.  PCR primers and sequences used for quantitative PCR 
*Used as a reference gene, selected using the Genorm method 
 
Western blot  
For Western blot analysis of hCAP18/LL-37 release, basal medium was applied to 
Oasis HLB 1cc extraction cartridges (Waters Chromatography, Etten-Leur, The 
Netherlands) and the eluate was dried by vacuum centrifugation (CHRIST RVC2-25 
Vacuüm system) (41). Lyophilized protein samples were resuspended in 100 µl 
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reducing SDS-PAGE sample buffer, heated for 5 minutes at 100° C and applied on a 
16.5% Tris-Tricine gel as previously described (5). Next, proteins were blotted on a 
Polyvinylidene fluoride (PVDF) membrane and non-specific binding sites were 
blocked in PBS containing 5% (v/v) heat-inactivated new born calf serum, 5% (w/v) 
skimmed milk in PBS. Membranes were probed with 1/200 diluted mouse 
monoclonal anti-hCAP18/LL-37 (clone 1.1.C12; Hycult Biotech, Uden, The 
Netherlands) in blocking buffer. Next, the membranes were incubated in 1/1000 
diluted rabbit-anti-mouse-HRP (Cell Signaling Technology, Leiden, The Netherlands) 
in blocking buffer. SuperSignal West Pico ECL Substrate (Thermo Fisher scientific) 
was used to visualize hCAP18/LL-37 protein using The ChemiDoc™ Touch imager in 
combination with Image Lab™ software (Biorad).  
Immunofluorescence staining of CYP24A1, SLPI, sPLUNC and pIgR 
Cells were fixed on Transwell inserts in 1% paraformaldehyde (Millipore B.V.) in PBS 
for 10 minutes on ice and washed with ice-cold PBS. Next, cells were permeabilized 
with methanol for 10 minutes at 4° C, washed in PBS and blocked with PBS/1% (w/v) 
BSA/0.3% (v/v) Triton-X-100 (PBT) for 30 minutes at 4° C. Next, cells were treated 
for 30 minutes with SFX-signal enhancer (Thermo Fisher scientific) followed by 
incubation with primary antibodies in PBT for 1 h at RT (table II). After washing in 
PBS, cells were incubated with an Alexa Fluor 488 labeled secondary antibody 
(1/200, Alexa Fluor 488 goat anti-rabbit IgG; Thermo Fisher scientific) and Alexa 
Fluor 568 goat anti-mouse IgG together with DAPI (Sigma Aldrich) in PBT for 30 
minutes at RT in the dark. Finally, cells were mounted in ProLong™ Gold Antifade 
Mountant (Thermo Fisher scientific) and images were acquired using a TCS SP5 
Confocal Laser Scanning Microscope (Leica Microsystems B.V., Eindhoven, The 
Netherlands) and LAS AF Lite software (Leica Microsystems B.V.). 
Antibody Supplier Catalog # species Antibody dilution 
CYP24A1 Sigma HPA022261 rabbit 1/100 
pIgR R&D Systems MAB27171 mouse 1/50 
P63 Abcam ab124762 rabbit 1/100 
P63 Leica NCL-P63 mouse 1/100 
sPLUNC Hycult Biotech HM2314 mouse 1/100 
SLPI Hycult Biotech HM2037 mouse 1/100 
Mucin 5AC Labvision Neomarkers MS-145-P1 mouse 1/1000 
CC16 Hycult Biotech HM2178 mouse 1/50 




Apical washes were obtained by washing the apical surface of the stimulated ALI-
PBEC with 200 μl warm PBS for 10 minutes at 37⁰ C. SLPI in apical washes of the 
treated ALI-PBEC was measured using an ELISA as previously described (42).  
Antibacterial activity assay  
Antibacterial activity was assessed by applying log-growing cultures of nontypeable 
Haemophilus influenzae (NTHi) on the apical surface of the treated cells as 
previously described with a few modifications (40). NTHi strain D1 was cultured in 
Tryptone soya broth containing X and V-factor (TSB XV, Mediaproducts BV, 
Groningen, the Netherlands) while shaking overnight at 37⁰ C (2). Next, 2 ml of the 
overnight culture was transferred into fresh 10 ml TSB XV medium and incubated 
for 4 h at 37° C while shaking to obtain mid log phase growing bacteria. Before 
applying the washed bacterial suspensions to the apical surface of ALI-PBEC, excess 
mucus was removed by washing both treated and untreated cells with 200 µl 10 
mM sodium phosphate buffer (NaPB) for 15 minutes at 37ᵒ C 6 h before the assay. 
We applied approximately 1 multiplicity of infection (MOI) NTHi in 20 μl NaPB + 1% 
v/v TSB XV per insert for 2 h. Next, membranes containing the cells with bacteria 
were dissected from the inserts and placed into tubes containing sterile glass beads 
and 1% TSB in PBS and cells were disrupted by using a Minilys personal 
homogenizer (Bertin Instruments, Montigny-le-Bretonneux, France) for 2 times 30 
seconds and kept on ice between treatments. Serial dilutions of bacterial 
suspensions were plated on chocolate agar plates (Biomerieux, Zaltbommel, The 
Netherlands), and incubated overnight at 37° C to assess surviving bacteria by 
colony forming unit (CFU) determination. 
Statistical analysis 
Statistical analysis was conducted using GraphPad Prism 7 (GraphPad Software Inc., 
La Jolla, CA, U.S.A.). To analyse qPCR results, fold change in gene expression of the 
stimuli compared to control (CNTRL) was first calculated, followed by log-
transformation. All data were analysed using a two-way ANOVA and the Bonferroni 
post-hoc test. Differences at p values < 0.05 were considered statistically 
significant.  
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TGF-β1 impairs baseline and vitamin D-induced expression and release of 
hCAP18/LL-37 in differentiated primary bronchial epithelial cells 
We have previously shown that exposure to pro-inflammatory stimuli impairs VD-
induced expression and release of the HDP hCAP18/LL-37 in differentiated ALI-PBEC 
(43). To investigate if TGF-β1 also affects expression of the VD-responsive HDP 
hCAP18/LL-37 (CAMP), we exposed differentiated ALI-PBEC to various 
concentrations of TGF-β1 for 24-48 h in presence and absence of 25(OH)D3 (this 
inactive form of VD is converted in PBEC by CYP27B1 into active 1,25(OH)2D3)). We 
first confirmed that both 25(OH)D3 and 1,25(OH)2D3 clearly increased expression of 
CAMP mRNA in ALI-PBEC after 24-48 h of incubation (Figure 1A). TGF-β1 dose-
dependently limited the VD-increased expression of CAMP at both time points, 
whereas all concentrations of TGF-β1 also decreased baseline expression of CAMP 
after 24 h and - only at the highest dose - after 48 h (Figure 1A). To verify TGF-β1-
mediated repression of CAMP at the protein level, we exposed ALI-PBEC to the 
highest dose TGF-β1 (5 ng/ml) in presence and absence of 25(OH)D3 and/or 
1,25(OH)2D3 for 48 h, and assessed hCAP18/LL-37 secretion in basal medium using 
Western blot analysis. Using Western blot analysis, both 1,25(OH)2D3 and 25(OH)D3 
clearly increased release of hCAP18/LL-37 in basal medium, which was reduced by 
TGF-β1, in line with gene expression data (Figure 1B). These data demonstrate that 
TGF-β1 interferes with baseline and VD-mediated signalling, resulting in reduced 




Figure 1.  TGF-β1 impairs baseline and vitamin D-induced expression and release of hCAP18/LL-37 
in primary bronchial epithelial cells (PBEC). PBEC were differentiated at the air-liquid interface (ALI) 
followed by 24-48 h stimulation with TGF-β1 with or without inactive 25(OH)D3, active 1,25(OH)2D3 
or medium control (CNTRL) to determine mRNA expression of CAMP (hCAP18/LL-37) by qPCR (A), and 
cells were stimulated for 48 h to assess release of hCAP18/LL-37 by Western blot analysis (B). (A) 
Relative mRNA expression of CAMP was determined by qPCR. Normalized gene expression was 
calculated by using the expression of tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein zeta (YWHAZ) and ribosomal protein L27 (RPL27) as reference genes. Fold change 
in gene expression of 25(OH)D3 and 1,25(OH)2D3 compared to CNTRL was first calculated, followed by 
a log-transformation of the data. To assess effects of different doses of TGF-β1 on CAMP expression 
in 25(OH)D3, 1,25(OH)2D3 and CNTRL-treated cells, fold change for each group was calculated 
separately. Data are presented as individual values, including means ± SEM and were tested for 
significance using the two-way ANOVA and the Bonferroni post-hoc test (n = 6 donors). (B) Tris-Tricine 
gel electrophoresis, followed by Western blot analysis was used to detect hCAP18/LL-37 production 
in basal medium. Nasal secretion was used as positive control to show both intact hCAP18 peptide 
and cleaved mature LL-37 peptide at 18 and 4.5 kDa respectively. Western blots are a representative 
of 4 different donors. The image was cut to include the image of the nasal secretion. *** p < 0.001, 
**** p < 0.0001. 
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TGF-β1 affects the vitamin D-metabolic pathway 
To investigate if the effects of TGF-β1 on VD-mediated expression of hCAP18/LL-37 
were mediated by changes in the VD-metabolic pathway, we assessed the effects 
TGF-β1 on the expression of the VD-degrading enzyme CYP24A1, the VD-activating 
enzyme CYP27B1 and the VD receptor (VDR). ALI-PBEC were exposed to various 
concentrations of TGF-β1 for 24–48 h in presence and absence of 25(OH)D3 and 
1,25(OH)2D3. As expected, both forms of VD increased CYP24A1 expression (Figure 
2A left side) compared to control treated cells. In absence of VD, TGF-β1 markedly 
increased CYP24A1 expression, and even caused a small further increase in 
presence of both forms of VD (Figure 2A). Furthermore, we also observed a minor 
dose-dependent change in VDR expression and no effect of TGF-β1 on the 
expression of CYP27B1 (Figure 2A). To verify these effects of TGF-β1 on CYP24A1 at 
the protein level, we performed immunofluorescence staining using CYP24A1 
antibodies and confirmed the ability of TGF-β1 to increase CYP24A1 expression at 
the protein level in presence and absence of 1,25(OH)2D3 (Figure 2B). Together 
these data indicate that TGF-β1 affects VD-metabolism by increasing expression of 





Figure 2.  TGF-β1 affects the vitamin D-metabolic pathway in primary bronchial epithelial cells 
(PBEC). PBEC were differentiated at the air-liquid interface (ALI) followed by 24 h stimulation with 
TGF-β1 in presence or absence of 25(OH)D3, 1,25(OH)2D3 or medium control (CNTRL) to assess mRNA 
expression of the vitamin D (VD)-degrading enzyme (CYP24A1), VD receptor (VDR) and the VD-
activating enzyme (CYP27B1) by qPCR (A). In addition, cells were stimulated with TGF-β1 with or 
without 1,25(OH)2D3 or medium control (CNTRL) for 48 h to assess expression of CYP24A1 by 
immunofluorescence (B). (A) Relative mRNA expression of CYP24A1, VDR and CYP27B1 was 
determined by qPCR. Normalized gene expression was calculated by using the expression of tyrosine 
3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) and ribosomal 
protein L27 (RPL27) as reference genes. To determine effects of 25(OH)D3 and 1,25(OH)2D3 on 
CYP24A1 expression, fold change in gene expression was first calculated, followed by a log-
transformation of the data. Furthermore, effects of different doses of TGF-β1 on CYP24A1, VDR and 
CYP27B1 expression were determined by calculating the fold change relative to the corresponding 
control without TGF-β1 (CNTRL, 25(OH)D3 or 1,25(OH)2D3). Data are presented as individual values, 
including means ± SEM and were tested for significance using the two-way ANOVA and the Bonferroni 
post-hoc test (n = 6 donors). (B) Cells were stimulated for 48 h to assess expression of CYP24A1 and 
basal cells (P63) by confocal immunofluorescence staining (data of 1 donor are shown, similar findings 
in 3 other donors). DAPI (blue) was used to stain the nuclei together with antibodies detecting 
CYP24A1 (green) and P63 (red). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
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Effects of inhibition of CYP24A1 activity and canonical TGF-β-Smad 
signalling on the expression of hCAP18/LL-37 (CAMP) and CYP24A1 
We used S-PBEC to further elucidate the underlying mechanisms of TGF-β1-
mediated decreases of hCAP18/LL-37 and increases of CYP24A1 (Figure 3A-B), after 
observing that modulation of CAMP and CYP24A1 expression by TGF-β1 was similar 
in S-PBEC and ALI-PBEC (data not shown). We first investigated if the TGF-β1-
mediated repression of VD-induced hCAP18/LL-37 was fully mediated by increases 
of CYP24A1 expression. To this end, S-PBEC were exposed for 24 h to TGF-β1 and 
1,25(OH)2D3 in presence or absence of the CYP-inhibitor ketoconazole (KTZ) that is 
known to inhibit CYP24A1 and CYP27B1 activity (44, 45). To circumvent the effect 
of KTZ-mediated inhibition of the CYP27B1-mediated hydroxylation of inactive 
25(OH)D3 into active 1,25(OH)2D3, we used only 1,25(OH)2D3 in these experiments. 
Whereas KTZ significantly increased 1,25(OH)2D3-mediated expression of CAMP in 
both presence and absence of TGF-β1, CAMP levels were lower in 1,25(OH)2D3-
treated cells in presence of TGF-β1 than in absence of TGF-β1 (Figure 3A). This 
suggests that the VD-mediated reduction of CAMP by TGF-β1 was not fully 
explained by increased CYP24A1, suggesting involvement of mechanisms other 
than the VD-metabolic pathway in the observed effects of TGF-β1.  
In addition to VD-mediated expression of CAMP, the baseline expression of CAMP 
was also reduced by TGF-β1 and this could not be restored by inhibition of CYP24A1 
(Figure 3A). TGF-β1 signals through either the canonical-Smad signalling pathway 
or the non-canonical (MAPK/NF-ƘB)-pathway (46). To investigate if the canonical 
TGF-β-Smad signalling pathway was involved in the inhibition of baseline CAMP 
expression as well as the increase in CYP24A1, we exposed S-PBEC to TGF-β1 and 
1,25(OH)2D3 in presence or absence of SB431542 (an inhibitor of TGF-β type I 
receptor activin receptor-like kinase (ALK5) and further downstream signalling i.e. 
via receptor regulated (R)-Smads) (46). We found that treatment with SB431542 
fully reversed the effects of TGF-β1 on both CAMP and CYP24A1 expression both in 
absence or in presence of 1,25(OH)2D3 (Figure 3B). These results indicate that the 
canonical TGF-β-Smad signalling pathway mediates the reduction of CAMP and the 




Figure 3.  Effects of inhibition of CYP24A1 activity and canonical TGF-β-Smad signaling on expression 
of hCAP18/LL-37 (CAMP) and CYP24A1 in primary bronchial epithelial cells (PBEC). Semi-confluent 
layers of submerged (S)-PBEC were cultured in starvation medium overnight and subsequently 
exposed to the cytochrome P-450 (CYP)-inhibitor ketoconazole (KTZ)  (A) or to the canonical TGF-β-
Smad signaling-inhibitor SB421543 (B) in presence or absence of TGF-β1 and 1,25(OH)2D3, or medium 
control (CNTRL) for 24 h to assess mRNA expression of CAMP (hCAP18/LL-37) and the vitamin D-
degrading enzyme (CYP24A1) by qPCR. Relative mRNA expression of CAMP and CYP24A1 was 
determined by qPCR. Normalized gene expression was calculated by using the expression of tyrosine 
3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) and ribosomal 
protein L27 (RPL27) as reference genes. To determine effects of the stimuli, fold change in gene 
expression compared to CNTRL was first calculated, followed by a log-transformation of the data. Data 
are presented as individual values, including means ± SEM and were tested for significance using the 
two-way ANOVA and the Bonferroni post-hoc test (A, n = 4 donors; B, n = 6-10 donors). ** p < 0.01, 
*** p < 0.001, ****/#### p < 0.0001. 
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TGF-β1 decreases expression of CAMP via the transcription factor CCAAT 
enhancer binding protein (C/EBP)α 
In addition to VD-responsive elements (VDREs) that bind the VDR-RXR-1,25(OH)2D3-
complex, the promotor of CAMP also contains a binding site for the transcription 
factor C/EBPα, which was shown to be required for induction of CAMP independent 
of VD (47). A Study by Li et al. showed that TGF-β-Smad signalling inhibits the 
expression of C/EBPα mRNA in mesenchymal stem cells (48), which suggests 
involvement of C/EBPα in the suppressive effect of TGF-β1 on CAMP expression. 
We first demonstrated that TGF-β1 also reduced C/EBPα mRNA (CEBPA) expression 
in S-PBEC after 24 h (Figure 4A). To investigate the involvement of C/EBPα in 
baseline and VD-induced CAMP expression we used siRNA. S-PBEC were 
transfected with CEBPA-specific siRNA or negative control siRNA and next cells 
were exposed to TGF-β1 and 1,25(OH)2D3 for 24 h. siRNA caused a marked 
suppression of CEBPA expression, and both basal- and 1,25(OH)2D3-mediated 
expression of CAMP was reduced (Figure 4B).  The siRNA induced reductions in both 
CEBPA and CAMP expression were more pronounced in TGF-β1-treated cells (Figure 
4B). We next measured expression of CYP24A1, to exclude possible non-specific 
effects of CEBPA siRNA transfection. Unexpectedly, CYP24A1, a gene without any 
known binding sides for C/EBPα in its promotor, was also decreased (Figure 4B). 
Since the CYP24A1-promotor does contain binding sides for C/EBPβ (CEBPB) (49), 
we considered the possibility that CEBPA siRNA also had reduced CEBPB mRNA 
levels. We therefore assessed expression of CEBPB and found that this was not 
affected, suggesting that inhibition of C/EBPα might have indirectly affected 
expression of CYP24A1 (Figure 4B). Collectively, these data show that TGF-β1-
mediated changes in CAMP or CYP24A1 expression are mediated through 




Figure 4.  TGF-β1 decreases expression of the CAMP-transcription factor CCAAT enhancer binding 
protein (C/EBP)α in primary bronchial epithelial cells(PBEC). Semi-confluent cultures of submerged 
(S)-PBEC were cultured in starvation medium overnight and subsequently exposed to TGF-β1 or 
medium control (CNTRL) for 24 h to assess mRNA expression of C/EBP)α (CEBPA) by qPCR (A). PBEC 
were refreshed with starvation medium containing medium alone (CNTRL) or TGF-β1 with and without 
1,25(OH)2D3 and subsequently transfected with CEBPA siRNA for 24 h. Scrambled siRNA was used as 
a control (CNTRL siRNA). mRNA expression of CEBPA, CAMP (hCAP18/LL-37), the vitamin D-degrading 
enzyme (CYP24A1) and C/EBP)β (CEBPB) was assessed by qPCR (B). Relative mRNA expression was 
determined by qPCR. Normalized gene expression was calculated by using the expression of tyrosine 
3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) and ribosomal 
protein L27 (RPL27) as reference genes. To determine effects of the stimuli, fold change in gene 
expression compared to CNTRL was first calculated, followed by a log-transformation of the data. Data 
are presented as individual values, including means ± SEM and were tested for significance using the 
two-way ANOVA and the Bonferroni post-hoc test (A, n= 10 donors; B, n = 4 donors). * p < 0.05, ** p 
< 0.01, *** p < 0.001, ****/#### p < 0.0001. 
 
Effect of TGF-β1 on the expression of constitutively expressed luminal cell-
restricted host defence mediators 
Since we demonstrated reduced expression levels of the inducible HDP hCAP18/LL-
37 in the presence of VD and TGF-β1, we were next interested to investigate 
whether a similar decrease was also observed in expression of constitutively 
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expressed host defence mediators such as the HDP SLPI and pIgR, since previous 
studies showed that were repressed by TGF-β1 alone in ALI-PBEC (31, 50). 
Investigating effects of the combination of TGF-β1 and VD is especially relevant, 
since VD reduces the effects of TGF-β1-mediated EMT in airway epithelial cell lines 
(35). We therefore investigated in ALI-PBEC if VD affected the TGF-β1-induced 
repression of a selected group of constitutively expressed host defence mediators 
such as SLPI, s/lPLUNC and pIgR. To this end, differentiated ALI-PBEC were exposed 
to both TGF-β1 and 1,25(OH)2D3 for 24-48 h and expression of these mediators was 
assessed. TGF-β1 decreased the expression of all four selected HDPs after 24 h 
(Figure 5A) and which continued up to 48 h (data not shown). However, 
1,25(OH)2D3 did not prevent the TGF-β1-meditiated repression of mRNA expression 
of these constitutively expressed HDPs (Figure 5A). We additionally verified these 
effects of TGF-β1 at the protein level using confocal immunofluorescence, and 
using ELISA to detect SLPI in apical secretions (Figure 5B-C). TGF-β1-treatment 
reduced both the staining intensity as well as the number of SLPI- and sPLUNC-
positive cells, whereas only the number of pIgR-positive cells was reduced upon 
TGF-β1-treatment. In cultures from some donors, pIgR was relocated from the cell 




Figure 5.  Effect of TGF-β1 on expression of constitutively expressed luminal cell-restricted host 
defence proteins (HDPs) in primary bronchial epithelial cells (PBEC). PBEC were differentiated at the 
air-liquid interface (ALI) followed by stimulation for 24 h with TGF-β1 in presence or absence of 
1,25(OH)2D3 and medium control (CNTRL) to assess mRNA expression of secretory leukocyte protease 
inhibitor (SLPI), short- and long- Palate, lung, and nasal epithelium clone protein (PLUNC) (BPIFA1 and 
BPIFB1 respectively) and polymeric immunoglobulin receptor (PIGR) by qPCR (A). In addition, cells 
were stimulated for 48 h to assess expression of these HDPs by confocal immunofluorescence (SLPI, 
sPLUNC and pIgR) and the apical side of the inserts were washed in PBS to assess release of SLPI by 
ELISA (B). A. Relative mRNA expression of  SLPI, BPIFA1, BPIFB1 and PIGR was determined by qPCR. 
Normalized gene expression was calculated by using the expression of tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) and ribosomal 
protein L27 (RPL27) as reference genes. Fold changes in gene expression of the stimuli compared to 
control (CNTRL) were first calculated, followed by a log-transformation of the data. Data are presented 
as individual values, including means ± SEM and were tested for significance using the two-way 
ANOVA and the Bonferroni post-hoc test (n = 6 donors). (B) Confocal immunofluorescence staining of 
HDPs and basal cells in ALI-PBEC (of 1 donor, which was confirmed in 3-5 other donors), DAPI (blue) 
was used to stain the nuclei and antibodies (table II) were used for detection of HDPs (green) and 
basal cells (P63, red) respectively. C. Analysis of SLPI in apical wash by ELISA. Data are presented as 
individual values, including mean ± SEM and were tested for significance using the two-way ANOVA 
and the Bonferroni post-hoc test (n = 6 donors). * p < 0.05, *** p < 0.001, **** p < 0.0001. 
 
We furthermore investigated functional consequences of the reduced expression 
of the HDPs by TGF-β1 in presence and absence of VD by studying effects of TGF-
β1 and VD on antibacterial activity. Differentiated ALI-PBEC were exposed to TGF-
β1 for 48 h in presence and absence of 1,25(OH)2D3 and a killing assay was 
performed by applying log-growing NTHi on the apical surface of 48 h-exposed cells 
for 2 h. The cell lysates were next diluted and incubated on agar plates overnight 
to determine surviving bacteria. In contrast to what we previously observed using 
a different type of antibacterial assay (5), we found that treatment with 
1,25(OH)2D3 did not increase antibacterial activity against NTHi. Although not 
significant, there was a small trend towards reduction of antibacterial activity by 












Figure S1.  Effects of TGF-β1 on antibacterial activity in differentiated bronchial epithelial cells 
(PBEC). PBEC were differentiated at the air-liquid interface (ALI) followed by stimulation for 48 h with 
TGF-β1 with or without 1,25(OH)2D3 or medium control (CNTRL) to assess antibacterial activity by 
applying log-growing cultures of nontypeable Haemophilus influenzae (NTHi) on the apical surface of 
the treated cells for 2 h. Next, membranes containing the cells with bacteria were dissected from the 
inserts and mechanically disrupted. Serial dilutions of bacterial suspensions were plated on chocolate 
agar plates and incubated overnight at 37° C to assess surviving bacteria by CFU determination. Data 
are presented as means ± SEM % surviving bacteria compared to medium control stimulated cells 
(CNTRL) and were tested for significance using the two-way ANOVA and the Bonferroni post-hoc test 
(n = 9 donors). 
 
TGF-β1 modulates epithelial differentiation 
To investigate whether the ability of TGF-β1 to reduce expression and release of 
the constitutively expressed HDPs SLPI, s/lPLUNC and pIgR was explained by TGF-
β1-induced changes in epithelial differentiation, effects on differentiation markers 
were assessed. These experiments were prompted by our recent finding that 
chronic exposure to CS also impairs expression and release of these HDPs, 
accompanied by an impairment of end-stage airway epithelial cell differentiation 
towards club- and goblet cells, being the main source of these HDPs (40). 
Furthermore it was shown that TGF-β1 directs epithelial cells to dedifferentiate and 
we therefore investigated if specialized epithelial cells were reduced by TGF-β1 and 
if VD might counteract this reduction (51). We therefore exposed differentiated 
ALI-PBEC to TGF-β1 and 1,25(OH)2D3 for 24-48 h and indeed observed that TGF-β1 
caused a clear reduction in both mRNA expression of the club- and goblet cell 
markers SCGB1A1 and CLCA1 respectively as well as in the number of CC16 (club 
cell) and MUC5AC (goblet cell)-positive cells, observed by confocal 
























as well the number of ciliated cells were unaffected by TGF-β1 (Figure 6 A-B). 
1,25(OH)2D3 alone did not affect mRNA or protein expression of these cell markers, 
and did not prevent the TGF-β1-induced decreases in SCGB1A1 and CLCA1 mRNA 
(Figure 6A; immunofluorescence data not shown). This indicates that TGF-β1 
impairs expression of luminal expressed HDPs by reducing the number of secretory 
cells that express these HDPs, which is not modulated by VD. 
 
 
Figure 6.  TGF-β1 affects composition of airway epithelium by decreasing the number of secretory 
epithelial cells in primary bronchial epithelial cells (PBEC). PBEC were differentiated at the air-liquid 
interface (ALI) followed by stimulation for 24 h with TGF-β1 in presence or absence of 1,25(OH)2D3 or 
medium alone (CNTRL) to assess mRNA expression of markers related to ciliogenesis (FOXJ1), club 
cells (SCGB1A1) and goblet cells (CLCA1) by qPCR (A). In addition, cells were stimulated for 48 h to 
assess the numbers of ciliated-, club- and goblet cells by confocal immunofluorescence (B). (A) 
Relative mRNA expression of FOXJ1, SCGB1A1 and CLCA1 was determined by qPCR. Normalized gene 
expression was calculated by using the expression of tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein zeta (YWHAZ) and ribosomal protein L27 (RPL27) as reference 
genes. Fold changes in gene expression of the stimuli compared to control (CNTRL) were first 
calculated, followed by a log-transformation of the data. Data are presented as individual values, 
including means ± SEM and were tested for significance using the two-way ANOVA and the Bonferroni 
post-hoc test (n = 6 donors). (B) Confocal immunofluorescence staining of ciliated- (α-tubulin), club- 
(CC-16), goblet (MUC5AC) and basal cells (P63) in ALI-PBEC (of 1 donor, which was confirmed in 3 
other donors), DAPI (blue) was used to stain the nuclei and antibodies (table II) were used for 
detection of luminal cell markers (green) and basal cells (P63, red) respectively. ** p < 0.01, *** p < 
0.001. 
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Here we demonstrate that TGF-β1 affects VD-metabolism by increasing expression 
of the VD-degrading enzyme CYP24A1 and reduces VD-mediated expression of the 
HDP hCAP18/LL37 in both submerged undifferentiated PBEC and in differentiated 
ALI-PBEC. Moreover, TGF-β1 also reduces baseline expression of hCAP18/LL-37 via 
its ability to reduce expression of C/EBPα. In fully differentiated ALI-PBEC, TGF-β1 
represses expression of constitutively expressed HDPs such as SLPI, s/lPLUNC and 
pIgR, which might in part be attributed to decreases in the number of secretory 
club- and goblet cells. Treatment with VD did not counteract these effects of TGF-
β1 on HDP expression and epithelial differentiation.  
To the best of our knowledge, we are the first to show that TGF-β1 affects vitamin 
D-metabolism by increasing expression of the VD-degrading enzyme CYP24A1, 
although an earlier study using hepatic cells did show an association between 
CYP24A1 and TGF-β1 expression (24). The involvement of CYP24A1 in the TGF- β1 
induced decrease in VD-mediated expression of hCAP18/LL-37 was confirmed by 
inhibiting its activity by KTZ. Since KTZ inhibits also other CYP-enzymes such as 
CYP27B1, we used 1,25(OH)2D3 to avoid the inhibitory effects of KTZ on the 
conversion of 25(OH)D3 into 1,25(OH)2D3 by CYP27B1. These TGF-β1-mediated 
effects on CYP241 help to explain the inhibitory effects of TGF-β1 on VD-induced 
expression of hCAP18/LL-37 in both undifferentiated and differentiated PBEC. We 
observed no changes in CYP27B1 expression and minor changes in VDR expression 
after TGF-β1 treatment, whereas a study in colon cancer cells showed that VDR 
expression was repressed by Snail1 and Snail2 that are known TGF-β1-inducible 
transcription factors (52). Previous to our findings, Kulkarni et al. demonstrated 
that TGF-β1 reduces baseline expression as well as phenylbutyrate-mediated 
increases in CAMP mRNA expression in a bronchial epithelial cell line, which was 
reversed by SB421543, an inhibitor of the canonical TGF-β-Smad signalling pathway 
(53). In line with this, we confirmed that SB421543 also reduced the TGF-β1-
mediated increase in CYP24A1 expression. Furthermore, VD-mediated expression 
of CAMP was even further enhanced when SB421543 was added, suggesting that 
VD-mediated CAMP expression was negatively affected by endogenous TGF-β 
activity. We examined the underlying mechanisms of TGF-β1-mediated inhibition 
of baseline CAMP expression and demonstrated that TGF-β1 repressed mRNA 
expression of the transcription factor C/EBPα (CEBPA). We furthermore 
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demonstrated the relevance of this transcription factor by inhibition of CEBPA using 
siRNA, which resulted in a decrease of CAMP. TGF-β1 further repressed expression 
of CEBPA and CAMP in siRNA treated cells. The importance of C/EBPα in the VD-
independent induction of hCAP18/LL-37 (CAMP) expression was previously 
demonstrated by Park and colleagues in keratinocytes (47). Unexpectedly, siRNA-
mediated inhibition of CEBPA also inhibited expression of CYP24A1. By excluding 
the possibility that CEBPB was also targeted by siRNA, we conclude that CYP24A1 
expression may have been indirectly affected by TGF-β1.  
In addition to alterations in VD-metabolism and effects, TGF-β1 was also found to 
reduce the number of luminal secretory cells, possibly via initiation of EMT, and 
impaired expression of constitutively expressed HDPs SLPI and pIgR, which is in line 
with previous findings (31, 39, 50). We are however the first to report that TGF-β1 
decreases expression of the constitutively expressed HDP s/lPLUNC. We have 
recently demonstrated that expression of these constitutively expressed host 
defence mediators was also impaired following chronic CS-exposure, which was 
accompanied by a selective reduction of differentiation into specialized airway 
epithelial cells (40). Since CS-exposure is also known to increase expression of TGF-
β1 in airway epithelial cells (30, 31), we consider the possibility that the CS-induced 
repression of constitutive expressed HDPs in airway epithelial cells is in part 
mediated via the induction of TGF-β1. Interestingly and in line with our finding that 
TGF-β1 decreases the number of club- and goblet cells, Gohy et al. reported 
correlations between a TGF-β1-mediated decrease of pIgR, epithelial 
dedifferentiation and increased expression of mesenchymal markers (31). It is 
important to consider that TGF-β1 only alters differentiation markers at 
concentrations above 0.5 ng/ml, as shown by Harrop et al (54). Additionally, they 
demonstrated that expression of MUC5AC and MUC5B in differentiated PBEC was 
decreased by TGF-β2, which is another TGF-β-isoform and uses the same receptors 
(54). In contrast to other studies showing inhibition of TGF-β1-mediated effects on 
EMT by VD (35, 36), we have not observed any ameliorating effects of VD on TGF-
β1-mediated effects on expression of SLPI, s/lPLUNC and pIgR, nor on expression of 
secretory cell markers. This may be explained by the fact that we used 
differentiated primary airway epithelial cells, where VD-activity may be more 
efficiently inhibited by TGF-β1, or by the possibility that autocrine expression or 
processing of secreted immature TGF-β1 might be more efficient in differentiated 
primary epithelial cells than in bronchial epithelial cell lines. The underlying 
mechanism for this difference needs to be further elucidated, for example by 
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comparing CYP24A1 levels, autocrine production of TGF-β1, expression of TGF-β-
receptors or extracellular activation of TGF-β1 between cell lines and differentiated 
primary cells.  
One of the strengths of this study is that we used differentiated primary airway 
epithelial cells that were obtained from multiple donors, instead of tumour-derived 
or immortalized airway epithelial cell lines, thereby increasing the relevance of our 
findings. It needs to be noted that PBEC used in this study were not derived from 
healthy donors, but from healthy parts of lung tissue derived from patients who 
often have smoked and underwent lung resection surgery for lung cancer. 
However, we have previously demonstrated that these cells differentiate into 
ciliated-, club and goblet cells similar to healthy individuals, develop a strong 
epithelial barrier and that expression of constitutively expressed HDPs and airway 
epithelial differentiation between donors with and without COPD do not differ in 
our hands (40). This was in contrast to the findings by Gohy and colleagues, who 
showed that features of EMT persist in PBEC derived from COPD patients (51), most 
likely as they used material from patients with more severe stages of COPD. 
This study also has a few limitations. First, we were not able to detect hCAP18/LL-
37 peptide in apical washes of the stimulated PBEC using Western blot analysis, 
which is in line with our previous study (5). Therefore, we used pooled and 
concentrated basal medium and in line with our previous report detected a 
hCAP18/LL-37 immunoreactive peptide at the size of 14 kDa, and did not detect the 
4.5 kDa mature antimicrobial peptide LL-37. Levels of this peptide were increased 
by VD and reduced by TGF-β1. Another limitation of this study is that we were not 
able to fully confirm TGF-β1-mediated decreases in HDPs at the functional level by 
measuring antibacterial activity against NTHi. As hCAP18/LL-37, SLPI and s/lPLUNC 
also have other activities such as anti-biofilm, immunomodulatory and anti-
protease activities in addition to their antibacterial activities (55-57), a more 
complex culture model using a combination of immune cells and airway epithelial 
cells might be relevant as an alternative approach to establish the consequences of 
these changes on host defence.  
To extend the relevance of our findings to the situation in vivo, further studies are 
required to compare lung tissue levels of CYP24A1, 1,25(OH)2D3 and expression of 
these HDPs in healthy donors and donors with chronic inflammatory lung disease 
or fibrosis. We showed that TGF-β1 reduces the number of club cells, which is in 
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line with observations in diseases associated with both elevated TGF-β1-levels and 
reduced numbers of club cells such as COPD, asthma and bronchiolitis obliterans 
syndrome (46, 58, 59). A contribution of TGF-β1 to the pathogenesis of COPD is 
supported by findings of two studies showing that TGF-β1 levels correlated with 
disease severity and airflow limitation in COPD patients (27, 60). In addition, TGF-
β1 expression was higher in airway epithelium of smokers with COPD compared to 
smokers without COPD (26, 27). To date, no treatment is available for COPD 
patients that selectively targets the harmful effects of TGF-β1, without affecting 
beneficial effects of TGF-β1. Clinical trials that investigated the use of global 
inhibitors of TGF-β signalling in oncology or in idiopathic pulmonary fibrosis (IPF) 
showed that these compounds are frequently associated with adverse (health) 
effects and limited clinical benefit (61). Drugs such as pirfenidone that block 
downstream TGF-β pathways without affecting the immune system, might be a 
better approach and showed promising results in clinical trials in IPF (61, 62). Our 
study additionally suggests that vitamin D is not a candidate to ameliorate the 
negative effects TGF-β1 on airway host defence.  
In conclusion, we have shown that TGF-β1 reduces host defence of airway epithelial 
cells by impair  ring VD-mediated expression of HDPs as well as constitutively 
expressed luminal HDPs such as SLPI and s/lPLUNC and pIgR. We have additionally 
shown that TGF-β1 reduces the number of secretory club- and goblet cells, which 
might have additional consequences for host defence. We furthermore conclude 
that TGF-β1 reduces VD-mediated expression of hCAP18/LL-37 via a dual 
mechanism: directly by reducing expression of an important transcription factor for 
hCAP18/LL-37 and indirectly via increasing of CYP24A1 that promotes degradation 
of VD. These findings may have implications our understanding of the role of TGF-
β1 in COPD by extending the range of mechanisms affected by TGF-β1. 
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Abstract 
 
Vitamin D is a regulator of host defense against infections and induces expression 
of the antimicrobial peptide hCAP18/LL-37. Vitamin D deficiency is associated with 
chronic inflammatory lung diseases and respiratory infections. However, it is 
incompletely understood if and how (chronic) airway inflammation affects vitamin 
D metabolism and action. We hypothesized that long-term exposure of primary 
bronchial epithelial cells (PBEC) to pro-inflammatory cytokines alters their vitamin 
D metabolism, antibacterial activity and expression of hCAP18/LL-37. To investigate 
this, PBEC were differentiated at the air-liquid interphase for 14 days in presence 
of the pro-inflammatory cytokines TNF-α and IL-1β (TNF-α/IL-1β), and subsequently 
exposed to vitamin D (inactive 25(OH)D3 and active 1,25(OH)2D3). Expression of 
hCAP18/LL-37, vitamin D receptor (VDR) and enzymes involved in vitamin D 
metabolism (CYP24A1 and CYP27B1) was determined using qPCR, Western blot and 
immunofluorescence staining. Furthermore, vitamin D-mediated antibacterial 
activity was assessed using non-typeable Haemophilus influenzae (NTHi). We found 
that TNF-α/IL-1β treatment reduced vitamin D-induced expression of hCAP18/LL-
37 and killing of NTHi. In addition, CYP24A1 (a vitamin D-degrading enzyme) was 
increased by TNF-α/IL-1β, whereas CYP27B1 (that converts 25(OH)D3 to its active 
form) and VDR expression remained unaffected. Furthermore, we demonstrated 
that the TNF-α/IL-1β–mediated induction of CYP24A1 was at least in part mediated 
by the transcription factor specific protein 1 (Sp1) and the EGFR-MAPK-pathway. 
These findings indicate that TNF-α/IL-1β decreases vitamin D-mediated 
antibacterial activity and hCAP18/LL-37 expression via induction of CYP24A1, and 






Our respiratory tract is continuously exposed to microbes and microbial products. 
The airway epithelium serves as the front line of host defense in the lung by 
preventing those microbes to enter the tissue and bloodstream. Airway epithelial 
host defense is mediated by the physical barrier provided by tight- and adherens 
junctions, mucociliary clearance and a variety of other mechanisms, including 
secretion of antimicrobial peptides and proteins (AMPs), reactive oxygen- and 
nitrogen species, interferons, chemokines and cytokines (1). Impairment of this 
host defense activity of airway epithelial cells might contribute to chronic 
inflammatory lung diseases such as asthma, chronic obstructive pulmonary disease 
(COPD) and cystic fibrosis (CF) (1). Various studies have demonstrated an 
association between low serum 25(OH)vitamin D3 (25(OH)D3)-levels and severity 
and/or prevalence of these chronic inflammatory lung diseases (2-4). These findings 
suggest a role for vitamin D in chronic lung diseases. Reduced levels of vitamin D 
could further aggravate host defense and inflammation in these conditions as 
vitamin D exerts a range of anti-inflammatory activities, including immune 
modulation, inhibition of oxidative stress, remodeling and enhancement of 
antimicrobial activity (2-4). In airway epithelial cells, vitamin D promotes host 
defense in the lung by enhancing the killing of pathogens and by modulation of 
immune responses (3, 4). This is to some extent mediated via expression of the 
cathelicidin antimicrobial peptide hCAP18/LL-37, whose precursor hCAP18 is 
cleaved by proteases into the 4.5 kD LL-37 mature peptide that displays both 
antimicrobial and immunomodulatory properties (5-7). This relation was confirmed 
by several studies that have revealed an important role for vitamin D in regulating 
hCAP18/LL-37 expression in e.g. macrophages and epithelial cells (7-9). 
The main circulating form of vitamin D is 25(OH)D3, which requires hydroxylation 
by α1-hydroxylase (CYP27B1) in the kidney or locally in tissues and immune cells for 
conversion into the active form of vitamin D3 (1,25(OH)2D3). This active form binds 
to the nuclear vitamin D receptor (VDR) which subsequently heterodimerizes with 
the retinoic acid receptor to interact with vitamin D response elements (VDREs). 
VDREs are present in the promoter region of more than 900 vitamin D-regulated 
genes (10), including CAMP, which encodes for hCAP18/LL-37. Vitamin D also 
promotes its own catabolism by inducing CYP24A1, which converts both 25(OH)D3 
and 1,25(OH)2D3 into inactive 24,25(OH)2D3 and 1,24,25(OH)2D3 (11). The 
inactivation by CYP24A1 plays a critical role in the availability of active vitamin D, 
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and overexpression of this enzyme might therefore contribute to impaired vitamin 
D availability. 
It remains however unclear whether modulation of the activity of airway epithelial 
cells due to airway inflammation contributes to an impairment of vitamin D-
induced defense mechanisms in chronic inflammatory lung diseases. It has been 
shown that pro-inflammatory mediators can alter the expression of CYP27B1, 
CYP24A1 and VDR in extra-renal cells (8, 9, 12-15). Increased local levels of pro-
inflammatory cytokines and other mediators, as well as microbes are indeed 
present in the airways of patients suffering from chronic inflammatory lung 
diseases (16-20). We hypothesized that chronic exposure of airway epithelial cells 
to pro-inflammatory cytokines alters both the metabolism and antimicrobial 
responses of these cells to vitamin D. To investigate this, we used cultures of 
primary bronchial epithelial cells (PBEC), which were differentiated in presence and 
absence of the pro-inflammatory cytokines TNF-α and IL-1β and subsequently 
treated with vitamin D. Next we assessed expression and release of hCAP18/LL-37 
and bactericidal activity against non-typeable Haemophilus influenzae [NTHi, a 
Gram-negative bacterium, which is found in the lungs of COPD, CF and (refractory) 
asthma patients (21, 22)]. Furthermore, effects of TNF-α and IL-1β and also of other 
pro-inflammatory mediators such as IL-17A and NTHi on the expression of vitamin 
D-metabolic enzymes CYP24A1, CYP27B1, and of VDR were also investigated. 
Finally, we assessed the signaling mechanisms underlying the modified vitamin D 
metabolism in PBEC cultures.  
Materials and Methods 
 
Cell culture 
PBEC were obtained from tumor-free bronchial lung tissue from anonymous 
donors, collected during lung resection surgery for lung cancer. Cells were cultured 
at the air-liquid interface (ALI) as described in the online data supplement.  
Experimental design  
To assess the effects of the combination of TNF-α and IL-1β (TNF-α/IL-1β), or IL-17A 
on PBEC, cells were cultured for 14 days in presence or absence of 2.5 ng/ml TNF-
α/IL-1β (Peprotech, Rocky Hill, NJ) or 5 ng/ml IL-17A (R&D Systems, Abingdon, UK) 
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at the ALI . At day 14, cells in presence or absence of 2.5 ng/ml TNF-α/IL-1β or 5 
ng/ml IL-17A were exposed to 10-7 M 25(OH)D3 (Merck), 10-9 M 1,25(OH)2D3 (Merck) 
for 24 h to assess gene expression, or for 48 h to assess antibacterial activity, 
hCAP18/LL-37 release, protein expression by Western blot or immunofluorescence. 
In experiments using the specificity protein 1 (Sp1) inhibitor mithramycin A (R&D 
Systems) and the CYP24A1 inhibitor ketoconazole (Sigma Aldrich), ALI-PBEC were 
cultured in presence or absence of TNF-α/IL-1β for 14 days and subsequently 
stimulated for 24 h with 3 x 10-7 M mithramycin A or 10-7, 10-6 and 10-5 M 
ketoconazole. To investigate effects of short-term exposures to NTHi, 
differentiated ALI-PBEC were exposed to UV-inactivated NTHi for 12 h. 
Submerged undifferentiated cultures of PBEC were used to elucidate the 
mechanism of action of TNF-α/IL-1β-induced expression of CYP24A1. Cells were 
cultured in supplemented-BEGM:DMEM until a confluence of 70% was reached and 
cultured overnight in starvation medium (BEGM:DMEM, w/o EGF, BPE and BSA), 
pre-incubated for 1 hour with 2.5 x 10-5 M GM6001 (matrix metalloprotease [MMP] 
inhibitor; Millipore B.V., Amsterdam, The Netherlands), 1 x 10-6 M AG1478 
(epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor; Millipore B.V.), 
2.5 x 10-5 M U0126 (MEK inhibitor; Promega, Leiden, The Netherlands) and 
stimulated with 10 ng/ml TNF-α/IL-1β for 15 min for collection of protein lysates, 
and 24 h for gene expression analyses. For the assessment of protein lysates by 
Western blot, 25 µg/ml synthetic LL-37 was included as a positive control (23).  
RNA Isolation, reverse transcription (RT) and quantitative (q)PCR   
Methods for total RNA isolation, reverse transcription and qPCR reactions (primers 
shown in table I) are described in the online data supplement.  
Preparation of UV-inactivated NTHi 
NTHi strain D1 was cultured and killed by UV-inactivation as described in the online 
data supplement.  
Bacterial killing assay  
Killing of NTHi by ALI-PBEC was assessed as described by Pezzulo et al. (24) with a 
few modifications as described in the online data supplement.  
Western blot  
Methods for Western blot analysis are described in the online data supplement.  
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Immunofluorescence staining of LL-37 and CYP24A1  
Cells were fixed on Transwell inserts in 1% paraformaldehyde (Merck) in PBS for 10 
min on ice and washed with ice-cold PBS. Next, cells were stained as described in 
the online data supplement. 
Statistical analysis    
Statistical analysis was conducted as described in the online data supplement. Data 
are shown as medians ± min/max values. Differences at p values < 0.05 were 




TNF-α/IL-1β decreases vitamin D-mediated expression and release of 
hCAP18/LL-37 
To determine if chronic exposure to pro-inflammatory cytokines affects cellular 
responses to vitamin D, we exposed PBEC to the pro-inflammatory cytokines TNF-
α/IL-1β during differentiation, followed by 25(OH)D3-treatment or control 
(medium) in presence or absence of TNF-α/IL-1β (Figure 1A). 25(OH)D3 increased 
expression of CAMP (hCAP18/LL-37) mRNA in well-differentiated PBEC after 24 h of 
incubation by 15.1-fold. Moreover, in presence of TNF-α/IL-1β, expression of CAMP 
was 5.2-fold increased by 25(OH)D3, which was significantly less compared to 
control treated cells (p < 0.0001, Figure 1B). We further confirmed these findings at 
the protein level after 48 h 25(OH)D3 exposure by immunofluorescence staining, 
which demonstrated that 25(OH)D3-induced hCAP18/LL-37 was decreased in TNF-
α/IL-1β-treated cells (Figure 1C), and by Western blot analysis showing that both 
25(OH)D3 and 1,25(OH)2D3-induced hCAP18/LL-37 release in basal medium was 




Figure 1.  TNF-α and IL-1β (TNF-α/IL-1β) decreases 25(OH)D3-mediated expression and release of 
hCAP18/LL-37 in primary bronchial epithelial cells (PBEC) (A) PBEC were seeded on Transwell inserts 
and cultured for 5-7 days until confluence was reached. Subsequently PBEC were cultured at the air-
liquid interface (ALI) and exposed with and without TNF-α/IL-1β for 14 days followed by 24 h 
stimulation with 25(OH)D3 or medium control (CNTRL) for assessing CAMP (hCAP18/LL-37) expression 
by qPCR. In addition, cells were stimulated for 48 h to assess release of hCAP18/LL-37 by Western blot 
analysis (1,25(OH)2D3 was included as an additional stimulation) and immunofluorescence. (B) 
Relative mRNA expression of CAMP was determined by qPCR. Normalized gene expression was 
calculated by using the expression of the β2-microglobulin (B2M) and ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta polypeptide (ATP5B) as reference genes. Data are presented as 
medians ± min/max values. Fold change in gene expression of the stimuli compared to control (CNTRL) 
was first calculated, followed by a log-transformation of the data. Next, data were analyzed using two-
way ANOVA and the Bonferroni post-hoc test (n = 11 donors) and differences between CNTRL and 
25(OH)D3 ratios were calculated in CNTRL and TNF-α/IL-1β-treated cells using a paired t-test (C) 
Immunofluorescence staining of hCAP18/LL-37 in bronchial epithelial cells (of 1 donor, which was 
confirmed in 3 other donors), DAPI (blue) was used to stain the nuclei and rabbit anti-LL-37 antibody 
together with Alexa Fluor 488 goat anti-rabbit IgG (green) were used for detection of hCAP18/LL-37. 
(D) Tris-Tricine gel electrophoresis, followed by Western blot analysis in combination with a LL-37 
specific mouse antibody was used to detect hCAP18/LL-37 production in basal medium of the exposed 
cells. Nasal secretion was used as positive controls to show intact hCAP18 peptide at 18 kDa. Western 
blots are a representative of 3 independent experiments using 6 different donors. The image was cut 
to switch sample order for increased consistency. ### p < 0.001, *** p < 0.001, **** p < 0.0001. 
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TNF-α/IL-1β impairs 25(OH)D3-mediated killing of NTHi by ALI-PBEC 
Previous studies have reported that vitamin D treatment induces antibacterial 
activity of bronchial epithelial cells (14, 25). We therefore investigated whether 
TNF-α/IL-1β modulated the vitamin D-induced antibacterial activity of ALI-PBEC. 
First, ALI-PBEC were differentiated in presence of TNF-α/IL-1β and subsequently 
stimulated with 25(OH)D3 or 1,25(OH)2D3 for 48 h (as indicated in Figure 1A). 
Bacterial killing activity was determined against the respiratory pathogen NTHi 
(Figure 2A). We observed that killing of NTHi was higher in cells stimulated with 
25(OH)D3 and 1,25(OH)2D3 compared to unstimulated controls, and that this effect 
was decreased by TNF-α/IL-1β (Figure 2B). This suggests that in addition to reducing 
hCAP18/LL37, chronic exposure to TNF-α/IL-1β also decreases vitamin D-induced 
antibacterial activity of ALI-PBEC.   
 
 
Figure 2.  TNF-α and IL-1β (TNF-α/IL-1β) impairs vitamin D-mediated killing of non-typeable 
Haemophilus influenzae (NTHi). Primary bronchial epithelial cells (PBEC, n = 6 donors) were 
differentiated with and without TNF-α/IL-1β for 14 days followed by 48 h 25(OH)D3- and 1,25(OH)2D3 
treatment or medium control (CNTRL) in duplicate for assessing antibacterial activity of PBEC. (A) This 
was performed by binding biotin-linked mid-log phase growing NTHi to streptavidin-linked 6 mm glass 
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coverslips followed by application on the apical surface for 1 min of the stimulated cells. Next, 
coverslips were mounted on slides and visualized using SYTO9 (live + dead bacteria) and PI (dead 
bacteria) and quantified by using fluorescent microscopy. ML = mucus layer, PCL = periciliary liquid 
layer. (B) The percentage of dead bacteria was assessed by manual counting and data are presented 
as medians ± min/max values. To analyze the data, a two-way ANOVA and the Bonferroni post-hoc 
test was used. * p < 0.05, ** p < 0.01, *** p < 0.001.  
 
Elevated CYP24A1 levels induced by chronic exposure of ALI-PBEC to TNF-α/IL-1β 
decrease vitamin D-mediated expression of hCAP18/LL-37 
We determined whether alterations in 25(OH)D3-induced responses by TNF-α/IL-
1β were caused by changes in expression of genes important in vitamin D 
metabolism (CYP27B1 and CYP24A1) or VDR. Cells were cultured as previously 
indicated (Figure 1A) and assessed for mRNA expression of VDR, CYP27B1 and 
CYP24A1. Expression of the vitamin D degrading enzyme CYP24A1 was increased 
after both treatment with TNF-α/IL-1β and 25(OH)D3 with no changes in expression 
of VDR and CYP27B1 (Figure 3A). Western blot analysis showed that CYP24A1 was 
strongly increased by TNF-α/IL-1β-treatment and only modestly by 25(OH)D3 and 
1,25(OH)2D3 in absence of TNF-α/IL-1β-treatment (Figure 3B). Immunofluorescence 
staining of CYP24A1 showed similar effects of TNF-α/IL-1β-treatment as observed 
by Western blot analysis. CYP24A1 was modestly increased by 25(OH)D3 and this 
effect was also lower than the effect of TNF-α/IL-1β alone. However, this 25(OH)D3-
mediated effect was more pronounced in immunofluorescence than observed by 
Western blot analysis (Figure 3C).  
Next, we assessed the contribution of CYP24A1 to the vitamin D-mediated 
reduction of CAMP using ketoconazole, which blocks CYP24A1 activity. ALI-PBEC 
were cultured with or without TNF-α/IL-1β for 14 days, followed by 24 h pre-
incubation in presence or absence of different doses of ketoconazole before 24 h-
treatment with 1,25(OH)2D3 or control. 1,25(OH)2D3 was used for stimulation since 
ketoconazole is a broad-spectrum CYP-inhibitor that also blocks CYP27B1, and 
therefore may affect 25(OH)D3 conversion into 1,25(OH)2D3 (26). We demonstrated 
that ketoconazole partly restored expression of CAMP in a dose-dependent manner 
and did not affect CYP24A1 expression. However, in cells exposed to 1,25(OH)2D3 
in absence of TNF-α/IL-1β, a small ketoconazole-induced increase in CYP24A1 was 
observed, which might be explained by inhibition of CYP24A1, increasing the 
availability of 1,25(OH)2D3 and thus the 1,25(OH)2D3-mediated expression of 
CYP24A1 (Figure 3D). 
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Figure 3.  CYP24A1 is induced by chronic exposure to TNF-α and IL-1β (TNF-α/IL-1β) and decreases 
vitamin D-mediated expression of hCAP18/LL-37. Primary bronchial epithelial cells (PBEC) were 
cultured as described in Figure 1A for assessing CYP24A1, VDR and CYP27B1 mRNA expression and 
CYP24A1 protein by Western blot analysis and immunofluorescence. (A) Relative mRNA expression of 
CYP24A1, VDR and CYP27B1 was determined by qPCR. Normalized gene expression was calculated by 
using the expression of β2-microglobulin (B2M) and ATP synthase, H+ transporting, mitochondrial F1 
complex, beta polypeptide (ATP5B) as reference genes. Data are presented as medians ± min/max 
values. Fold change in gene expression of the stimuli compared to control (CNTRL) was first calculated, 
followed by a log-transformation of the data. Next, data were analyzed using two-way ANOVA and 
the Bonferroni post-hoc test (n = 9-11 donors). (B) Presence of CYP24A1 and GAPDH in protein cell 
lysates of the exposed cells was assessed by SDS-PAGE followed by Western blot analysis. Western 
blots are a representative of 3 independent experiments using cells from 6 different donors. The 
original image was cut to switch sample order for increased consistency. (C) Immunofluorescence 
staining of CYP24A1 in bronchial epithelial cells (of 1 donor, which was confirmed in 3 other donors). 
DAPI (blue) was used to stain the nuclei, and rabbit anti-CYP24A1 antibody together with Alexa Fluor 
488 goat anti-rabbit IgG antibody (green) were used for detection of CYP24A1. (D) In addition, PBEC 
were cultured with or without TNF-α/IL-1β for 14 days, followed by 24 h pre-incubation in presence 
or absence of increasing concentrations ketoconazole (CYP24A1 inhibitor). Afterward, cells were 
treated for 24 h with 1,25(OH)2D3 or medium control (CNTRL) in presence or absence of both TNF-
α/IL-1β and ketoconazole. Relative mRNA expression of CYP24A1 and CAMP (hCAP18/LL37) was 
determined by qPCR. Normalized gene expression was calculated by using the expression of B2M and 
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ATP5B as reference genes. Fold change in gene expression of the stimuli compared to control (CNTRL) 
was first calculated, followed by a log-transformation of the data. Next, data were analyzed using two-
way ANOVA and the Bonferroni post-hoc test (n = 3 donors). * p < 0.05, ** p < 0.01, **** p < 0.0001. 
 
Epithelial differentiation reduces expression of CYP24A1 in time, whereas 
TNF-α/IL-1β-treatment increases expression of both CYP24A1 and mucins 
(MUC5AC and MUC5B) 
We next investigated the effect of duration of exposure and concentration of TNF-
α/IL-1β on expression levels of CYP24A1. To this end, cells were differentiated in 
the presence of 0, 0.6, 2.5, 10 ng/ml of TNF-α/IL-1β followed by analysis of CYP24A1 
mRNA expression at day 14. Results showed a dose-dependent increase of CYP24A1 
expression (Figure 4A). Additionally, we assessed CYP24A1 mRNA expression at day 
1, 7 and 14 after starting culture at the ALI in presence and absence of 2.5 ng/ml 
TNF-α/IL-1β. In control-treated cells, CYP24A1 expression was decreased between 
day 1 and 14. In contrast, CYP24A1 expression was already increased at day 1 in 
TNF-α/IL-1β-treated cells and remained elevated during 14 days (Figure 4B). This 
suggests that the enhanced CYP24A1 expression is not a result of an altered 
differentiation induced by TNF-α/IL-1β, but a direct effect of this stimulation.  
This was also verified by analysis of expression of various markers of epithelial 
differentiation: whereas TNF-α/IL-1β-treatment caused a significant increase in 
expression of mucins (MUC5AC and MUC5B) at day 7 and 14, expression of the 
goblet cell marker CLCA1 and markers of ciliated cells (FOXJ1), club cells (SCGB1A1) 
and basal cells (TP63) were not affected.  
To further determine the individual contribution of TNF-α and IL-1β, we compared 
the effect of both cytokines alone versus the combination on CYP24A1 and CAMP 
mRNA expression. Therefore, cells were differentiated with and without TNF-α and 
IL-1β alone or in combination, and subsequently exposed to 25(OH)D3 or medium 
control. Both TNF-α and IL-1β alone increased expression of CYP24A1 and reduced 
25(OH)D3-mediated expression of CAMP. The combination of TNF-α/IL-1β gave the 
strongest effect on both CYP24A1 and CAMP expression, but no synergism between 
the actions of TNF-α and IL-1β was observed, (Figure E1).  
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Figure 4.  Time- and dose-dependent effects of TNF-α and IL-1β (TNF-α/IL-1β) on CYP24A1 
expression and epithelial differentiation. (A) Primary bronchial epithelial cells (PBEC) were exposed 
to TNF-α/IL-1β or CNTRL for 1, 7 and 14 days or exposed for 14 days to increasing concentrations of 
TNF-α/IL-1β for determining relative CYP24A1 mRNA expression by qPCR. Normalized gene expression 
was calculated by using the expression of β2-microglobulin (B2M) and ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta polypeptide (ATP5B) as reference genes. Data are presented as 
medians ± min/max values. Fold change in gene expression of the stimuli compared to control (CNTRL) 
was first calculated, followed by a log-transformation of the data. Next, data were analyzed using two-
way ANOVA and the Bonferroni post-hoc test (n = 3 donors) (B) PBEC were exposed to TNF-α/IL-1β or 
medium control (CNTRL) for 1, 7 and 14 days and epithelial differentiation of bronchial epithelial cell 
was assessed by measuring relative mRNA expression of Forkhead box protein J1 (FOXJ1, ciliated 
cells), secretoglobin family 1A member 1 (SCGB1A1, club cells), tumor protein p63 (TP63, basal cells), 
Mucin-5AC (MUC5AC), Mucin-5B (MUC5B) and chloride channel accessory 1 (CLCA1, goblet cells) by 
qPCR. Normalized gene expression was calculated by using the expression of ribosomal protein L13A 
(RPL13A)- and ribosomal protein L27 (RPL27) as reference genes. Data are presented as medians ± 
min/max values. Fold change in gene expression of the stimuli compared to control (CNTRL) was first 
calculated, followed by a log-transformation of the data. Next, data were analyzed using two-way 




TNF-α/IL-1β-induced expression of CYP24A1 is mediated by activation of 
EGFR, ERK1/2 and Sp1 
 In addition to two VDREs, the promoter of CYP24A1 also contains three Sp1-
binding sites (27). To investigate if the transcription factor Sp1 contributes to the 
TNF-α/IL-1β-induced expression of CYP24A1, ALI-PBEC were cultured for 14 days in 
presence and absence of TNF-α/IL-1β and subsequently treated with the Sp1 
inhibitor mithramycin A for 24 h. Expression of CYP24A1 mRNA was inhibited by 
mithramycin A in both untreated as well as TNF-α/IL-1β-treated cells (Figure 5A).  
To further explore signaling mechanisms that may contribute to TNF-α/IL-1β-
induced expression of CYP24A1, submerged cultures of undifferentiated PBEC were 
used. Cells were pre-treated with and without inhibitors of MMP (GM6001), EGFR 
(AG1478) and MEK1/2 (U0126) and subsequently exposed to TNF-α/IL-1β and LL-
37 (used as a positive control for transactivation of the EGFR for 15 min (23). 
Western blot analysis assessing p-EGFR and p-ERK1/2 showed that inhibition of 
MMP, MEK1/2 and EGFR decreased both TNF-α/IL-1β and LL-37-induced 
phosphorylation of EGFR and ERK1/2 (Figure 5B).  
We then investigated if MMP, EGFR and MEK1/2 are involved in TNF-α/IL-1β-
mediated expression of CYP24A1. PBEC were treated for 24 h with TNF-α/IL-1β, and 
CYP24A1 mRNA expression was assessed by qPCR. First, we confirmed that 
CYP24A1 mRNA was also increased by TNF-α/IL-1β in undifferentiated PBEC after 
24 h (Figure 5C). Furthermore, we showed that inhibition of EGFR and MEK1/2 
decreased expression of CYP24A1 mRNA (Figure 5C). However, whereas inhibition 
of MMP by GM6001 did inhibit phosphorylation of EGFR and ERK1/2 after 15 min, 
it did not affect TNF-α/IL-1β-induced expression of CYP24A1 after 24 h. Although 
no cytotoxic effects were observed microscopically, there was some degree of 
toxicity as indicated by an increase in LDH release in cells that were exposed for 24 
h to AG1478 and GM6001 (Figure E2). 
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Figure 5.  TNF-α and IL-1β (TNF-α/IL-1β)-induced expression of CYP24A1 is mediated by activation 
of EGFR, ERK1/2 and Sp1. To investigate the role of the transcription factor Sp1 in TNF-α/IL-1β-
mediated expression of CYP24A1, Primary bronchial epithelial cells (PBEC) were differentiated for 14 
days in presence or absence (CNTRL) of TNF-α/IL-1β and subsequently exposed in presence or absence 
of TNF-α/IL-1β with mithramycin A or medium control (CNTRL). (A) qPCR was used to assess relative 
expression of CYP24A1 mRNA and normalized gene expression was calculated by using the expression 
of β2-microglobulin (B2M) and ATP synthase, H+ transporting, mitochondrial F1 complex, beta 
polypeptide (ATP5B) as reference genes. Data are presented as medians ± min/max values. Fold 
change in gene expression of the stimuli compared to control (CNTRL) was first calculated, followed 
by a log-transformation of the data. Next, data were analyzed using two-way ANOVA and the 
Bonferroni post-hoc test (n = 4 donors) (B) Next, submerged cultures of PBEC (n = 3) were used to 
investigate the mechanism involved in TNF-α/IL-1β-mediated CYP24A1 expression: cells were exposed 
to TNF-α/IL-1β for 15 min after 1 hour pre-treatment with CNTRL (0.25% v/v DMSO in PBS) and MMP, 
EGFR and MEK-inhibitors. Protein expression of tyrosine phosphorylated (p)-and total (t)-epidermal 
growth factor receptor (EGFR), p-ERK1/2 and t- ERK1/2 was determined by SDS-PAGE Western blot. 
Western blots are a representative of 3 independent experiments using 3 different donors. The 
images were cropped to paste the images of t-EGFR and t-ERK1/2 directly below p-EGFR and t-EGFR 
(C) In addition, submerged cultures of PBEC were pre-incubated with CNTRL (0.25% v/v DMSO) and 
inhibitors of MMP (GM6001), EGFR (AG1478) and MEK (U0126) followed by stimulation for 24 h with 
TNF-α/IL-1β to assess relative gene expression of CYP24A1 mRNA by qPCR. Normalized gene 
expression was calculated by using the expression of B2M and ATP5B as reference genes. Data are 
presented as medians ± min/max values. Fold change in gene expression of the stimuli compared to 
control (CNTRL) was first calculated, followed by a log-transformation of the data. Next, data were 
analyzed using two-way ANOVA and the Bonferroni post-hoc test (n = 9 donors). * p < 0.05, ** p < 
0.01, *** p < 0.001.  
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Both chronic exposure to IL-17A and short exposure to NTHi increase 
expression of CYP24A1 
In addition to TNF-α and IL-1β, also IL-17A is increased in the airways of patients 
suffering from chronic inflammatory lung diseases (20). Furthermore, the 
respiratory pathogen NTHi also activates epithelial cells and NTHi infections are 
found in CF, COPD and poorly controlled asthma patients (21, 22). To investigate if 
these epithelial triggers have similar effects on epithelial vitamin D metabolism as 
TNFα and IL-1β, we stimulated epithelial cells with IL-17A and NTHi and assessed 
their effects. To study the effect of IL-17A exposure, ALI-PBEC were differentiated 
with or without IL-17A. After 14 days of culture, cells were stimulated for another 
24 h with or without IL-17A and 25(OH)D3 and next expression of CYP24A1 and 
CAMP mRNA was assessed by qPCR. Similar to TNFα/IL-1β, IL-17A treatment 
increased CYP24A1 expression and impaired 25(OH)D3-mediated expression of 
CAMP  from a 20.3-fold increase down to a 3.5-fold increase (Figure 6A), while VDR 
and CYP27B1 expression remained unaffected by IL-17A (data not shown). To 
examine if exposure to NTHi affects expression of CYP24A1, ALI-PBEC were 
differentiated for 14 days and subsequently stimulated with 2.5 – 5 - 10 x 107 
CFU/ml of UV-inactivated NTHi for 12 h and assessed for CYP24A1 expression by 
qPCR. We observed that NTHi dose-dependently increased expression of CYP24A1 
compared to medium control (Figure 6B). These data suggest that inflammatory 
triggers related to COPD pathology can all affect CYP24A1 expression and thereby 
negatively affect vitamin D-mediated effects. 
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Figure 6.  Chronic IL-17A-exposure and short exposure to non-typeable Haemophilus influenzae 
(NTHi) increase expression of CYP24A1. (A) To investigate effects of IL-17A, primary bronchial 
epithelial cells (PBEC) were differentiated with or without IL-17A for 14 days and stimulated for 
another 24 h with or without IL-17A and 25(OH)D3 or medium control (CNTRL) to measure relative 
mRNA expression of CAMP (hCAP18/LL-37) and CYP24A1 by qPCR. Normalized gene expression was 
calculated by using the expression of β2-microglobulin (B2M) and ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta polypeptide (ATP5B) as reference genes. Data are presented as 
medians ± min/max values. Fold change in gene expression of the stimuli compared to control (CNTRL) 
was first calculated, followed by a log-transformation of the data. Next, data were analyzed using two-
way ANOVA and the Bonferroni post-hoc test (n = 9 donors) and differences between CNTRL and 
25(OH)D3 ratios were calculated in CNTRL and IL-17A treated cells using a paired t-test (B) To examine 
if NTHi affects expression of CYP24A1 mRNA in air-liquid interface cultures of PBEC, cells were 
differentiated for 14 days and subsequently stimulated with increasing concentrations of UV-
inactivated NTHi for 12 h before analysis of CYP24A1 expression by qPCR. Normalized gene expression 
was calculated by using the expression of Ribosomal Protein L13a (RPL13A) and ATP5B as reference 
genes. Data are presented as medians ± min/max values. Fold change in gene expression of the stimuli 
compared to control (CNTRL) was first calculated, followed by a log-transformation of the data. Next, 
data were analyzed using one-way ANOVA and the Bonferroni post-hoc test (n =  19-21 donors). #### 




Figure 7.  Summary and proposed mechanism for TNF-α/IL-1β-mediated increase of CYP24A1. In 
primary bronchial epithelial cells, the circulating metabolite of vitamin D, 25(OH)D3 is converted by 
CYP27B1 into the active 1,25(OH)2D3, resulting in expression of the antimicrobial peptide hCAP18/LL-
37 and killing of NTHi via the vitamin D receptor (VDR) and subsequent binding of vitamin D response 
elements (VDREs), which are present on the promoter of CAMP and encodes for hCAP18/LL-37. 
Expression of hCAP18/LL-37 and killing of NTHi is impaired by TNF-α/IL-1β exposure via increased 
expression of CYP24A1, which degrades both 25(OH)D3 and 1,25(OH)2D3. The loss of hCAP18/LL-37 
expression can be restored by ketoconazole, which suppresses CYP24A1-activity. The promoter of 
CYP24A1 contains in addition of VDREs, CCAAT-enhancer-binding protein (C/EBP), vitamin D 
stimulation element (VSE), ets-1 binding site (EBS), CCAAT also of GC-rich boxes, which are binding 
sites for the transcription factor Sp1. Blocking Sp1-binding sites by mithramycin A, decreases TNF-α 
and IL-1β-mediated expression of CYP24A1. In addition, expression of TNF-α and IL-1β-mediated 




Here we show that inflammatory conditions negatively affects vitamin D 
metabolism in airway epithelial cells resulting in reduced vitamin D-induced 
expression of hCAP18/LL-37 and antibacterial activity against NTHi. These findings 
are explained at least in part by the ability of TNF-α/IL-1β and IL-17A to increase 
expression of the vitamin D-degrading enzyme CYP24A1, whereas expression of 
VDR and CYP27B1 was not affected. The ability of TNF-α/IL-1β to increase 
expression of CYP24A1 was in part mediated by EGFR, MEK and Sp1. These findings 
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are summarized in Figure 7, showing that a local pro-inflammatory environment in 
the airways might impair the ability of vitamin D to regulate epithelial antibacterial 
activity. 
Effects of vitamin D on hCAP18/LL-37 expression and antibacterial activity in 
differentiated bronchial epithelial cells have been reported previously (8, 14, 25). 
However, to our knowledge this is the first study that demonstrates how pro-
inflammatory conditions affect these activities. Our observation that CYP24A1 is 
increased by pro-inflammatory stimuli in primary airway epithelial cells is in line 
with another study showing that TNF-α, IL-1β, IL-6 and IFN-γ increased expression 
of CYP24A1 in human trophoblasts (13). Moreover, the importance of CYP24A1 on 
negatively affecting  vitamin D-induced antibacterial defense are supported by a 
recent study by Wang and colleagues, showing that vitamin D-induced bacterial 
killing by immortalized human oral keratinocytes was increased by knockdown of 
CYP24A1 via siRNA transfection (28). It was also shown in this study that vitamin D-
mediated expression of hCAP18/LL-37 correlated with killing of F. nucleatum 
(growth of three other bacterial strains were not affected by vitamin D).  
In addition to hCAP18/LL-37, previous reports demonstrated that vitamin D also 
increases other AMPs, such as human-beta-defensin-2 (hBD-2) in oral squamous 
cells and 16HBE-cells (29, 30). However in ALI-PBEC, no effects of vitamin D on hBD-
2 expression were observed (Figure E3). Our finding that inflammatory cytokines 
affect airway epithelial vitamin D metabolism and thus decrease AMP expression 
further extends other findings showing alterations in the antibacterial activity of 
airway epithelial cells due to changes in the local environment, such as alterations 
in airway surface liquid pH and mucus accumulation (24, 31).  
The promoter of CYP24A1 contains, in addition to 2 VDREs, other promoter 
elements such as 3 GC-rich boxes, to which the transcription factor Sp1 can bind. 
To investigate if TNF-α and IL-1β increase transcription of CYP24A1 via Sp1, we 
blocked Sp1-binding by using mithramycin A and demonstrated that it reduced 
expression of CYP24A1 in ALI-PBEC. Since CYP24A1 expression was not fully 
inhibited by mithramycin A, we cannot exclude other mechanisms via other 
promoter elements such as the ETS-1 binding site (EBS) (32). Moreover, others 
demonstrated the involvement of SP1 in expression of genes other than CYP24A1 
by TNF-α and/or IL-1β in epithelial cells (33, 34). Additionally, it was shown that 
Sp1-mediated gene expression was facilitated via TNFR1, MEK1/2, ERK1/2 (34). In 
line with these findings, we demonstrated that TNF-α and IL-1β increased 
phosphorylation of ERK1/2 and that blocking MEK1/2 decreased expression of 
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CYP24A1. We furthermore showed that TNF-α and IL-1β increased phosphorylation 
of EGFR, and that inhibition of EGFR phosphorylation decreased phosphorylation of 
ERK1/2, providing evidence for an additional involvement of the EGFR. This is in line 
with other studies showing that EGFR phosphorylation was increased by TNF-α or 
IL-1β (35, 36). Although Inhibition of MEK1/2 and EGFR by U0126 and AG1478 
respectively decreased TNF-α/IL-1β-mediated CYP24A1 expression, inhibition of 
MMP by GM6001 did not show this effect. This was unexpected since GM6001 did 
reduce TNF-α/IL-1β-mediated phosphorylation of EGFR and ERK1/2. TNF-α/IL-1β 
also phosphorylates the EGFR via activation of TAK1 independently of MMP-
mediated cleavage and release of membrane-bound EGFR-ligands, indicating that 
also other pathways might play a role (37). Furthermore, possible toxic or non-
selective effects of these signaling inhibitors upon prolonged incubation (24 h) 
cannot be fully excluded, since LDH release was increased after 24 h exposure to 
GM6001 and AG1478 (Figure E2). Taken together, one of the mechanisms that 
results in vitamin D-independent CYP24A1 expression by TNF-α and IL-1β in PBEC, 
likely involves activation of EGFR, MEK1/2 and Sp1. Since studies have shown that 
IL-17A and NTHi promote MAPK/ERK signaling (38, 39), we speculate that IL-17A 
and NTHi also mediate CYP24A1 expression via similar pathways as TNF-α and IL-
1β. However, more studies are necessary to elucidate this. 
We used differentiated primary airway epithelial cells obtained from multiple 
donors, instead of tumor-derived or immortalized airway epithelial cell lines, 
thereby increasing the relevance of our findings. We have used selected 
recombinant pro-inflammatory cytokines to mimic the inflammatory environment 
in the lung, whereas in the lung such cytokines are produced by immune and 
resident cells. Future studies using co-culture systems may provide additional 
information, because immune cells are also capable of converting vitamin D into its 
active form. In our study, we confirmed the involvement of CYP24A1 in decreasing 
vitamin D-mediated expression of hCAP18/LL-37 by inhibiting its activity by 
ketoconazole. However, we have not verified that 25(OH)D3-induced killing of NTHi 
is a consequence of the increased hCAP18/LL-37 by vitamin D. Unfortunately, 
blocking LL-37-activity by using LL-37 specific blocking antibodies was not 
successful and neither was transfection using siRNA in 14-days differentiated ALI-
PBEC cultures. However, we did demonstrate antibacterial activity and also 
expression of hCAP18/LL-37, which was mainly located at the apical side of the ALI-
PBEC by immunofluorescence, and we detected hCAP18/LL-37 in basal medium by 
Western blot analysis. Using LL-37 specific monoclonal antibodies, strong 
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expression of a peptide at 14 kDa and also weaker expression of a peptide at 18 
kDa (size of uncleaved hCAP18) was detected, yet expression of a peptide at 4.5 
kDa (mature antimicrobial active LL-37) was absent. Western blots showing 
peptides containing LL-37 immunoreactivity at 14 kDa were previously reported by 
us and other studies (6, 14, 40-42). For example, Sӧrensen and colleagues detected 
14 kDa hCAP18 fragments, in addition to 18 kDa and 4.5 kDa fragments, following 
cleavage of hCAP18 by extracts of neutrophil- azurophilic granules, elastase or 
cathepsin G by Western blot using LL-37-specific antibodies (6). Based on our 
analysis of basal conditioned medium, we therefore speculate that hCAP18 was 
mainly cleaved at a different location than in neutrophils, or that the detection of 
the 4.5 kDa LL-37 peptide was masked.  
To further verify that 25(OH)D3-induced killing of NTHi is a consequence of the 
increased hCAP18/LL-37 by vitamin D, the arrival of new genome editing tools such 
as CRISPR-Cas9 provides new opportunities to identify the precise contribution of 
hCAP18/LL-37 or other AMPs to vitamin D-mediated antimicrobial activity in 
bronchial epithelial cells. To extend the relevance of our findings to the in vivo 
situation, further studies are required to compare lung tissue levels of CYP24A1, 
CYP27B1, VDR and 1,25(OH)2D3 in healthy donors and donors with chronic 
inflammatory lung disease.  
We have demonstrated in our in vitro model that 1,25(OH)2D3 treatment increases 
killing of NTHi and that this vitamin D-induced killing was impaired in presence of 
pro-inflammatory cytokines. Furthermore, decreased availability of vitamin D in an 
inflammatory environment also reduces the impact of vitamin D on inflammation 
through its anti-inflammatory and immune modulating properties. These 
observations may help to explain why vitamin D supplementation only prevents 
exacerbations in severely deficient individuals (43, 44). Our studies suggest that 
inhibition of CYP24A1, supplementation with CYP24A1-resistant vitamin D 
analogues, decreasing inflammation and supplementation with higher doses of 
vitamin D may increase vitamin D-responses in patients suffering from chronic 
inflammatory lung diseases. Inhibiting CYP24A1 by ketoconazole might not be a 
good strategy, since oral administration of the drug is reported not to be safe and 
causes serious side effects, including endocrine dysregulation and interactions with 
other drugs (45). Other more selective compounds targeting CYP24A1 such as 
styrylbenzamides and VID400 have not yet been evaluated in clinical trials  (46, 47). 
Another option is the use of 1,25(OH)2D3-analogs that are currently under 
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investigation in some clinical trials. These substances are less sensitive to 
degradation by CYP24A1, and have been modified in such a way that the risk of 
hypercalcemia is reduced (48). Using anti-inflammatory drugs such as 
glucocorticoids in combination with 25(OH)D3-supplementation seems an 
attractive strategy. However, the use of inhaled corticosteroids is largely ineffective 
in reducing inflammation in most COPD patients and in corticosteroid-resistant 
asthma patients and long-term use may cause side effects such as pneumonia and 
osteoporosis (49, 50). Therefore, 25(OH)D3-supplementation might counteract this 
by increasing both the host defense and the sensitivity to corticosteroids, as 
previously shown in corticosteroid-resistant asthma patients (3, 4, 51-53).  
In summary, we have demonstrated that epithelial exposure to pro-inflammatory 
cytokines reduces the vitamin-D induced antibacterial activity in primary bronchial 
epithelial cells. These data suggest that a local pro-inflammatory environment 
might impair local vitamin D-mediated host defense in the lung and that circulating 
vitamin D levels may not always reflect local activity. However, we cannot formally 
exclude that low-degree systemic inflammation, as observed in  patients with 
(severe) chronic airway inflammation, might affect circulating vitamin D levels and 
thus contributes to the vitamin D deficiency in such patients (2). These data 
therefore point to novel mechanisms whereby inflammation-triggered alterations 
in vitamin D metabolism impair host defense at the airway epithelial surface, 
increase the risk of infection and thus contribute to more (severe) exacerbations 
and progression of disease. 
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Figure E1.  Effect of TNF-α and IL-1β together versus TNF-α and IL-1β alone on expression of CYP24A1 
and hCAP18/LL-37 in primary bronchial epithelial cells (PBEC). PBEC (n = 2 donors) were cultured 
with or without the pro-inflammatory cytokines TNF-α/IL-1β or TNF-α and IL-1β in combination or 
alone for 14 days followed by 24 h 10-7 M 25(OH)D3-treatment or medium control (CNTRL) to assess 
CYP24A1 and CAMP (hCAP18/LL-37) mRNA expression by qPCR. Normalized gene expression was 
calculated by using the expression of the β2-microglobulin (B2M) and ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta polypeptide (ATP5B) as reference genes. Fold change in gene 
expression of the stimuli compared to control (CNTRL) was calculated. Data were represented as 
means. 
 
Figure E2. Effect of inhibitors and TNF-α/IL-1β on LDH release in primary bronchial epithelial cells 
(PBEC). Submerged PBEC cultures (n = 4 donors) were pre-incubated with medium alone (CNTRL; 
0.25% v/v DMSO) and inhibitors of MMP (GM6001), EGFR (AG1478) and MEK (U0126) followed by 
stimulation for 24 h with TNF-α/IL-1β or with 0.1% Triton X-100 (positive control) to assess LDH 
relaese. Percentage LDH release was calculated as followed: (OD490nm samples x 
dilutionfactor/OD490nm Triton X-100 controls x dilutionfactor) x 100%. Data were analyzed using a 










































































Figure E3.  Effect of 25(OH)D3 and 1,25(OH)2D3 on hBD-2 (DEFB4) expression in primary bronchial 
epithelial cells (PBEC). PBEC were differentiated for 14 days and subsequently exposed to 10-7 M 
25(OH)D3 and 1,25(OH)2D3 for 24 h in duplicate. DEFB4 (hBD-2) expression was assessed using qPCR. 
Normalized gene expression was calculated by using the expression of the β2-microglobulin (B2M) 
and ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide (ATP5B) as reference 
genes. Data were log-transformed and represented as means ± SEM. Data are presented as medians 
± min/max values. Fold change in gene expression of the stimuli compared to control (CNTRL) was 
























PBEC were obtained from tumor free bronchial lung tissue from anonymous 
donors, collected during lung resection surgery for lung cancer. Cells were cultured 
as previously described with adaptations (54). Briefly, cultures of bronchial 
epithelial cells (passage 1) were first expanded in 9 cm culture plates, pre-coated 
with 10 μg/ml BSA (Sigma Aldrich, Zwijndrecht, The Netherlands), 30 μg/ml Purecol 
(Advanced BioMatrix, San Diego, CA) and 10 μg/ml fibronectin, before seeding at a 
density of 40,000 cells per insert (passage 2) on pre-coated semi-permeable 
Transwell inserts (12 mm, 0.4 μm pore-size, Corning Costar, Cambridge, MA). When 
confluence was reached (after 5-7 days), apical medium was removed and the cells 
were cultured at the air-liquid interface (ALI) and refreshed 3 times a week with 
BEGM:DMEM medium (1:1) (Lonza, Breda, The Netherlands and Invitrogen, Breda, 
The Netherlands respectively) supplemented with BEGM BulletKit singlequots 
(bovine pituitary extract (BPE), hydrocortisone, human epidermal growth factor 
(hEGF), epinephrine, transferrin, insulin, T3, and retinoic acid) (all from Lonza), and 
additional 15 ng/ml retinoic acid (Sigma-Aldrich), 15 μg/ml BSA (Sigma Aldrich), 1 
mM HEPES, 100 U/ml penicillin and 100 µg/ml streptomycin (Lonza). During 
refreshment the apical surface was washed with PBS to remove excess mucus. After 
14 days of air-exposed culture, the cells produced both mucus and had developed 
cilia (55).  
RNA Isolation, reverse transcription (RT) and quantitative (q)PCR   
Cells were lysed in RNA lysis buffer (Promega). Total RNA was automatically 
extracted using the Maxwell tissue RNA extraction kit (Promega) and quantified 
using the Nanodrop ND-1000 UV-Vis Spectrophotometer (Nanodrop technologies, 
Wilmington, DE). For cDNA synthesis, 1 µg of total RNA was reverse transcribed 
using oligo dT primers and M-MLV Polymerase (Promega) at 37° C. All qPCR 
reactions, using primers shown in table I, were performed in triplicate on a CFX-384 
Real-Time PCR detection system (Bio-Rad Laboratories, Veenendaal, The 
Netherlands) with the use of SensiFast supermix (GC-Biotech, Alphen aan de Rijn, 
The Netherlands). The relative standard curve method was used to calculate 
arbitrary gene expression using CFX-manager software (Bio-Rad). Reference genes, 
selected using the “Genorm method” (Genorm, Primer design, Southampton, UK), 
were included to calculate normalized gene expression. 
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Table 1.  PCR primers and sequences used for quantitative PCR 
*Used as a reference gene, selected using the Genorm method 
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Preparation of UV-inactivated NTHi 
NTHi strain D1 was cultured on chocolate agar plates (bioMérieux, Zaltbommel, The 
Netherlands) overnight at 7% CO2 and 37°C (56). Next, one colony was picked and 
plated on a second chocolate agar plate and cultured overnight at 7% CO2 and 37°C. 
From this culture, multiple colonies were picked and resuspended in 10 ml Tryptone 
soya broth containing X- and V-factor (TSB XV, Mediaproducts BV, Groningen, the 
Netherlands) and incubated overnight at 37°C while shaking. Two ml of the 
overnight culture was transferred into fresh 10 ml TSB XV medium and incubated 
for 4 hours at 37°C while shaking. Next, the bacteria-containing broth was 
centrifuged for 10 minutes at 3000 rpm, the pellet was resuspended in PBS and the 
concentration was adjusted to 1 × 109 CFU/ml based on OD 600 nm measurements. 
Bacteria were next inactivated by UV-light exposure for 2 hours and killing was 
confirmed by plating on chocolate plates. 
Bacterial killing assay  
Killing of NTHi by ALI-PBEC was assessed as described by Pezzulo et al. with a few 
modifications (24). We used 6 mm glass coverslips instead of gold grids, which were 
coated with 2% (v/v) 3-aminopropyltriethoxysilane (APTES, H2N(CH2)3Si(OC2H5)3; 
Sigma-Aldrich) solution in acetone for 10 seconds, washed in H2O and dried at RT. 
Next, coverslips were immersed in 1 mM 11-mercaptoundecanoic acid (MUA, 
HS(CH2)10COOH, Sigma-Aldrich) for 30 minutes at room temperature (RT), next in a 
freshly prepared mixture of 0.1 M N-hydroxysuccinimide (NHS) and 0.1 M 1-ethyl-
3-(3-diethylaminopropyl)carbodiimide (EDC) (1:2 molar ratio) (Sigma-Aldrich) for 
30 minutes at RT, followed by coupling with 10 ug/mL streptavidin (Sigma-Aldrich) 
in PBS for 30 minutes. Finally, coverslips were treated with 1 M glycine for 30 
minutes, washed in PBS and kept on ice until use.  
NTHi strain D1 were cultured as described in TSB XV medium (bioMérieux) while 
shaking overnight at 37⁰ C. Next, 2 ml of the overnight culture was transferred into 
fresh 10 ml TSB XV medium and incubated for 4 hours at 37°C while shaking to 
obtain mid log phase-growing bacteria. 1 x 108 CFU/ml of bacteria (determined at 
OD 600 nm), were labeled with 0.88 mg/ml EZ-Link sulfo-N-hydroxysuccinimide 
(NHS)-Biotin (Thermo Scientific) in PBS for 30 minutes on ice. Next, biotin-labeled 
NTHi were linked to the streptavidin-coated glass coverslips in PBS for 30 minutes 
and washed two times in PBS and finally in 0.01 M sodium phosphate buffer (pH 
7.4), containing 1% TSB XV to remove the unbound bacteria. Expression of MUC5AC 
and MUC5B mRNA was elevated by TNF-α and IL-1β-treatment (Figure 4C) and 
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excessive mucus secretion might interfere with the antibacterial assay by binding 
of the negatively charged mucins to the cationic AMPs (31). To rule out this 
possibility, we removed the excess mucus by washing both treated and untreated 
cells with 200 µl sodium phosphate buffer for 30 minutes at 37ᵒ C 6 h before the 
assay. NTHi-coated coverslips were placed on the apical surface of ALI-PBEC for 1 
minute on each side of the coverslip followed by a staining for 30 seconds with ice-
cold SYTO 9 and propidium iodide (PI) (Baclight LIVEDEAD staining kit, Life 
Technologies) and mounting on microscopic slides using Baclight mounting oil (Life 
Technologies). Digital images were taken with a Zeiss Axio Scope A1 fluorescent 
microscope and Zeiss Axiocam mRc 5 camera (Carl Zeiss Microscopy, Göttingen, 
Germany), and live and dead bacteria were counted using Image J software 
(National Institutes of Health, Bethesda, MD, USA). The antibacterial activity was 
determined by calculating the percentage of dead bacteria. 
Western blot  
For Western blot analysis of hCAP18/LL-37 release, basal medium was pooled and 
purified using Oasis HLB 1cc extraction cartridges (Waters Chromatography, Etten-
Leur, The Netherlands) and the eluate was dried by vacuum centrifugation (CHRIST 
RVC2-25 Vacuüm system) (57). Lyophilized protein samples were resuspended in 
100 µl reducing SDS-PAGE sample buffer, heated for 5 minutes at 100°C and applied 
on a 16.5% Tris-Tricine gel as previously described (14). Cells were lysed in ice-cold 
RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 100 mM Na3VO4, 100 mM PMSF, 100 
mM EDTA, 1% Triton X-100, 1% sodium dodecyl sulfate [SDS], containing protease 
inhibitors [Complete Mini, Roche Diagnostics, Almere, The Netherlands]). RIPA 
lysates were incubated for 30 minutes at 4°C, sonicated and centrifuged at 10,000 
× g for 10 minutes. Supernatants were collected, and stored at - 20°C until use. For 
detection of CYP24A1, phosphorylated (p)-EGFR, total (t)-EGFR, p-ERK1/2 and t-
ERK1/2, and GAPDH, RIPA protein lysates were dissolved in reducing SDS sample 
buffer, heated for 5 minutes at 100° C and applied on a 10% SDS-PAGE gel. Next, 
proteins were blotted on a Polyvinylidene fluoride (PVDF) membrane and non-
specific binding sites were blocked in PBS containing 5% (v/v) heat-inactivated new 
born calf serum, 5% (w/v) skimmed milk (for detection of hCAP18/LL-37 or 
CYP24A1), or in Tris-buffered saline (TBS) containing 0.01% Tween 20 (v/v) and 1% 
BSA (w/v) for detection of p-EGFR, t-EGFR, p-ERK1/2, t-ERK1/2, and GAPDH. 
Membranes were probed with 1/200 diluted mouse monoclonal anti-hCAP18/LL-
37 (clone 1.1.C12; Hycult Biotech, Uden, The Netherlands), 1/1000 diluted rabbit-
anti-CYP24A1 (Sigma Aldrich), 1/1000 diluted rabbit-anti-p-EGFR (tyrosine), 1/1000 
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diluted rabbit-anti-t-EGFR, 1/1000 diluted rabbit-anti-p-ERK1/2, 1/500 diluted 
rabbit-anti-t-ERK1/2 or with 1/10000 diluted rabbit anti-GAPDH (Cell Signaling 
Technology, Leiden, The Netherlands) in their respective blocking buffers. Next, the 
membranes were incubated with 1/1000 diluted goat-anti-mouse-HRP conjugated 
antibody (DAKO, Heverlee, Belgium) for hCAP18/LL-37, or in 1/10.000 diluted goat-
anti-rabbit-HRP (Cell Signaling Technology) for CYP24A1, p-EGFR, t-EGFR, p-ERK1/2, 
t-ERK1/2 and GAPDH in their blocking buffers. ECL (Thermo Scientific) was used to 
visualize hCAP18/LL-37, CYP24A1, and GAPDH on film (GE Healthcare, Hoevelaken, 
The Netherlands); SuperSignal West Pico ECL Substrate (Thermo Scientific) was 
used to visualize p-EGFR, t-EGFR, p-ERK1/2, t-ERK1/2 using The ChemiDoc™ Touch 
imager in combination with Image Lab™ software (Biorad).  
Immunofluorescence staining of LL-37 and CYP24A1  
Cells were fixed on Transwell inserts in 1% paraformaldehyde (Millipore B.V.) in PBS 
for 10 minutes on ice and washed with ice-cold PBS. Next, cells were permeabilized 
with methanol for 10 minutes at 4°C and blocked with PBS/1% BSA/0.3% Triton-X-
100 (PBT) for 30 minutes at 4 °C. Cells were incubated with 1/100 diluted rabbit-
anti-hCAP18/LL-37 (Innovagen, Lund, Sweden) or 1/100 diluted rabbit-anti-
CYP24A1 (Sigma Aldrich) in PBT for 1 hour at RT, followed by incubation with an 
Alexa Fluor 488 labeled secondary antibody (1/200, Alexa Fluor 488 goat anti-rabbit 
IgG; Invitrogen) together with DAPI in PBT for 30 minutes at RT. Images were 
acquired using a TCS SP5 Confocal Laser Scanning Microscope (Leica Microsystems 
B.V., Eindhoven, The Netherlands) and LAS AF Lite software (Leica Microsystems 
B.V.). 
LDH assay 
Submerged PBEC cultures were pre-incubated with medium alone (CNTRL; 0.25% 
v/v DMSO) and inhibitors of MMP (GM6001), EGFR (AG1478) and MEK (U0126) 
followed by stimulation for 24 h with TNF-α/IL-1β or with 0.1% Triton X-100 (used 
as a positive control for LDH release). Samples were 10 times diluted in PBS and the 
positive control was 50 times diluted in PBS. LDH release was assessed using a 
Roche Cytotoxicity Detection Kit (Sigma-Aldrich, Zwijndrecht, the Netherlands) 
according to manufactures’ protocol. Percentage of LDH release was calculated as 
followed: (OD490nm samples x dilution factor/OD490nm positive control x dilution 
factor) x 100%. 
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Statistical analysis    
Statistical analysis was conducted using GraphPad Prism 6 (GraphPad Software Inc., 
La Jolla, CA, U.S.A.) To analyze qPCR results, fold change in gene expression of the 
stimuli compared to control (CNTRL) was first calculated, followed by a log-
transformation. Next, data were analyzed using either a one- or two-way ANOVA 
and the Bonferroni post-hoc test. To analyze data of the bacterial killing assay, the 
two-way ANOVA test was used followed by a Bonferroni post-hoc test. Data of the 
LDH assay were analyzed using a paired t-test and a two-way ANOVA followed by a 
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Vitamin D is an important regulator of the expression of antimicrobial peptides, and 
vitamin D deficiency is associated with respiratory infections. Regulating expression 
of antimicrobial peptides, such as the human cathelicidin antimicrobial peptide 
18(hCAP18)/LL-37, by vitamin D in bronchial   cells requires local conversion of 
25(OH)-vitamin D3 (25D3) into its bioactive metabolite, 1,25(OH)2-vitamin D3 
(1,25D3), by CYP27B1. Low circulating vitamin D levels in childhood asthma are 
associated 
with more-severe exacerbations, which are often associated with infections. Atopic 
asthma is accompanied by Th2-driven inflammation mediated by cytokines such as 
interleukin 4 (IL-4) and IL-13, and the effect of these cytokines on vitamin D 
metabolism and hCAP18/LL-37 expression is unknown. Therefore, we investigated 
this with well-differentiated bronchial epithelial cells. To this end, cells were 
treated with IL-13 with and without 25D3, and expression of hCAP18/LL-37, 
CYP27B1, the 1,25D3-inactivating enzyme CYP24A1, and vitamin D receptor was 
assessed by quantitative PCR. We show that IL-13 enhances the ability of 25D3 to 
increase expression of hCAP18/LL-37 and CYP24A1. In addition, exposure to IL-13 
resulted in increased CYP27B1 expression, whereas vitamin D receptor (VDR) 
expression was not significantly affected. The enhancing effect of IL-13 on 25D3-
mediated expression of hCAP18/LL-37 was further confirmed using SDS-PAGE 
Western blotting and immunofluorescence staining. In conclusion, we demonstrate 
that IL-13 induces vitamin D-dependent hCAP18/LL-37 expression, most likely by 
increasing CYP27B1. These data suggest that Th2 cytokines regulate the vitamin D 






The upper respiratory tract is continuously exposed to pathogens. Epithelial cells 
function as the front line of host defense in the lung by preventing microbes from 
entering the bloodstream through the physical barrier provided by the tight 
junctions (1) and mucociliary clearance (2). Furthermore, epithelial cells secrete 
antimicrobial peptides and proteins (AMPs), such as lysozyme, lactoferrin and 
defensins, reactive oxygen and nitrogen species, interferons, and chemokines and 
cytokines, which eliminate pathogens directly or indirectly via attraction of 
phagocytic leukocytes (3, 4). In the lung, the AMP human cathelicidin (hCAP18/LL-
37) is mainly secreted by neutrophils and epithelial cells, and the active peptide LL-
37 displays broad-spectrum antimicrobial activity against bacteria, fungi, and 
viruses. It also contributes to microbial clearance by other mechanisms, including 
attraction of phagocytes (5, 6). In epithelial cells, a variety of stimuli, including 
proinflammatory cytokines (7, 8), microbial products (9), injury (10), endoplasmic 
reticulum (ER) stress (11), and butyrate, a short-chain fatty acid produced by 
resident colonic bacteria (12, 13), have been shown to increase expression of 
hCAP18/LL-37. Recent studies also showed that vitamin D is an important regulator 
of hCAP18/LL-37 expression in epithelial cells and macrophages (4, 14). Other 
studies showed that microbial exposures may also increase vitamin D-mediated 
expression of hCAP18/LL-37 through the induction of 25-hydroxy-vitamin D-1-α-
hydroxylase (CYP27B1), which converts 25-hydroxy-vitamin D3 (25D3) into the 
active 1,25(OH)2-vitaminD3 (1,25D3) (15, 16). One of the well-established functions 
of vitamin is mediating calcium absorption and bone homeostasis. The major 
circulating form of vitamin D is the inactive form of vitamin D, 25D3, which is bound 
to the vitamin binding protein (VDBP) and represents the organism‘s vitamin D 
stock. 25D3 is converted into 1,25D3 by CYP27B1 in the kidneys. Recent data show 
that other extrarenal tissues, such as the skin, prostate, lung, and gastrointestinal 
tract, but also macrophages and monocytes, express CYP27B1 locally (15-17), 
indicating that vitamin D exerts its actions beyond bone mineralization and could 
play a role in pathological conditions. In bronchial epithelial cells, 25D3 is converted 
by the locally expressed CYP27B1 into its active metabolite, 1,25D3, which binds the 
vitamin D receptor (VDR) (15, 18). Subsequently, the 1,25D3-VDR complex binds to 
the retinoic X receptor, moves to the nuclei, and binds to vitamin D response 
elements present in the promoter regions of genes important for recognition and 
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defense against microbes, such as those encoding hCAP18/LL-37, human β-
defensins 2 (hBD-2), NGAL, and CD14 (19-21). In addition, 1,25D3 also induces 
expression of the catabolic enzyme 1,25D3 24-hydroxylase (CYP24A1), resulting in 
a negative feedback loop (22). In addition to increasing expression of AMPs, such 
as hCAP18/LL-37, vitamin D exerts various other effects on pulmonary immunity. 
Vitamin D reduces respiratory syncytial virus (RSV) or double-stranded RNA-
induced expression of interleukin 8 (IL-8) in primary tracheal bronchial epithelial 
cells (23). In addition, vitamin D induces IL-10 secretion by T regulatory cells (Tregs) 
and therefore may possibly restore defects in IL-10 production by Tregs in steroid-
resistant asthma (24). Several epidemiological studies suggest associations 
between vitamin D status and lung diseases, such as asthma, chronic obstructive 
pulmonary disease (COPD), and respiratory infections, including tuberculosis (25). 
In asthma, reduced serum levels of vitamin D are associated not only with lower 
lung function (24, 26, 27) but also with increased airway hyperresponsiveness, 
reduced corticosteroid sensitivity (24), and more-severe exacerbations in children 
(28). The Th2 cytokines IL-13 and IL-4 play an important role in asthma and allergic 
disorders and are locally produced in the airway wall in atopic asthma (29). These 
cytokines may modulate susceptibility to bacterial infections, as demonstrated in, 
e.g., keratinocytes and airway epithelial cells (30-32). This is important, since the 
bacterial load is higher in asthmatics than in healthy controls and the composition 
of the bacterial communities in the airways is different from that in healthy 
subjects, which is associated with the severity of airway hyperresponsiveness (33). 
In addition, exacerbations of asthma, which are caused mainly by viral infections 
(34), are also major problem and frequently require hospitalization. Vitamin D may 
play a protective role in the severity of airway hyperresponsiveness and 
development of exacerbations, which may be partially explained by its ability to 
regulate expression of AMPs and reduce airway inflammation. However, the effect 
of Th2 cytokines on vitamin D responses is not understood. The aim of the present 
study was to investigate the role of the Th2 cytokine IL-13 on 25D3-dependent 
expression of antimicrobial peptides in well-differentiated bronchial epithelial cells. 
First, the release of proinflammatory cytokines and chemokines and expression of 
hCAP18/LL-37 after exposing the cells to poly(I:C) with and without 25D3 were 
determined. Next, the effects of the Th2 cytokine IL-13 on the expression and 
release of hCAP18/LL-37 in 25D3-exposed cells were examined and subsequently 
expression of genes involved in the vitamin D metabolic pathway, e.g., those 
encoding CYP24A1, CYP27B1, and VDR, was assessed to examine the mechanisms 
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of action of IL-13. Finally, antimicrobial activity of the 25D3- and/or IL-13-stimulated 
cells was assessed using an antimicrobial assay. 
Materials and Methods 
Cell culture  
Primary bronchial epithelial cells obtained from tumor-free bronchial lung tissue 
from anonymous donors, acquired during lung resection surgery for lung cancer, 
were cultured as described previously (35). Briefly, cultures of bronchial epithelial 
cells (passage 1) were first expanded and then grown submerged on PureCol 
(Advanced BioMatrix, San Diego, CA) and fibronectin-coated 24-mm Transwell-
clear culture inserts (Corning Costar Corporation, Cambridge, MA) in humidified air 
supplemented with 5% (vol/vol) CO2. When the cells reached confluence, they were 
cultured exposed to air, and 3 times a week the apical side was washed in 
phosphate-buffered saline (PBS) and the basal side refreshed with fresh Dulbecco’s 
modified Eagle medium (DMEM)-bronchial epithelial cell growth medium (BEGM) 
(1:1) (Invitrogen, Breda, The Netherlands, and Lonza, Breda, The Netherlands, 
respectively) supplemented with 15 ng/ml retinoic acid (Lonza). During 14 days of 
air-exposed culture, the cells started producing mucus and develop cilia (36).  
 
Cell exposures 
Differentiated bronchial epithelial cells were exposed at the apical (in 100 µl PBS) 
and basal sides to poly(I:C) (5 and 50 µg/ml; Invivogen, Toulouse, France) with or 
without 25D3 (100 nM, Merck, Darmstadt, Germany) for 24 h in duplicate. Tumor 
necrosis factor alpha (TNF-α) and IL-1β (20 ng/ml; Peprotech, Rocky Hill, NJ) were 
included as positive controls. In experiments to assess the effects of IL-13 on 25D3 
responses, cells were pretreated with 100 ng/ml IL-13 (Peprotech) to induce the 
CYP27B1 protein prior to exposing the cells to 25D3 for 24 h and then exposed for 
another 48 h in triplicate to IL-13 with and without 10-7 M 25D3 or 10-7 M 1,25D3 
(Merck), included as a positive control. Antibiotics-free medium was used when an 
antimicrobial assay was performed. Basal medium was collected and either used 
for enzyme-linked immunosorbent assay (ELISA) or for Western blot analysis of 
hCAP18/LL-37 release. For Western blot analysis of hCAP18/LL-37 release, basal 
medium was pooled and purified using Oasis HLB 1-ml extraction cartridges 
(Waters Chromatography, Etten-Leur, The Netherlands), and the eluate was dried 
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by vacuum centrifugation (Christ Rvc2-25 Vacuüm system) (2). Lyophilized protein 
samples were resuspended in 100 µl SDS-PAGE sample buffer (12% SDS, 30% 
glycerol, and 150 mM Tris-HCl, pH 7.0). Apical surface fluid was collected using 100 
µl 10 mM sodium phosphate buffer for antimicrobial assays. Cells were either fixed 
in 1% paraformaldehyde (Merck) for immune fluorescence (IF) or lysed in either 
RNA lysis buffer RP1 (Macherey-Nagel, Düren, Germany) or in ice-cold RIPA buffer 
(50 mM Tris [pH 7.4], 150 mM NaCl, 100 mM Na3VO4, 100 mM 
phenylmethylsulfonyl fluoride [PMSF], 100 mM EDTA, 1% Triton X-100, 1% sodium 
dodecyl sulfate [SDS], containing a protease inhibitor tablet [Complete Mini; Roche 
Diagnostics, Almere, The Netherlands]). RIPA lysates were incubated for 30 min at 
4°C, sonicated, and centrifuged at 10,000  g for 10 min. Supernatants were 
collected, with protein levels determined using a bicinchoninic acid (BCA) protein 
assay kit (Thermo Scientific, Etten-leur, The Netherlands), and stored at -20°C until 
use. 
  
RNA isolation, reverse transcription (RT), and qPCR 
Total RNA was extracted using the nucleospin RNA kit (Macherey-Nagel) and 
quantified using the Nanodrop ND-1000 UV-visibile (UV-Vis) spectrophotometer 
(Nanodrop Technologies, Wilmington, DE). For cDNA synthesis, 1 µg of total RNA 
was reverse transcribed using oligo(dT) primers and Moloney murine leukemia 
virus (M-MLV) polymerase (Promega, Leiden, The Netherlands) at 37°C. All 
quantitative PCRs (qPCRs), using primers shown in Table 1, were carried out in 
triplicate on a MyiQ singlecolor real-time PCR detection system or a CFX-384 real-
time PCR detection system (Bio-Rad Laboratories, Veenendaal, The Netherlands) 
with the use of IQ SYBR green supermix (Bio-Rad). The relative standard curve 
method was used to calculate arbitrary gene expression using the IQ5 software 
program (Bio-Rad). Three reference genes, encoding β2-micro- globulin (B2M), β-
actin (ACTB), and phospholipase A2 (YWHAZ), selected using the “Genorm method” 
(Genorm; Primer Design, Southampton, United Kingdom), were included to 
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Table 1.  Primer Tm and sequences of hCAP18, CYP24A1, CYP27B1, VDR, hBD-2 and hBD-3 genes 
 
SDS-PAGE Western blot  
For detection of hCAP18/LL-37, protein samples were dissolved in SDS sample 
buffer, containing 40 mM 1,4-dithioerythritol (DTE), 6% (wt/vol) SDS, 21% (vol/vol) 
glycerol, and 160 mM Tris-HCl (pH 7.0), heated for 5 min at 100°C, and applied on 
a 16.5% Tris-Tricine gel as previously described (37). For detection of CYP27B1 and 
β-actin, 30 µg protein lysate/lane was dissolved in SDS sample buffer containing 50 
mM dithiothreitol (DTT), 4% (wt/vol) SDS, 20% (vol/vol) glycerol, and 200 mM Tris-
HCl (pH 7.0), heated for 5 min at 100°C, and applied on a 10% SDS-PAGE gel. Next, 
proteins were blotted on a polyvinylidene difluoride (PDVF) membrane, and 
nonspecific binding sites were blocked in PBS containing 5% (vol/vol) heat-
inactivated newborn calf serum and 5% (wt/vol) skimmed milk for hCAP18/LL-37 
detection, in PBS containing 5% (wt/vol) skimmed milk for detection of CYP27B1, 
or in PBS containing 0.1% (vol/vol) Tween 20 and 1% (wt/vol) bovine serum albumin 
(BSA) for detection of β-actin. Membranes were probed with 1/400 diluted 
monoclonal anti-hCAP18/LL-37, clone 1.1.C12 (Hycult Biotech, Uden, The 
Netherlands), 1/100-diluted goat-anti-CYP27B1 (Santa Cruz clone C-12; Bio-
Connect B.V., Huissen, The Netherlands), or 1/10,000-diluted mouse monoclonal 
anti-β-actin (clone AC-74; Sigma- Aldrich, Zwijndrecht, The Netherlands) in their 
blocking buffer. Next, the membranes were incubated with 1/1,000-diluted goat 
anti-mouse– horseradish peroxidase (HRP)-conjugated antibody (Dako) for 
hCAP18/LL-37 and β-actin detection or in rabbit anti-goat–HRP-conjugated 
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antibody (Dako) for detection of CYP27B1. Finally, enhanced chemiluminescence 
(ECL) was used to visualize hCAP18/LL-37, CYP27B1, and β-actin on film (GE 
Healthcare, Hoevelaken, The Netherlands).  
 
Measurement of IP-10, IL-6, CCL5, CXCL8, and hBD-3  
Protein levels in basal media of gamma interferon-induced protein 10 (IP-10), IL-6 
(Hycult Biotech, Uden The Netherlands), chemokine (C-C motif) ligand 5 (CCL5) 
(R&D Systems, Minneapolis, MN), chemokine (C-X-C motif) ligand 8 (CXCL8) 
(Sanquin, Amsterdam, The Netherlands) and hBD-3 (Alpha Diagnostics, San 




Pseudomonas aeruginosa, clone PAO1 (ATCC, LGC Standards GmbH, Wesel, 
Germany) (32) was used to investigate the effects of both IL-13 and 25D3 on the 
antibacterial activity of bronchial epithelial cells. A single colony of PAO1 was 
inoculated into LB broth overnight. One part culture volume was transferred into 
nine parts of fresh LB broth and incubated for 3 h to obtain bacteria in the mid-log 
phase of the growth curve. Two hundred fifty CFU of bacteria, determined at a 
wavelength of 620 nm, in 42.5 µl 10 mM sodium phosphate buffer was mixed with 
7.5 µl of apical surface fluid (ASF) and incubated shaking for 3 h at 37°C. The 
mixtures were next plated on LB plates and incubated overnight at 37°C to assess 
surviving bacteria by CFU determination. 
 
Immunofluorescence staining of hCAP18/LL-37 in bronchial epithelial cells  
Cells that were fixed on Transwell inserts in 1% paraformaldehyde were 
permeabilized with PBS–1% BSA–0.05% Tween 20 for 30 min at 4°C and next fixed 
in methanol for 20 min at 4°C. Primary antibodies were incubated for 1 h at room 
temperature (rabbit-anti-hCAP-18/LL-37, 1/100, (Innovagen, Lund, Sweden) in 
PBS–1% BSA (PBS-BSA) with the cells, followed by incubation with an Alexa Fluor 
647-labeled secondary antibody (1/200, Alexa Fluor 647 goat anti-rabbit IgG; 
Invitrogen) together with DAPI in PBS-BSA for 30 min at room temperature. Images 





Results are expressed as means ± standard errors of the means (SEM), and data 
were analyzed using the paired Student t test. Differences at P values of < 0.05 were 




25D3 suppresses poly(I:C)-induced release of proinflammatory mediators, 
while 25D3-mediated hCAP18/LL-37 expression is partly inhibited by 
poly(I:C) in well-differentiated bronchial epithelial cells 
We first determined whether our bronchial epithelial cells that were cultured at the 
air-liquid interface responded to the inactive 25D3. Previously it was shown that 
25D3 decreased expression of chemokine CXCL8 induced by poly(I·C) (15). To 
investigate whether 25D3 also reduces chemokine and cytokine expression in our 
well-differentiated bronchial epithelial cell cultures, cell cultures from 10 different 
donors were incubated with 50 and 5 µg/ml poly(I·C) in the presence or absence of 
25D3 for 24 h. Prior to the collection of the supernatants, cells were visually checked 
for any toxic effects and showed no signs of any toxicity. Poly(I:C) induced release 
of CXCL8, CCL5, IP-10, and IL-6. Release of IP-10 and CCL5 was suppressed in the 
presence of 25D3, whereas a trend toward suppression was observed in CXCL8 and 
IL-6 release by 25D3 (Figure 1A). These data suggest that in addition to poorly 
differentiated submerged cultures of tracheobronchial epithelial cells (15), well-
differentiated bronchial epithelial cells also respond to 25D3 and are most likely to 
be able to convert inactive 25D3 into active 1,25D3. Poly(I:C) was previously found 
to increase 25D3-mediated expression of hCAP18/LL-37 in submerged 
tracheobronchial epithelial cells via induction of the 25D3-activating enzyme 
CYP27B1 (25). In contrast, when we examined this in air-liquid-interface cultured 
cells, poly(I:C) was found to decrease 25D3-induced hCAP18/LL-37 expression 
(Figure 1B).  
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Figure 1. Effect of 25D3 and poly(I:C) on hCAP18/LL-37 expression and cytokine and chemokine 
release by bronchial epithelial cells. Well-differentiated epithelial cells were stimulated with poly(I·C) 
(at 50 and 5µg/ml) with and without 10-7 M 25D3 and by 25D3 alone for 24 h in duplicate. (A) 
Inflammatory mediators were measured in basal medium using ELISA. Data are shown as means ± 
SEM (n = 10 different donors). (B) Quantitative PCR was used to assess relative mRNA expression for 
hCAP18/LL-37. The expression of the β2-microglobulin, β-actin, and phospholipase A2 reference 
genes was used to calculate normalized gene expression. Data are represented as means ± SEM. 
 
IL-13 increases 25D3-mediated hCAP18/LL-37 expression and release in 
bronchial epithelial cells  
To examine whether the Th2 cytokine IL-13 affects vitamin D-mediated hCAP18/LL-
37 expression in air-liquid-interface cultures, we assessed hCAP18/LL-37 expression 
after preincubating the cells with IL-13 for 24 h to examine the effect of allergic 
airway inflammation on responses to vitamin D. 25D3 treatment following IL-13 
exposure increased hCAP18/LL-37 mRNA compared to the effects of 25D3 
treatment alone (Figure 2A). This was confirmed at the protein level by SDS PAGE 
Western blot analysis showing an increased hCAP18/LL-37 protein release in basal 
medium after exposure to IL-13 and 25D3 compared to the effects of 25D3 alone 
(Figure 2B). In addition to Western blotting, the findings were also confirmed using 
immunofluorescence staining (IF) of hCAP18/LL-37 on bronchial epithelial cells. We 
observed an intense staining of hCAP18/LL-37, which was increased after exposure 
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presented in a granular pattern (Figure 2C), which was also found in keratinocytes 
by Braff and colleagues (38). 
 
Figure 2. Effect of IL-13 on 25D3-mediated induction of hCAP18/LL-37 in bronchial epithelial cells. 
Cells were pretreated with 100 ng/ml IL-13 for 24 h and then exposed for another 48 h in duplicate to 
100 ng/ml IL-13 with and without 10-7 M 25D3 or 10-7 M 1,25D3, included as a positive control. (A) 
Quantitative PCR was used to assess relative mRNA expression for hCAP18/LL-37. The expression of 
the β2-microglobulin, β-actin, and phospholipase A2 reference genes was used to calculate 
normalized gene expression. Data are represented as means ± SEM(n = 7). (B) SDS-PAGE, followed by 
Western blot analysis, was used to assess LL-37 production in basal medium of the exposed cells. This 
Western blot is illustrative of 5 separate experiments using different donors. Nasal secretion and 25 
pg synthetic LL-37 were used as positive controls to show intact hCAP18 and mature LL-37 peptide, 
respectively. (C) Immune fluorescence staining of hCAP18/LL-37 in bronchial epithelial cells. DAPI 
(blue) was used to stain the nuclei, and rabbit anti-LL-37 antibody together with Alexa Fluor 647 goat 
anti-rabbit IgG (red) were used for detection of hCAP18/LL-37. The detailed picture shows hCAP18/LL-
37 as a granular staining pattern in the cytoplasm of the cells. 
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Effect of IL-13 on expression of VDR, CYP24A1, and CYP27B1  
To investigate possible mechanisms underlying the effect of IL-13 on 25D3-induced 
hCAP18/LL-37 expression, cells were exposed to IL-13 for 24 h and next incubated 
for another 48 h in the presence of IL-13 and 25D3 to assess expression of VDR, 
CYP27B1, and CYP24A1. In addition to increasing hCAP18/LL-37, preincubation with 
IL-13 also increased the effect of 25D3 treatment on CYP24A1 mRNA (Figure 3A). 
Whereas IL-13 caused a significant increase in the expression of CYP27B1, the 
observed increase in VDR expression did not reach statistical significance (Figure 3B 
and C). The increase of CYP27B1 mRNA expression by IL-13 was furthermore 
confirmed by analysis of the CYP27B1 protein in a Western blot (Figure 3D). To 
verify whether related Th2 cytokines also induce CYP27B1 expression in bronchial 
epithelial cells, cells from two different donors were exposed to 20 ng/ml of IL-4 for 
24 h, resulting in an increased expression of CYP27B1 mRNA (see Figure S1 in the 
supplemental material). The observation that IL-13 increased 25D3-mediated 
expression of both CYP24A1 and hCAP18/LL-37 suggested that the effect of IL-13 







Figure 3. Effect of IL-13 on expression of CYP24A1, CYP27B1, and VDR in bronchial epithelial cells. 
Cells (n = 5 to 7 donors) were pretreated with 100 ng/ml IL-13 for 24 h and then exposed for another 
48 h in duplicate to 100 ng/ml IL-13 with and without 10-7 M 25D3 or 10-7 M 1,25D3, included as a 
positive control. Quantitative PCR was used to assess relative mRNA expression for CYP24A1 (A), 
CYP27B1 (B), or VDR (C). Data are represented as means ± SEM. SDS-PAGE followed by Western blot 
analysis was used to assess CYP27B1 and β-actin in protein lysates of the treated cells (D). 
 
IL-13 increases hBD-3 expression  
In addition of hCAP18/LL-37, epithelial cells also express a variety of other 
antimicrobial peptides. To investigate whether expression of other antimicrobial 
peptides was affected by IL-13 and 25D3 or 1,25D3, hBD-2 and hBD-3 expression 
was analyzed using qPCR (Figure 4A and B). Whereas hBD-2 was not affected by 
these stimuli, hBD-3 expression was increased in IL-13-treated cells. An ELISA was 
performed, using apical surface fluid (ASF) to confirm increased expression of hBD-
3 by IL-13 at the protein level (Figure 4C). In contrast to what was observed for hBD-
3 mRNA, IL-13 exposure did not increase hBD-3 peptide in ASF.  
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Figure 4. Effect of IL-13 on expression and/or release of hBD-2 and hBD-3 in bronchial epithelial 
cells. Cells (n = 5 to 7 donors) were pretreated with 100 ng/ml IL-13 for 24 h and then exposed for 
another 48 h in duplicate to 100 ng/ml IL-13 with and without 10-7 M 25D3 or 10-7 M 1,25D3, included 
as positive control. Quantitative PCR was used to assess relative mRNA expression for hBD-2 and hBD-
3. Data are represented as means ±  SEM. (A) hBD-2 expression. (B) hBD-3 expression. (C) Apical hBD-
3 release was measured in apical surface fluid (ASF) using ELISA. Cells from only 3 out of 6 donors had 
detectable hBD-3 levels. Data are shown as mean ± SEM. 
 
Both 25D3 and 1,25D3 increase antimicrobial activity against Pseudomonas 
aeruginosa 
To explore whether the increased release of hCAP18/LL-37 in IL-13- and 25D3-
exposed bronchial epithelial cells was also accompanied by increased antimicrobial 
activity, an antimicrobial activity assay was performed using ASF incubated with 
Pseudomonas aeruginosa PAO1 (Figure 5). ASF of cells stimulated with 25D3 or 
1,25D3 displayed increased antimicrobial activity against PAO1. However, exposure 





Figure 5. Effect of IL-13 on 25D3-mediated antimicrobial activity. Apical surface fluid of cells (n = 3) 
was pretreated with 100 ng/ml IL-13 for 24 h and then exposed for another 48 h in triplicate to 100 
ng/ml IL-13 with and without 10-7 M 25D3 or 10-7 M 1,25D3, included as a positive control in antibiotics 
free medium. After 48 h, apical surface fluid was harvested using phosphate buffer (ASF), and pooled. 





In the present study, we have shown that exposure to IL-13 increases the ability of 
25D3 to induce expression of hCAP18/LL-37 and CYP24A1. The induced expression 
of hCAP18/LL-37 by IL-13 in 25D3-treated cells was furthermore confirmed by 
Western blot analysis and immunofluorescence staining. IL-13 alone did not affect 
expression of hCAP18/LL-37 and hBD-2 but did increase expression of hBD-3. 
However, the ELISA data show that hBD-3 was not increased in the apical surface 
fluid after IL-13 exposure. Secretions from cells treated with 25D3 or 1,25D3 showed 
increased antimicrobial activity against P. aeruginosa compared to data for control-
treated cells. However, the antimicrobial activity was not further increased by IL-
13. Analysis of genes involved in vitamin D response and metabolism showed that 
exposure to IL-13 induced expression of CYP27B1 but did not significantly increase 
expression of the VDR. However, a small but nonsignificant increase in VDR 
expression was observed in cells after exposure to IL-13. These results suggest that 
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mediated mainly by the enhanced conversion of 25D3 into 1,25D3 caused by 
increased expression of CYP27B1.  
Results from previous studies in epithelial cells that investigated the effects of 
vitamin D on hCAP18/LL-37 expression are in line with our results showing that 25D3 
increases expression and release of hCAP-18/LL-37. However, whereas poly(I·C) 
increased 25D3-mediated hCAP18/LL-37 expression in other studies (15), we 
observed a decrease. Our study adds to these studies that we used fully mucociliary 
differentiated air-liquid-interface cultures instead of the poorly differentiated 
submerged cultures used in the other studies, which may possibly explain the 
observed difference in effects of poly(I:C) on hCAP18/LL-37 expression. We also 
demonstrate for the first time that the Th2 cytokine IL-13 increases vitamin D-
induced expression of hCAP18/LL-37, most likely by increasing expression of the 
25D3-activating CYP27B1. A recent study by Liu et al. reported increased levels of 
LL-37, 1,25D3, and 25D3 in bronchoalveolar lavage (BAL) fluid from allergic subjects 
after segmental allergen challenge, which is in line with our observations (39). 
However, their observations could be partly explained by vascular leakage. In 
addition to the effect of IL-13 on vitamin D-induced expression of hCAP18/LL-37 
that was observed in the present study, IL-17A, which is also elevated in asthmatics, 
also increases vitamin D-mediated expression of hCAP18/ LL-37 in keratinocytes 
(40). In contrast to what was observed for IL-13 and also for IL-4, we observed that 
IL-17A did not increase induction of CYP27B1 expression (see Figure S1 in the 
supplemental material). A MEK-extracellular signal-regulated kinase (ERK)-
dependent mechanism was shown to increase vitamin D-induced hCAP18/LL-37 
expression by IL-17A (40). In addition to IL-13 in bronchial epithelial cells, 
transforming growth factor-β (TGF-β) also increases expression of CYP27B1 in 
keratinocytes (41), resulting in increased vitamin D-dependent hCAP18/LL-37 
expression, which is likely important for protection against pathogens during the 
wound-healing process (42). CYP27B1 expression is also induced by Toll-like 
receptor 2 (TLR2) agonists in keratinocytes and macrophages (20) and by TLR3 
agonists in poorly differentiated bronchial epithelial cells (15). Effects of Th2 
cytokines alone on expression of antimicrobial peptides and activity have been 
investigated previously in epithelial cells, showing inconsistent results. For 
example, Beisswenger and colleagues reported decreased hBD-2 expression and 
antimicrobial activity after 4 days’ exposure to IL-4 or IL-13 followed by exposure 
to P. aeruginosa and IL-4 or IL-13 (31), while we have previously shown that 
expression of hBD-2 and hCAP18/LL-37 was increased after 14 days’ exposure to IL-
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4 and IL-13 (32). In addition to these observations in bronchial epithelial cells, IL-4 
and IL-13 were shown to inhibit TNF-α- and IFN-γ- induced hBD-2 and hBD-3 
expression in keratinocytes (30), while increased expression of various 
antimicrobial genes in the gastrointestinal tract of IL-9 transgenic mice was 
dependent on IL-13 (43).  
We observed that 25D3 increases both expression and release of hCAP18/LL-37. In 
addition, we show increased killing of P. aeruginosa in apical surface fluid obtained 
from cells exposed to 1,25D3 or the combination of IL-13 and 25D3. However, in 
cells pretreated with IL-13 subsequently exposed to 25D3, we did not detect 
additional killing of P. aeruginosa compared to results with 25D3 alone, which is in 
contrast to what was expected based on the findings in our qPCR, Western blot, 
and immunofluorescence studies. To check if hCAP18/LL-37 was not released only 
at the basal side, we used the dot blot technique and observed that hCAP18/LL-37 
was also increased in the apical airway surface fluid of these cells stimulated with 
IL-13 and 25D3 compared to findings with 25D3 alone (see Figure S2A in the 
supplemental material). This apically secreted hCAP18/LL-37 may have been 
inhibited by mucins, since IL-13 also increases mucin production (44), which was 
confirmed in this study by showing increased MUC5AC protein in apical surface fluid 
from IL-13-treated cells (see Figure S2B). Therefore, the excess anionic mucus 
present in the apical washes of IL-13-treated cells may have bound the cationic LL-
37 in our samples, thereby reducing antimicrobial activity (45). In the lung, the 
mucus layer is separated from the epithelium by a periciliary layer, both of which 
are likely mixed during collection of apical surface fluid by washing. A recent study 
has shown that membrane-bound mucins form a barrier to prevent the mucus from 
penetrating the periciliary space (46) and thus may protect the AMPs present in this 
periciliary space from being inhibited by secreted mucins. Furthermore, the 
membrane-bound mucins that form this barrier may also bind secreted AMPs, 
which 
may therefore not be fully collected by apical washings. In addition, IL-13 might also 
decrease expression of other AMPs or e.g. affect ion concentrations (47), which 
may also result in suboptimal 
killing of pathogens by hCAP18/LL-37. Analysis of other AMPs, such as hBD-2 and 
hBD-3, by qPCR did not reveal a decrease in expression of these AMPs by IL-13. 
Whereas hBD-2 was not affected, hBD-3 expression was significantly higher after 
IL-13 treatment. However, this was in contrast with the hBD-3 levels in the apical 
surface fluid and could possibly be explained by the presence of anionic mucins in 
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the apical surface fluid binding the cationic hBD-3, resulting in lower detection of 
the hBD-3 peptide. 
Nevertheless, since IL-13 exposure may also decrease the expression of other 
antimicrobial molecules, as has been shown for short palate, lung, and nasal 
epithelium clone 1 (SPLUNC1) in primary airway epithelial cells (48-50), this 
possibility cannot be formally ruled out.  
Previously it was shown that airway surface fluid has a complex composition of 
antimicrobial mediators, suggesting that they might act in concert to kill pathogens 
(51). At 20 µg/ml of LL-37, P. aeruginosa survival was reduced by 90% in our 
experiments (data not shown). However, the amount of the detected hCAP18/LL-
37 protein is likely lower than the 25 pg synthetic LL-37 that was used for 
comparison in our Western blot. It is therefore likely that the observed increase of 
antimicrobial activity against P. aeruginosa by 25D3 or 1,25D3, cannot be explained 
only by the induction of hCAP18/LL-37 but may have resulted from the synergistic 
action with other antimicrobial substances present in the apical surface fluid (52, 
53). We demonstrate that exposing the cells to 25D3 with and without IL-13 and 
1,25D3 induced release of hCAP18/LL-37 in basal medium. Various studies have 
shown that extracellular hCAP18 is cleaved by proteases releasing the antimicrobial 
C-terminal cationic 4.5-kDa peptide LL-37 and a 14-kDa N-terminal cathelin protein. 
Other studies also reported Western blots showing proteins containing LL-37 
immunoreactivity at 14 kDa. Edfeldt and colleagues reported the presence of a 14-
kDa protein that bound anti-LL-37 antibodies in atherosclerotic lesions (54). In 
addition, Oren and colleagues reported that dimers or trimers of LL-37 may occur 
in solution (54, 55). Therefore, it is possible that the 14-kDa anti-LL-37 
immunoreactive peptides detected in our experiments were in fact polymers of 4.5-
kDa LL-37 peptides or partially cleaved hCAP18. 
Effects of Th2 cytokines on expression of other cytochrome P450 (CYP) molecules 
that are not involved in vitamin D metabolism were demonstrated earlier. Stoilov 
and colleagues showed that expression of Cyp genes, such as those encoding 
Cyp4f18, Cyp5a1, and Cyp7b1, were elevated in ovalbumin (OVA)-induced allergic 
airway disease in mice (56). In addition, IL-4 was shown to increase CYP2E1, most 
likely via protein kinase C (57). In this study, we report for the first time that IL-13 
increases expression of CYP27B1. However, future studies are needed to unravel 




Our study has some limitations. We were not able to detect increased generation 
of 1,25D3 in IL-13- and 25D3-exposed cell cultures, since these levels were below 
detection limits. Indirect evidence for the generation of increased 1,25D3 was the 
observation that IL-13 also increased 25D3-induced expression of CYP24A1. 
Moreover, whereas the presence of hCAP18/LL-37 in basal medium was readily 
detected by Western blotting, in the apical surface fluid hCAP18/LL-37 was 
demonstrated only by dot blot analysis.  
What is the clinical relevance importance of our findings? Viral and bacterial 
infections are a major cause of exacerbations in asthmatics. Viral infections cause 
release of proinflammatory cytokines and chemokines that mediate recruitment of 
various other inflammatory cells, which may contribute to inflammation during 
exacerbation in asthmatics. In the present study, we provide evidence that virus-
induced inflammation may be controlled by vitamin D and that vitamin D activation 
may be increased in atopic asthmatic airways resulting from Th2 inflammation. 
Importantly, our results show that in the presence of IL-13, vitamin D exposure 
results in higher expression of hCAP18/LL-37. This cathelicidin displays broad-
spectrum antimicrobial activity, affects inflammation and immunity, and stimulates 
wound repair (42, 58). Therefore, increased cathelicidin expression in asthma may 
contribute to increased host defense and wound repair. It is important to stress 
that epithelial cells produce much smaller amounts of hCAP18/LL-37 than 
neutrophils (59). Therefore, epithelial hCAP18/LL-37 may act initially by preventing 
the pathogens from disrupting the epithelial barrier. After disruption of the 
epithelial barrier, epithelial cell-derived hCAP18/LL-37 may serve as an alarmin by 
attracting neutrophils by its direct chemotactic activity or indirectly by increasing 
the release of CXCL8 from e.g., bronchial epithelial cells as well as airway smooth 
muscle cells (60, 61). Thus, recruited neutrophils could contribute to more-effective 
killing of pathogens and healing of the disrupted epithelium.  
In conclusion, our study shows that the Th2 cytokine IL-13 increases expression of 
the 25D3-activating CYP27B1, resulting in conversion of 25D3 into its active 
metabolite 1,25D3 and expression of the antimicrobial peptide hCAP18/LL-37 in 
bronchial epithelial cells. These data suggest that the vitamin D metabolic pathway 
in these cells, important in modulating the host defense against viral and bacterial 
infections, might be enhanced by Th2 cytokines. 
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Figure S1. Effect of IL-17A and IL-4 on CYP27B1 expression in bronchial epithelial cells. Bronchial 
epithelial cells (n= 2 donors) were exposed to 20 ng/ml IL-4 or 10 ng/ml IL-17A for 24 hours in 
duplicate. RNA isolation, cDNA synthesis, and quantitative PCR were performed as described in the 
Materials and Methods section. Quantitative PCR was used to assess relative mRNA expression for 
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Figure S2 A-B.  Effects of IL-13 and 25D3 on apical release of hCAP18/LL-37 and MUC5AC in bronchial 
epithelial cells. Cells of 2 different donors were pretreated with 100 ng/ml IL-13 for 24 hours and then 
exposed for another 48 hours in duplicate to 100 ng/ml IL-13 with and without 10-7 M 25D3 (or 10-7 M 
1,25D3 that was included as positive control). Dot blot analysis was used to assess LL-37 (A) and 
MUC5AC (B) production in ASF of the exposed cells. To determine apical release of MUC5AC protein 
and hCAP18/LL-37 protein, ASF of the cultures was diluted and spotted on a methanol pre-incubated 
PVDF-membrane using a Bio-Dot Microfiltration apparatus (Bio-Rad), and subsequently blocked with 
PBS/5% skimmed milk for MUC5AC detection or with PBS/5% heat-inactivated new born calf 
serum/5% skimmed milk overnight at 4°C. For detection  2 μg/ml of mouse-anti-MUC5AC (clone 
45M1;Labvision Neomarkers, Fremont, CA) or monoclonal anti-hCAP18/LL-37, clone 1.1.C12 (Hycult 
Biotech) was used. A HRP-conjugated goat-anti-mouse IgG (subclasses 1+2a+2b+3antibody) (Jackson 
ImmunoResearch Laboratory, Bar Harbor, ME) was used as a secondary antibody for MUC5AC and a 
HRP-conjugated goat-anti mouse Ig antibody(Dako) for the LL-37 dot blot and detected using ECL 
Western blotting substrate (Pierce, Rockford, IL). These Dot blots are both representative of 2 
separate experiments using different donors. Medium control (-) of Figure S2B was derived from a 
different part of the same membrane. Dot blot results show that hCAP18/LL-37 is increased in ASF 
after treatment with both 25D3 and IL-13, and that exposure of the cells to IL-13 resulted in an increase 
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Abstract 
 
Background: Vitamin D is well known for its function in calcium homeostasis and 
bone mineralisation, but is increasingly studied for its potential immunomodulatory 
properties. Vitamin D deficiency is a common problem in patients with COPD. 
Previous studies have not demonstrated a beneficial effect of vitamin D on 
exacerbation rate in COPD patients. However, subgroup analyses suggested 
protective effects in vitamin D deficient patients. Our objective is to assess the 
effect of vitamin D supplementation on exacerbation rate specifically in vitamin D 
deficient COPD patients. 
Methods/Design: We will perform a randomised, multi-center, double-blind, 
placebo-controlled intervention study. The study population consists of 240 COPD 
patients aged 40 years and older with vitamin D deficiency (25-hydroxyvitamin D 
concentration < 50 nmol/L). Participants will be recruited after an exacerbation and 
will be randomly allocated in a 1:1 ratio to receive vitamin D3 16800 IU or placebo 
orally once a week for 1 year. Participants will receive a diary card to register the 
incidence of exacerbations and changes in medication during the study period. 
Visits will be performed at baseline, at 6 months and at 12 months after 
randomisation. Participants will undergo spirometry, measurement of total lung 
capacity and assessment of maximal respiratory mouth pressure. Several physical 
performance and hand grip strength tests will be performed, questionnaires on 
quality of life and physical activity will be filled in, a nasal secretion sample and 
swab will be obtained, and blood samples will be taken. The primary outcome will 
be exacerbation rate.  
Discussion:  This study will be the first RCT aimed at the effects of vitamin D 
supplementation on exacerbation rate in vitamin D deficient COPD patients. Also, 
in contrast to earlier studies that used infrequent dosing regimens, our trial will 
study effects of a weekly dose of vitamin D supplementation. Second, the 
immunomodulatory effects of vitamin D on host immune response of COPD 
patients and underlying mechanisms will be studied. Finally, the effects on physical 






Chronic obstructive pulmonary disease (COPD) is characterized by a persistent 
airflow limitation and an abnormal inflammatory response of the airways. COPD is 
predicted to be the third worldwide cause of mortality by 2020 (1). Exacerbations 
in COPD determine disease-associated morbidity and mortality (2). Patients with 
frequent exacerbations have a more rapid decline in lung function, worse quality of 
life and decreased exercise performance. Yet, effective treatment alternatives to 
prevent exacerbations are still lacking.  
Vitamin D deficiency is highly prevalent in patients with COPD (3,4). Traditionally, 
vitamin D is associated with bone health. The discovery of the presence of vitamin 
D receptors (VDR) in many other cells, such as monocytes, macrophages, muscle 
cells and endothelial cells, has elicited hypotheses of direct vitamin D effects on 
these cells. These hypotheses are further strengthened by local 25-hydroxyvitamin 
D-1-alpha-hydroxylase activity, which converts the inactive 25-hydroxyvitamin D 
(25(OH)D) to the active 1,25-dihydroxyvitamin D (1,25(OH)2D), in many of these 
cells. The presence of vitamin D receptors on immune cells (5) and the high 
prevalence of vitamin D deficiency among COPD patients has given rise to the 
hypothesis that vitamin D might have a potential effect in preventing exacerbations 
in patients with COPD (6). 
 
Vitamin D and the immune system 
There is a large body of evidence being generated in vitro and in vivo to 
demonstrate that vitamin D influences the innate and adaptive immune system. 
1,25(OH)2D is the active form of vitamin D that binds to the VDR, thereby 
influencing the expression of more than 200 genes. VDR is expressed on a range of 
immune cells such as macrophages, dendritic cells, and CD4-positive T lymphocytes 
(5). In the innate immune system vitamin D modulates Toll-like receptor (TLR)-
induced immune responses through inhibition of the NF-κB-pathway  and appears 
to improve antimicrobial defences in general (7,8). Vitamin D is capable of inducing 
endogenous expression of the antimicrobial peptides (AMP) such as cathelicidin. 
This has been reported in monocytes, macrophages, keratinocytes and in lung 
epithelial cells (9,10). Because AMPs have been found in multiple experimental 
systems to be essential for defence against a variety of microbial infections, it has 
been hypothesised that vitamin D can enhance resistance to infections (11). In 
addition, vitamin D seems capable of modifying the function of cells classically 
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associated with adaptive immunity whereby activation of VDR downregulates 
autoimmunity by promoting the differentiation of T-cells into regulatory T-cells 
(12). 
 
Vitamin D and pulmonary infections 
Vitamin D might influence the development and course of tuberculosis. Patients 
with low 25(OH)D concentrations have a higher risk of active tuberculosis and 
vitamin D supplementation may shorten the duration of disease (13). It is also 
known that patients with rickets more frequently suffer from airway infections and 
pneumonia (14). Several prospective cohort studies in the general population show 
that lower levels of 25(OH)D are related to increased risk of respiratory infections 
(15,16). A trial with Japanese schoolchildren during the influenza season 
demonstrated that, compared to placebo, vitamin D supplementation lowered the 
incidence of influenza A infections (17). Trials assessing effects of vitamin D 
supplementation on prevention of respiratory infections in the general adult 
population have shown conflicting results, which may partly be attributed to 
differences in prevalence of vitamin D deficiency at baseline and rise of serum 
25(OH)D levels during treatments (18,19).  
 
Vitamin D and COPD  
Patients with COPD are characterised by an abnormal inflammatory response of the 
airways. Viral and bacterial infections are important triggers of exacerbations and 
contribute to its progression. Thus, potential effects of vitamin D on the immune 
system pose an attractive mechanism for the treatment of COPD. Also, in some 
(20,21), but not all (22) studies in the general population serum 25(OH)D is 
positively associated with lung function. Vitamin D deficiency is present in 40 – 80% 
of patients with COPD and is related to disease severity (3,4). Recent cohort studies, 
however, did not show a relationship between 25(OH)D levels and exacerbation 
rate (23,24), although these studies had limited statistical power to rule out effects 
of vitamin D deficiency. 
In addition to exacerbations and lung function, skeletal muscle dysfunction in COPD 
patients contributes to poor exercise capacity, decreased quality of life and 
increased mortality (25,26). In COPD patients, vitamin D deficiency is related to 
impaired physical performance (27). In healthy adults, positive effects of vitamin D 
supplementation have been demonstrated on muscle function and physical 
performance in older and frail individuals (28,29).  
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RCTs vitamin D supplementation in COPD 
Few studies have been performed on the effects of vitamin D supplementation in 
patients with COPD. In the trial performed by Lehouck et al. (30) vitamin D 
supplementation did not reduce the incidence of exacerbations. However, in a 
post-hoc analysis of a subgroup of severely vitamin D deficient patients (25(OH)D 
concentration < 25 nmol/L), vitamin D supplementation decreased the 
exacerbation rate. In a very recent multi-center trial by Martineau et al. (31) vitamin 
D protected against moderate to severe exacerbations in a pre-specified subgroup 
of vitamin D deficient (25(OH)D concentrations < 50 nmol/L) participants, but not 
in the study population as a whole.  
Two studies have been performed assessing the effect of vitamin D 
supplementation on physical performance in patients with COPD. A pilot RCT did 
not show effects of vitamin D supplementation on physical performance, but was 
limited by the small number of 36 participants and short follow-up of 6 weeks (32). 
Also, the study was not specifically aimed at patients with vitamin D deficiency. In 
the aforementioned RCT by Lehouck et al. a post-hoc subgroup analysis of 50 
participants following a rehabilitation programme during the trial was performed 
(33). Participants receiving vitamin D supplementation had significantly larger 
improvements in inspiratory muscle strength and peak exercise tolerance, but not 
in quadriceps strength and 6-minutes walking distance. However, this study had 
limited statistical power and is only applicable for patients following a rehabilitation 
programme. These findings justify a well-designed RCT to study effects of vitamin 
D supplementation on muscle strength and physical performance. 
Little is known about the total dose and dose interval needed for extra-skeletal 
effects of vitamin D. In the study of Lehouck et al. (30) participants received a 
monthly dose of 100.000 IU. In the study of Martineau et al. (31) participants 
received 120.000 IU every two months. A large dose interval improves compliance 
but might also cause fluctuating levels of vitamin D metabolites (34). In two RCTs 
assessing the effect of vitamin D supplementation on falls and fractures, an increase 
of fall and/or fracture incidence were shown using annual high dose 
supplementation (35,36). While the mechanism by which vitamin D might cause an 
increase in falls remains uncertain, several authors suggest it is the dosing interval 
rather than the total dose that determined these outcomes (37). These results 
emphasize the need for RCT studying a more frequent dosing regimen of vitamin D. 
In the present study we aim to study the effects of vitamin D supplementation on 
exacerbation rate in COPD patients with vitamin D deficiency. In addition, we will 
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also assess the effects of vitamin D on several measures of physical performance. 
In our trial, we will administer a weekly dosing regimen in contrast to earlier 




Study design and participants 
The study is designed as a randomised double-blind, multi-center, placebo-
controlled trial, with an intervention (n=120) and a control group (n=120). The 
study population consists of COPD patients with GOLD stages II-IV. Participants will 
be included if they have a vitamin D deficiency (25(OH)D concentrations <50 
nmol/L) and a recent exacerbation of COPD. The eligibility criteria are described in 
Table 1. Participants will be recruited if they present with an exacerbation of COPD 
at the outpatient clinic or emergency ward. Screening serum 25(OH)D 
concentration will be measured during the exacerbation period. Inclusion and 
randomization will take place 6-8 weeks after screening or at a later time point as 
soon as the participant has recovered. An exacerbation is defined as sustained 
worsening of respiratory symptoms during 48 hours requiring oral corticosteroid, 
antibiotic or combination treatment that was initiated by a physician (38). 
Convalescence is defined as recovery to the stable state. The recruitment will start 
in three academic hospitals and five peripheral hospitals in the surroundings of the 
academic centers. Study visits will be performed at baseline (t=0), 6 months (t=6) 
and 12 months (t=12) after randomization as depicted in Figure 1. Participants will 
be contacted by telephone at 2, 4, 8 and 10 months. The study is approved by the 
Medical Ethics Committee of the VU University Medical Center, Radboud University 
Medical Center and Leiden University Medical Center. Written consent will be 




Table 1. Eligibility criteria for the PRECOVID trial 
Table 1. Eligibility criteria for the PRECOVID trial.  25(OH)D: 25-hydroxyvitamin D; FEV1: 
Forced Expiratory Volume in one second; FVC: Forced Vital Capacity; eGFR: estimated Glomerular 
Filtration Rate with the MDRD formula. 
  
Inclusion criteria Exclusion criteria 
Vitamin D deficiency (serum 25(OH)D < 50 
nmol/l) 
Severe vitamin D deficiency (serum 25(OH)D 
<15 nmol/l),   
Postbronchodilator FEV1/FVC < 0.70, FEV1 < 
80%    and diagnosis COPD confirmed by a 
physician 
Use of a supplement containing more than 
400 IU vitamin D per day 
Recent COPD exacerbation Use of maintenance dose oral corticosteroids 
≥ 10 packyears of smoking Diagnosed asthma 
Age ≥ 40 years Diagnosed osteoporosis 
Written informed consent Self-reported history of hypercalcaemia or 
nephrolithiasis 
Ability to comply with all study requirements Self-reported presence of sarcoidosis 
 Diagnosed chronic kidney disease stage 4 or 
higher  
(eGFR ≤ 29 ml/min/1.73 m2) 
 Interfering malignant diseases 
 Life expectation of less than 1 year on the 
basis of concurrent disease 
 Current participation in a clinical 
rehabilitation programme 
 Pregnant or lactating women, or subjects 
who intend to become pregnant within the 
study period 
 Potentially unreliable patients and those 
judged by the investigator to be unsuitable 
for the study 
 Serious mental impairment i.e. preventing to 
understand the study protocol or comply 
with the study aim 
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Figure 1. Flowchart of study procedures during the PRECOVID trial.  Randomization will take place 
within 4-6 weeks after an exacerbation. During the study period of one year three study visits and four 
telephone contacts will take place. MIP: Maximal inspiratory pressure; MEP: Maximal expiratory 
pressure; TLC: Total lung capacity.  
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The participants will receive either vitamin D 16800 IU (3 tablets of 5600 IU) or a 
matching placebo (3 placebo tablets) orally once a week during 12 months in 
accordance with the randomisation. The study medication will be prepared under 
supervision of the clinical pharmacy of the VU University Medical Center. 
Participants will be asked to return the study medication that is left over, and these 
tablets will be counted as a measure for compliance. Participants are allowed to 
use a maximum of 400 IU a day during the study, as this is the recommended daily 
intake by the Dutch Health Council. Participants will be asked about the usual intake 
of dairy products. Participants are advised (according to the advice of the Dutch 
Health Council) to increase their intake to a level corresponding with 1000 mg 
calcium per day. If this is not feasible, it will be advised to use calcium supplements 
to a total calcium intake of 1000 mg/day during the study.   
Randomization and masking 
For treatment allocation in this trial, we will apply the sequential balancing method 
with study center as the first step in the balancing algorithm, followed by gender, 
age and current smoking. These variables are (potential) prognostic factors and 
thus should be balanced over the treatment arms. Pharmacists of the VU University 
Medical Center, who are independent from the clinical research team, will 
randomly assign participants by using a computer-generated randomisation list and 
will prepare the study medication. After the last participant finishes the trial 




Primary outcome is exacerbation rate. An exacerbation is defined as sustained 
worsening of respiratory symptoms during 48 hours requiring oral corticosteroid, 
antibiotic or combination treatment that was initiated by a physician. Respiratory 
symptoms include at least one of the Anthonisen criteria, which are increased 
dyspnea, sputum volume or sputum purulence, with or without minor symptoms 
such as cough, fever, common cold, wheezing or sore throat (38). Participants will 
register symptoms and changes in medication on a diary card during the whole 
study period. During each telephone contact and study visit diary cards will be 
discussed and reviewed. Also questions will be asked regarding hospitalization 
during the last months. If necessary, information on changes in medication and 
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COPD exacerbations during the study period will be confirmed through contact with 
the providing pharmacist, the general practitioner and hospital. 
 
Secondary outcomes 
Time to first and second exacerbation and time to fist hospitalisation 
Time to first and second exacerbation and time to first hospitalisation will be 
registered on the basis of the diary card and interviews.  
Use of antibiotic and corticosteroids 
With the use of earlier mentioned diary card and interviews the use of antibiotics 
and corticosteroids will be registered. 
Spirometry measures  
At t=0 and t=12 participants will undergo spirometry. The spirometry will be 
performed according to American Thoracic Society/European Respiratory Society 
(ATS/ERS) guidelines (39). Only post-bronchodilator forced expiratory volume in 
one second (FEV1) and forced vital capacity (FVC) will be determined. 
Measurements will take place after inhalation of the sympathomimetic salbutamol 
and/or the anticholinergic ipratropium bromide. Inspiratory capacity (IC) and 
expiratory reserve volume (ERV) will also be determined according to ATS/ERS 
guidelines (39).  
Lung volumes 
Measurements of absolute lung volume, residual volume (RV), functional residual 
capacity (FRC) and total lung capacity (TLC) will be assessed by body 
plethysmography according to guidelines of the ATS/ERS task force at t=0 and t=12 
(40) (41). 
 
Maximal respiratory mouth pressures 
Respiratory muscle strength will be tested by measurement of the maximal 
inspiratory and expiratory mouth pressure (MIP and MEP, respectively). 
Measurement will be made with a mechanical pressure gauge that is connected to 
a mouthpiece according to the revised ATS guideline (42).  
Physical performance 
During every visit (t=0, t=6 and t=12), participants will perform physical 
performance tests.  
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In the 6-minutes walking test the participant is asked to walk as far as possible 
during a period of 6 minutes. The participant will walk up and down a hallway. The 
6-minutes walking test is performed according to the ATS guidelines (43). In the 
chair-stands-test the participant will be asked to fold his arms across his chest and 
to stand up from a sitting position and sit down five times as quickly as possible 
(44,45). In the 3-meter walking test the participant is asked to walk three meters, 
turn around 180° and walk back (44,46). In the tandem test the participant is asked 
to stand with the heel of one foot directly in front of, and touching the toes of, the 
other foot for at least 20 seconds with his eyes open and closed (44,47).  
 
Muscle strength  
Muscle strength will be assessed with measurement of hand grip strength. The 
participant is seated in a chair and holds the dynamometer in the hand, with the 
arm at right angles and the elbow by the side of the body. The handle of the 
dynamometer is adjusted if required. When ready, he squeezes the dynamometer 
with maximum isometric effort, which is maintained for about 5 seconds. No other 
body movement is allowed. This measurement will be performed three times with 
both hands (48). 
Quality of life 
Quality of life will be assessed by three questionnaires These will be completed at 
every study visit. The St. George’s Respiratory Questionnaire (SGRQ) is designed to 
measure health impairment in patients with asthma and COPD (49,50) and 
produces a symptoms score and an activity and impacts score. The Short Form 12 
health Survey (SF-12) is a multipurpose short-form generic measure of health status 
(51). It is a validated subset of the larger SF-36 and monitors health in general and 
in specific populations. These scores correlate highly with the SF-36 versions (52). 
The SF-12 has been previously used in patients with COPD (50,53). The Clinical 
COPD questionnaire (CCQ) is a simple 10-item, health-related quality of life 
questionnaire with good psychometric properties (54). The questionnaire is 
responsive to pulmonary rehabilitation and a minimal clinically important 
difference has recently been defined (55).  
 
Anxiety and depression 
Anxiety and depression will be assessed by means of two questionnaires and will 
be completed at every study visit. The Hospital Anxiety Depression Scale (HADS) is 
a questionnaire measuring feelings of depression and anxiety (56). Reliability and 
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validation of the Dutch translation of the HADS has been reported (57). The HADS 
is frequently applied in research in patients with COPD (58,59). The Center for 
Epidemiologic Studies Depression Scale (CES-D) is a self-report scale designed to 
measure depressive symptoms in the general population. The development of the 
scale has been described in detail elsewhere (60). The scale has been used in several 
COPD populations (61,62). 
Physical activity 
Physical activity will be assessed by the Short QUestionnaire to ASses Health 
enhancing physical activity (SQUASH). SQUASH is a self-report instrument to 
measure habitual physical activity (63). The questionnaire has been used in COPD 
populations (64). 
Antimicrobial peptides and pro-inflammatory mediators in nasal secretions 
Nasal secretions will be collected by vacuum-aided suction to prevent dilution that 
occurs when using lavage-based methods (65). The nasal secretions will be analyzed 
for the presence of antimicrobial peptides and pro-inflammatory cytokines 
(hCAP18/LL-37, HNP1-3, NGAL, IL-1ß, TNF-α, IL-6) using enzyme-linked 
immunosorbent assays (ELISA). 
Typing of bacteria and viruses in nasal secretions 
A nasal swab will be obtained using standard procedures. PCR on presence of 
bacteria and respiratory viruses (non-typeable Haemophilus  influenzae, 
Streptococcus pneumoniae, Moraxella catarrhalis and a panel of respiratory viruses 
including rhinovirus) will be performed. 
Inflammation and host response against infectious agents 
In one of the academic centers peripheral blood mononuclear cells (PBMC) and 
platelets will be derived from 50 participants before and after the intervention. 
Venous blood will be drawn in EDTA and 3.2% sodium citrate tubes after which 
PBMC and platelet-rich plasma (PRP)will be isolated, washed and suspended.  
PBMC will be stimulated with various agonists to TLR (bacterial, fungal and viral) 
and with microbial stimuli. The following stimuli will be used: RPMI (control), LPS 
(TLR4), Pam3Cys (TLR2), Poly(I:C) (TLR 3), Streptococcus pneumoniae, Non-typeable 
Haemophilus influenza, Pseudomonas aeroginosa, Aspergillus fumigatus, sonicated 
Mycobacterium avium and Candida albicans.  Pro- and anti-inflammatory cytokines 
will be measured before and after stimulation: TNF-α, Il-1ß, IL-6, IFN-γ (24 hours 
incubation) and IL-10, IL-17 and IL-22 (7 days incubation). All cytokines will be 
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measured in cell culture supernatants using ELISA. PRP will be used for analyses of 
platelet function in terms of activation and aggregation. Second, phenotyping of 
circulating immune cells will be done using advanced multiparameter 
flowcytometry and functional readouts. A whole blood staining will be used to be 
able to calculate absolute numbers of CD4 (including Treg), CD8 T cells, NK cells, B 
cells and monocytes. Next, a detailed phenotypic analysis of the T cell compartment 
will be performed by additional staining of whole blood or isolated PBMC using 
antibodies. Functional characteristics of the T cell compartment (CD4+, CD8+, 
CD4+/Foxp3+ (Treg)) with respect to cytokine production (IFN-γ, IL-2, IL-4, IL-5, IL-
10 and IL-17A) and their associated transcription factors (Tbet, Gata-3, RORyt) will 
be analyzed.   
Sample size calculation 
The study is designed to demonstrate a minimum difference of one exacerbation 
per patient-year between the vitamin D and the placebo group. We based our 
assumptions on post-hoc analyses of the RCT by Lehouck et al.(30), which had a 
similar patient sample, although without selection for vitamin D deficiency. Based 
on differences in Poisson means, a sample size of 94 participants per group is 
needed to demonstrate a difference of 1 exacerbation per patient-year with 80% 
power at 5% significance. This number was based on the assumption of 2.45 
exacerbations per patient-year in the intervention group and 3.45 in the placebo 





The primary outcome of the trial, exacerbation rate, will be analyzed with 
generalized linear models for a Poisson distribution. Analyses will be adjusted for 
the variables included in the balancing algorithm for randomization, i.e. study 
center, gender, age and current smoking. The outcomes will be presented as rate 
ratios with their 95% confidence interval.   
Secondary outcomes 
Time to first exacerbation and hospitalisation will be assessed with Kaplan–Meier 
curves and Cox proportional hazard models. Dichotomous secondary outcomes will 
be analysed with logistic regression models and continuous secondary outcomes 
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with analysis of covariance. All analyses will be adjusted for the variables included 
in the balancing algorithm for randomisation, i.e. study center, gender, age and 
current smoking. Because of the exploratory nature of the analyses, no correction 
will be made for the multiple analyses. All analyses of the trial will use the intention-
to-treat population, defined as all randomly assigned participants who received at 
least 1 dose of study medication. A per-protocol analysis will be performed on those 
participants with a good compliance i.e. obtaining a serum 25(OH)D concentration 
above the 20th percentile after 12 months. Also, a subgroup analysis will be 
performed in participants with a baseline serum 25(OH)D concentration of 25 




This RCT is the first intervention study examining effects of vitamin D 
supplementation in a cohort of vitamin D deficient COPD patients. With this study 
we expect to gain more insight in the effects of vitamin D supplementation on 
exacerbation rate and both pulmonary and physical function. The two previous 
RCTs (30,31) did not show an effect of vitamin D supplementation in the total study 
population of COPD patients. They did, however, show a protective role of vitamin 
D against exacerbations in deficient patients. These are promising results and 
emphasise the need for an RCT specifically in vitamin D deficient patients 
considering the high prevalence of vitamin D deficiency in patients with COPD. In 
our study participants with a severe vitamin D deficiency (25(OH)D <15 nmol/L) will 
be excluded because of ethical considerations. 
Our study differs in several other aspects from previous studies. In addition to the 
effects of vitamin D on exacerbation rate, present study will focus on potential 
underlying mechanisms.  In nasal secretionthe presence of antimicrobial peptides 
and pro-inflammatory mediators will be measured and the microbial composition 
of the nasal mucosa will be analysed. Furthermore, PBMC’s from a subgroup of 
participants will be challenged with TLR-ligands and several pathogens in order to 
measure cytokine responses.  These tests will be performed before and after the 
intervention to measure effects of vitamin D supplementation on cytokine 
responses and therefore inflammation and host response. Finally, we will assess 
physical performance in several different manners. In contrast to earlier studies, 
we will use a weekly dosing regimen, which leads to more stable 25(OH)D levels 
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(34), but may influence compliance. This is important since little is known about the 
total dose and dose interval needed for extra-skeletal effects of vitamin D. 
As stated earlier exacerbations have a major impact on somatic and mental health 
status of COPD patients (2). With the increasing prevalence of COPD,  the economic 
burden will expand significantly (1). Exacerbations constitute the most important 
direct costs associated with COPD. Treatments directed to reduce incidence and 
severity of exacerbations improve long-term health status and reduce health care 
costs (66). Vitamin D might therefore be an attractive treatment alternative, as it is 
easily applicable, cheap and safe. 
6
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Vitamin D plays an active role in the modulation of innate and adaptive immune 
responses as well as in the protection against respiratory pathogens. Evidence for 
this immunomodulatory and protective role is derived from observational studies 
showing an association between vitamin D deficiency, chronic airway diseases and 
respiratory infections, and is supported by a range of experimental studies using 
cell culture and animal models. Furthermore, recent intervention studies have now 
shown that vitamin D supplementation reduces exacerbation rates in vitamin D-
deficient patients with chronic obstructive pulmonary disease (COPD) or asthma 
and decreases the incidence of acute respiratory tract infections. Vitamin D is 
known to contribute to the integrity of the mucosal barrier, promote killing of 
pathogens (via the induction of antimicrobial peptides) and to modulate 
inflammation and immune responses. These mechanisms may partly explain its 
protective role against infections and exacerbations in COPD and asthma patients. 
The respiratory mucosa is an important site of local vitamin D metabolism and 
signaling, a process that can be affected by exposure to inflammatory mediators. 
As a consequence, mucosal inflammation and other disease-associated factors, as 
observed in e.g. COPD and asthma, may modulate the protective actions of vitamin 
D. Here, we discuss the potential consequences of various disease-associated 
processes such as inflammation and exposure to pathogens and inhaled toxicants 
on vitamin D metabolism and local responses to vitamin D in both immune- and 
epithelial cells. We furthermore discuss potential consequences of disturbed 
vitamin D bioavailability for chronic lung diseases. Additional insight into the 
relationship between disease-associated mechanisms and local effects of vitamin D 
is expected to contribute to the design of future strategies aimed at improving local 






Vitamin D is a pleiotropic hormone that is well known for its role in the regulation 
of calcium and phosphate homeostasis and bone mineralization. The receptor for 
vitamin D (VDR) is however expressed in nearly all tissues and cells and regulates a 
large number of genes (approximately 0.8-5% of the total genome) (1, 2). As a 
result, vitamin D affects many additional processes including cell proliferation and 
differentiation, apoptosis, DNA repair, ion transport, metabolism, cell adhesion, 
and oxidative stress responses (1, 3). Vitamin D deficiency (serum 25(OH)D < 50 
nmol/L; 25(OH)D is the main circulating form of vitamin D and its levels are used to 
assess vitamin D status in the clinic (4, 5)) affects more than 30% of the children 
and adults worldwide and is a major cause of bone diseases such as rickets and 
osteoporosis (6). Increasing evidence has indicated that vitamin D deficiency is also 
associated with various other diseases such as cancer, cardiovascular disease, 
Alzheimer’s disease and muscle myopathy, as well as several immune-related 
diseases such as type 1 diabetes, multiple sclerosis, inflammatory bowel disease 
(IBD), psoriasis and chronic inflammatory lung diseases including asthma, cystic 
fibrosis (CF)  and chronic obstructive pulmonary disease (COPD) (6-9).  
Several studies have now shown that vitamin D deficiency is prevalent in COPD 
patients and inversely correlated with lung function and severity of the disease (8, 
10-12). It is currently unknown whether vitamin D deficiency is a cause or 
consequence of COPD, since many COPD patients have low physical activity levels 
and spend most time indoors (13). There are however studies suggesting that low 
vitamin D levels are associated with development of COPD, based on observed 
associations between polymorphisms in the vitamin D binding protein (VDBP), 
vitamin D serum levels and COPD severity (8, 10, 11, 14). In addition, one study in 
mice showed that maternal vitamin D deficiency can impair lung -development, -
structure and -function in the offspring and suggests that even before birth, 
maternal 25(OH)D serum levels are important for a healthy lung development (15). 
This might be relevant, since associations have been found between lower 
childhood lung function and development of COPD later in life (16). The link 
between maternal 25(OH)D status and asthma development is however much 
clearer, since two recent randomized controlled trials (RCTs) have shown that 
maternal vitamin D supplementation reduces the risk of childhood 
asthma/recurrent wheeze (17). This might be explained by the fact that multiple 
7
Impact of the local inflammatory environment on
mucosal vitamin D metabolism and signaling in chronic inflammatory lung diseases
173
vitamin D-regulated genes are transcriptionally active during alveolar maturation 
and a number of these genes are differentially expressed in asthma (18). 
Additionally, this protective effect was linked to  the GG-genotype of the 17q21 
functional SNP rs12936231, which is associated with lower expression of ORMDL3 
and increased sphingolipid metabolism (19). Moreover, maternal circulating 
25(OH)D levels affect the gut microbiota and can therefore indirectly modulate 
immune responses in the lung via the gut-lung-axis (20). Also later in life, optimal 
25(OH)D levels remain crucial for keeping the lungs healthy. For example, Heulens 
et al. showed that subacute and chronic cigarette smoke (CS) exposure decreased 
lung function and promoted early signs of emphysema and airway inflammation in 
vitamin D-deficient mice compared to vitamin D-sufficient animals (21). Similarly in 
an elastase-induced COPD mouse model, topical administration of vitamin D in the 
lungs counteracted alveolar damage and improved lung function (22). Yet in 
humans, it is still unclear whether vitamin D affects COPD development and disease 
progression. Taken together, these observations suggest an important role for 
vitamin D during fetal and childhood lung maturation, and indicate that sufficient 
vitamin D levels might contribute to protection against development of childhood 
asthma and possibly COPD at older age.  
Systemic levels of biologically active vitamin D are tightly regulated to preserve 
sufficient levels of calcium (Ca2+) and phosphate (PO42-) for optimal bone 
mineralization, whereas in mucosal tissues locally produced (autocrine) active 
vitamin D levels and signaling can be elevated or decreased upon exposure to 
inflammatory mediators, pathogens or inhaled toxicants (6). This could be 
important, since the inflamed airway mucosa of patients suffering from chronic 
inflammatory lung diseases is constantly exposed to these disease-associated 
factors (8, 23, 24). Impaired vitamin D bioavailability and signaling might have 
consequences for disease pathogenesis and progression. Dysregulated host 
defenses as found in patients with chronic inflammatory airway diseases include 
aberrant immune responses, altered microbiome composition, impaired epithelial 
barrier function and aberrant secretion of host defense molecules (25-27). 
Adequate vitamin D levels may provide protection against these dysregulated 
processes by maintaining the integrity of the mucosal barrier and promotion of 
killing of pathogens (e.g. via the induction of the antimicrobial peptide [AMP] 
hCAP18/LL-37) and via the modulation of both innate and adaptive immune 
responses (7, 28, 29).  
174
Chapter 7
In this review, we first discuss the effects of these disease-associated factors on 
local bioavailability of vitamin D and vitamin D-induced responses in the lung 
mucosa. In the second part of the review we will describe the mechanistic links 
between vitamin D deficiency and the pathogenesis of chronic inflammatory lung 
diseases such as asthma, CF and COPD, and discuss recent evidence related to the 
protective effects of vitamin D on COPD and on COPD exacerbations.  
 
Regulation of mucosal vitamin D metabolism in health  
 
Vitamin D enters the circulation either via food intake or as a result of its synthesis 
in the skin by UVB radiation. It subsequently binds to the VDBP (30, 31), after which 
this complex is transported to the liver where it is converted by vitamin D-25-
hydroxylases (CYP2RI and CYP27A1) into 25-hydroxy-vitamin D [25(OH)D]. 
However, recent studies showed that also other cell types such as airway epithelial 
cells, keratinocytes, intestinal epithelial cells, and monocytes/macrophages express 
CYP2RI and CYP27A1, and thus are able to (locally) convert vitamin D3 into 25(OH)D3 
(32, 33). This inactive 25(OH)D needs to be converted into the active 1,25 
dihydroxy-vitamin D (1,25(OH)2D) by 25-hydroxyvitamin D-1α-hydroxylase 
(CYP27B1) in the kidney and in other cells, including several immune- and epithelial 
cells (34-40). 1,25(OH)2D regulates expression of several genes by binding the 
nuclear VDR, which heterodimerizes with the retinoic acid receptor (RXR) to 
interact with vitamin D response elements (VDREs) that are present on the 
promoter region of these genes (1, 2). VDR is most abundantly expressed in 
intestinal enterocytes, pancreatic islets, renal distal tubules and osteoblasts, but is 
also present at lower levels in most other tissues and several other epithelial- and 
immune cells (41-45). Expression of VDR is classically regulated by 1,25(OH)2D, 
growth factors and hormones such as FGF-23 and PTH respectively, circulating 
calcium-levels, bile acids, transcriptional co-activators/repressors, and genetic- and 
epigenetic modifications, which is tissue specific (46-49). 1,25(OH)2D regulates its 
own negative feedback by several mechanisms, including induction of expression 
of the catabolic enzymes 25-hydroxyvitamin D-24-hydroxylase (CYP24A1) and 
CYP3A4 (50, 51). CYP24A1 is expressed in most tissues and converts both 25(OH)D 
and 1,25(OH)2D into biologically inactive 24,25(OH)2D and 1,24,25(OH)2D 
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respectively (50), whereas CYP3A4, mainly expressed in the liver and small 
intestines, contributes to the metabolic clearance of 25(OH)D and 1,25(OH)2D by 
converting 25(OH)D into 4β,25(OH)2D, and 1,25(OH)2D into 1,23R,25(OH)2D or 
1,24S,25(OH)2D (51). Expression of both CYP27B1 and CYP24A1 in the kidneys is 
tightly regulated to maintain optimal Ca2+- and PO42- levels in the circulation, which 
are important for bone mineralization(52). The complex mechanisms that explain 
how vitamin D and its metabolic enzymes maintain sufficient Ca2+ and PO42- levels 
in the circulation are explained by Quarles et al. (52). In summary, it has become 
increasingly evident that the effects of vitamin D are not limited to homeostasis of 
Ca2+ and PO42- and bone mineralization, because several extra-renal cells such as 
airway epithelial cells and immune cells express the VDR and are capable of 
converting circulating 25(OH)D into the active 1,25(OH)2D metabolite (Figure 1). 
 
Figure 1. Vitamin D metabolism and expression of hCAP18/LL-37 (CAMP) in epithelial cells. The 
vitamin D binding protein (VDBP)-25(OH)D complex enters the epithelial cell from the circulation and 
25(OH)D is subsequently released from the complex. In the cytoplasm, 25(OH)D is hydroxylated by 
25-hydroxyvitamin D-1α-hydroxylase (CYP27B1; localized to the inner mitochondrial membrane) into 
the active metabolite 1,25(OH)2D. 1,25(OH)2D subsequently binds to the nuclear vitamin D receptor 
(VDR) which heterodimerizes with the retinoic acid receptor (RXR) to interact with vitamin D response 
elements (VDREs) that are present on the promoter region of numerous genes, including CAMP 
(hCAP18/LL-37) and CYP24A1 (25-hydroxyvitamin D-24-hydroxylase). 1,25(OH)2D thereby regulates 
its own negative feedback via direct induction of CYP24A1 that converts both 25(OH)D and 1,25(OH)2D 




Altered regulation of mucosal vitamin D metabolism and 
vitamin D responsiveness in chronic inflammatory airway 
diseases 
 
Local bioavailability and activity of 1,25(OH)2D are in part determined by expression 
of VDR and the equilibrium between the vitamin D metabolic enzymes CYP27B1 
and CYP24A1. It is important to realize that mucosal expression of CYP24A1, 
CYP27B1 and also VDR can be affected by several disease-associated inflammatory 
mediators, toxicants and pathogens, summarized in Table I. As a consequence of 
this, the local bioavailability of vitamin D in tissues such as the inflamed airways of 
patients that suffer from chronic inflammatory airway diseases might be reduced. 
Cell/tissue type Stimulus Effect References 
Primary airway 
epithelial cells 
Poly(I:C); RSV; IL-13; IL-4; PM CYP27B1 ↑ (38, 54-56) 
 TNF-α; IL-1β; IL-17A; TGF-β1; 
NTHi 
CYP24A1 ↑ (57, 58) 
 CSE CYP27B1 ↓ (59, 60) 
 A. fumigatus; HRV; RSV VDR ↓ (56, 61) 
BEAS-2B  
(bronchial 
epithelial cell line) 
HRV; RSV VDR ↓ (56) 
 PM VDR ↑ (55) 
16HBE  
(bronchial 
epithelial cell line) 
A. fumigatus VDR ↑ (62) 
 TGF-β1 CYP27B1 ↑ (54) 




CSE VDR translocation ↓ (63) 
HCT116  
(colon cancer 
epithelial cell line) 
LPS; TNF-α CYP27B1 ↑ (64) 
 LPS; TNF-α VDR ↓ (64, 65) 
 LPS CYP24A1 ↓ (64) 
COGA-1A  
(colon cancer 
epithelial cell line) 
TNF-α ± IL-6 CYP27B1 ↓ (66) 
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Trophoblasts TNF-α; IL-1β; IL-6 CYP24A1 ↑ (67) 
 IFN-γ CYP27B1 ↑ (67) 










BaP CYP24A1 ↑ (70) 
Monocytes TLR2/1L ± IFN-γ; LPS; IL-15 CYP27B1 ↑ 
VDR ↑ 
(39, 71-73) 
 IL-4 ± TLR2/1L CYP24A1 ↑ (39) 
    
Neutrophils IFN-γ 





T cells T cell activators (anti-CD3/anti-









Table 1: Effects of inflammatory mediators on the expression of VDR, CYP24A1 and CYP27B1 in 
immune cells and epithelial cells.  
Abbreviations: Polyinosinic:polycytidylic acid (Poly(I:C); Particulate matter (PM); nontypeable 
Haemophilus influenzae (NTHi); Aspergillus fumigatus (A. fumigatus); Cigarette smoke extract (CSE); 
Human rhinovirus (HRV); Respiratory syncytial virus (RSV); Single stranded RNA (ssRNA); 
Benzo[a]pyrene (BaP); Toll like receptor 2/1 Ligand (TLR2/1L); Phytohemagglutinin (PHA); Phorbol 12-
myristate 13-acetate (PMA). 
Epithelial cells 
Chronic lung diseases are characterized by airway inflammation and impaired 
respiratory host defense, which is illustrated by the increased susceptibility for 
respiratory infections and exacerbations (77-79). Furthermore, exposure to inhaled 
toxicants such as cigarette smoke and air pollutants are associated with disease 
pathogenesis and exacerbations in COPD, CF and in asthma patients (80-82). It 
would therefore be of great interest to investigate these effects on vitamin D 
bioavailability and vitamin D-mediated respiratory host defense in the airway 
mucosa. Studies in airway epithelial cells have shown that exposure to UV-
inactivated nontypeable Haemophilus influenzae (NTHi) increased expression of 
the vitamin D-degrading enzyme CYP241, whereas exposure to viral double 
stranded-RNA analogue polyinosinic:polycytidylic acid (Poly[I:C]) increased 




57). On the other hand in the bronchial cell line BEAS-2B, expression of VDR was 
decreased after infection with respiratory viruses such as human rhinovirus (HRV) 
and respiratory syncytial virus (RSV) (56). Collectively, these studies have shown in 
airway epithelial cells that respiratory viral- and bacterial infections can either 
promote or impair vitamin D activation and responses.  
A local airway inflammatory milieu can also exert differential effects on vitamin D 
bioavailability and signaling, dependent on the type of inflammatory mediators that 
are predominantly present. We have shown in differentiated primary airway 
epithelial cells that Th2 cytokines such as IL-4 and IL-13, enhance expression of 
CYP27B1 and vitamin D-mediated expression of hCAP18/LL-37, which suggests that 
a Th2-inflammatory environment, as found in allergic airway inflammation 
increases vitamin D bioavailability (81, 83). The observation that levels of both 
1,25(OH)2D and hCAP18/LL-37 were increased in bronchoalveolar lavage (BAL) after 
allergen challenge is in line with this proposed mechanism (84). This effect of Th2 
cytokines was in contrast to the effects (chronic) exposures to the proinflammatory 
cytokines IL-1β, TNF-α and IL-17A that strongly increased the expression of the 
vitamin D-degrading CYP24A1, even in absence of vitamin D (57). Furthermore, 
short-term exposures to TGF-β1, a pleiotropic growth factor which is elevated in 
the lungs of COPD, CF and asthma patients, also increases the expression of 
CYP24A1 (85). As a consequence, 1,25(OH)2D-mediated expression of the AMP 
hCAP18/LL-37 was impaired, which was likely the result of the enhanced 
degradation of both 25(OH)D and 1,25(OH)2D by this enzyme (57, 58). In addition 
to pathogens and cytokines, exposure to inhaled toxicants such as cigarette smoke 
(CS) and particulate matter (PM) may also alter expression or activity of VDR and 
CYP27B1. Studies have demonstrated that cigarette smoking or exposure to CS 
extract (CSE) decreases expression of CYP27B1 and inhibited membrane bound 
(m)VDR translocation to the cell membrane in airway epithelial cells and A549 cells 
(an alveolar tumor cell line) respectively (59, 60, 63) This inhibition reduces the 
conversion of 25(OH)D to 1,25(OH)2D and 1,25(OH)2D-mediated gene expression as 
well as non-genomic actions of 1,25(OH)2D-membrane associated, rapid response 
steroid-binding (MARRS)- signalling (59, 60, 63). This adverse effect of cigarette 
smoking on vitamin D bioavailability and effects in airway epithelial cells was 
recently confirmed in vivo by Vargas Buonfiglio et al., who demonstrated that 
vitamin D supplementation increased antimicrobial activity in apical surface liquid 
(ASL) in the airway of healthy non-smokers, but not in smokers (59). On the other 
hand, exposure to PM increases the expression of both CYP27B1 and VDR in airway 
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epithelial cells, thereby possibly promoting vitamin D bioavailability (55). It is 
however important to consider that several retrospective and observational studies 
have demonstrated that air pollution is an independent risk factor for developing 
vitamin D deficiency (86). In conclusion, exposure to CS, TGF-β1 and presence of a 
proinflammatory milieu appeared to most strongly decrease vitamin D 
bioavailability and signaling in airway epithelial cells.   
Immune cells 
Whereas various studies show that exposure to proinflammatory stimuli affects 
vitamin D metabolism and reduces the effects of vitamin D in (airway) epithelial 
cells, the opposite appears to be the case for immune cells. In monocytes, 
macrophages and neutrophils, effects on vitamin D bioavailability and vitamin D-
mediated antimicrobial responses were generally enhanced by these 
proinflammatory stimuli as illustrated by increased expression of both VDR and 
CYP27B1 (39, 68, 71-74). It is therefore tempting to speculate that this apparent 
increase in vitamin D-mediated antimicrobial responses in immune cells in an 
inflammatory environment may serve as a second line of defense and compensate 
for the enhanced epithelial degradation of vitamin D during inflammation. Inhaled 
toxicants may also affect vitamin D responsiveness of immune cells. This is 
illustrated by two recent studies studying the effects of cigarette smoke on the 
human monocyte/macrophage-like cell line THP-1. One study showed that 
treatment with cigarette smoke extract (CSE) increased the expression of VDR 
without enhancing vitamin D responses (69), while the other study -that focused 
on the effects of Benzo[a]pyrene (BaP) (a component produced by cigarette 
combustion)- demonstrated that vitamin D-mediated CYP24A1 expression was 
induced, which was found to further enhance degradation of 1,25(OH)2D (70). In 
summary, proinflammatory stimuli generally increased vitamin D responses and 
bioavailability in immune cells, whereas more studies are needed to fully determine 
the impact of exposure to cigarette smoke and other inhaled toxicants. 
Lung mucosa 
Whereas these studies provide evidence that inflammation and inhaled toxicants 
may affect vitamin D metabolism and responsiveness in epithelial cells and immune 
cells, it is not clear whether this has an impact on these events in lung tissue of 
patients with chronic lung diseases. Although evidence is limited, we can speculate 
that vitamin D bioavailability and responses are also affected by disease-associated 




showed in a bleomycin fibrosis model and in primary lung mouse fibroblasts that 
TGF-β1 reduced expression of the VDR might support this assumption (87). It is 
currently insufficiently studied whether exposures to disease-associated factors 
promote or impair vitamin D bioavailability and responses in immune-, 
mesenchymal and epithelial cells combined to give a better reflection of the in vivo 
situation. Interestingly, one study did already show that nasal CYP27B1- and 
1,25(OH)2D-levels are both reduced in chronic rhinosinusitis (CRS) patients with 
nasal polyps as compared to CRS-patients without nasal polyps, whereas no 
difference was found in circulating 1,25(OH)2D-levels (88). Since most other studies 
were performed in vitro using monocultures of epithelial cells or immune cells, 
more complex models are needed to delineate this. Therefore, animal models or 
preferably more complex animal-free cell culture models using co-cultures or 
organ-on-a-chip models of primary fully differentiated epithelial cells, airway-
derived fibroblasts or smooth muscle cells and immune cells could be considered 
in future studies. 
 
Protective effects of vitamin D on mucosal homeostasis  
 
After discussing altered vitamin D metabolism and responsiveness in the inflamed 
airway mucosa, it is important to consider the possible consequences of these 
inflammation-induced changes in the airway mucosa keeping in mind the 
pleotropic effects of vitamin D that were introduced earlier. In several cells, tissues 
and organs, vitamin D regulates multiple cellular processes that affect normal and 
malignant cell growth and differentiation (89, 90). Vitamin D displays furthermore 
protective effects on mucosal host defense by maintaining the integrity of the 
epithelial barrier, inhibition of epithelial-to-mesenchymal transition (EMT), 
stimulating production of AMPs and modulating both innate- and adaptive immune 
functions (29, 91, 92). In addition, vitamin D maintains both energetic and survival 
homeostasis in the mucosal epithelium through the modulation of stress and 
damage responses, including clearance of disturbing and stressful agents (3, 93) 
(Figure 2).  
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Figure 2. Effect of vitamin D on airway epithelial host defense-mechanisms in chronic airway 
disease. The promoting or inhibitory effects of vitamin D are indicated by the red arrows.  
Abbreviations: Antimicrobial peptides (AMPs); Cystic fibrosis transmembrane conductance regulator 
(CFTR); Oxidative stress (Ox-stress); Suppressor of cytokine signaling proteins (SOCS); Tight junctions 
(TJs); Adherens junctions (AJs); Glucose-6-phosphate dehydrogenase (G6PD); Soluble suppression of 
tumorigenicity 2 (sST2); Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB); Naieve 
T cell (Th0); Regulatory T cell (Treg); T helper type 1 cell (Th1); T helper type 2 cell (Th2); T helper type 





Epithelial barrier function 
In chronic inflammatory lung diseases, epithelial barrier function is impaired, and 
as a consequence the susceptibility towards respiratory infections is increased (94). 
There is increasing evidence that vitamin D promotes epithelial barrier integrity or 
protects against epithelial barrier destruction. In cells of the bronchial epithelial cell 
line 16HBE, vitamin D inhibited CSE-mediated reduction of the epithelial barrier and 
expression of E-cadherin and β-catenin (95). Recently, two murine studies were 
published that investigated the effects of vitamin D on pulmonary epithelial barrier 
function. Shi et al. showed that vitamin D-supplementation alleviated lung injury in 
LPS-treated mice through maintenance of the pulmonary barrier by inducing 
expression of Zonula occludens (ZO)-1 and occludin in whole lung homogenates 
(96), whereas Gorman et al. showed in healthy mice, fed with a vitamin D-poor diet, 
that vitamin D supplementation had little effect on epithelial integrity (97). Only 
the first study that used a more severe mouse model with higher levels of 
inflammation and edema found an effect on vitamin D on epithelial barrier 
function. Since inflammation is detrimental for epithelial barrier integrity (98), it 
cannot be excluded that the main protective effects of vitamin D on the epithelial 
barrier in the first study by Shi et al. were in fact exerted through inhibition of 
inflammation rather than via direct induction of cell junction proteins. Vitamin D 
might also promote epithelial barrier function through its ability to increase 
expression of cystic fibrosis transmembrane conductance regulator (CFTR) in 
airway epithelial cells (99). CFTR maintains optimal ASL- and mucus hydration, 
volume and pH that support mucociliary clearance and activity of AMPs (100). 
Moreover, CFTR is also affected in the airways of smokers and COPD patients (101). 
In summary, these studies indicate that vitamin D promotes both the integrity and 
function of the epithelial barrier and might additionally protect against epithelial 
damage by dampening inflammatory responses. 
Anti-fibrotic effects of vitamin D 
The loss of epithelial barrier function with a decrease in epithelial polarization and 
cell-junction proteins and a gain of expression of mesenchymal markers is a 
hallmark of EMT (94). EMT is primarily involved in development, wound healing and 
stem cell differentiation, and TGF-β signaling plays a major role in this process 
(102). Elevated TGF-β1 levels are found in the lungs of patients with chronic 
inflammatory lung diseases and this was associated with cigarette smoking, 
inflammation and fibrosis (77, 103). There are indications that vitamin D 
counteracts various pathways leading to EMT. In mouse models and in airway 
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epithelial cell lines, vitamin D has been shown to inhibit EMT and fibrosis, in 
particular when this process is induced by TGF-β1 (87, 104-107).  
Effects of vitamin D on epithelial antimicrobial responses 
In addition to maintenance of the epithelial barrier and inhibition of fibrosis as 
discussed in the previous paragraphs, vitamin D is also actively involved in 
respiratory host defense by a variety of mechanisms (3, 29). Vitamin D is an 
important inducer of AMPs, which are mostly cationic peptides that have a broad-
spectrum antimicrobial activity, the ability to modulate immune responses and to 
promote epithelial wound repair and angiogenesis (108). hCAP18/LL-37 is likely to 
be the most prominent AMP that is induced by vitamin D and is expressed in several 
types of mucosal epithelial cells and immune cells such as monocytes and 
neutrophils (38, 74, 109). In macrophages and intestinal epithelial cells, vitamin D 
also increases expression of human β-defensin-2 (hBD-2), whereas in keratinocytes 
expression of both hBD-2 and human β-defensin-3 (hBD-3) is increased by vitamin 
D (110-113).  Collectively these data show that AMPs are modulated by vitamin D 
in mucosal tissues, which could have impact on susceptibility to both bacterial and 
viral infections and on the composition of the microbiota, which will be discussed 
in the next section .  
Effects of vitamin D on innate and adaptive immune responses 
Diseases such as COPD and asthma are characterized by chronic inflammation, a 
low-grade and prolonged inflammation that may result in destruction and aberrant 
repair of surrounding tissue by growth factors, proteases and cytokines that are 
released at the site of inflammation (114-116). Cumulative data suggest that 
vitamin D exerts anti-inflammatory effects via its actions on both innate and 
adaptive immune responses. Upon viral infection or exposure of pro-inflammatory 
stimuli such as Poly(I:C) or PM, vitamin D attenuates induced expression of 
cytokines and chemokines e.g. via inhibition of nuclear factor (NF)-κB or oxidative 
stress respectively in (airway) epithelial cells (38, 55, 117). Furthermore, vitamin D 
increases expression of the soluble decoy receptor for IL-33 (sST2) by airway 
epithelial cells, which in turn inhibits the actions of the type 2 alarmin IL-33 (118). 
Further effects of vitamin D on local innate and adaptive immune responses in the 
epithelial mucosa are mediated through its actions on immune and structural cells 
and have been reviewed by Heulens et al., Vanherwegen et al. and Pfeffer et al. 




Taken together, these findings suggest that on the one hand vitamin D protects 
against infections by enhancing epithelial barrier function and production of AMPs, 
and on the other hand vitamin D induces tolerance and dampens proinflammatory 
responses in various cell types of the airway mucosa. Thereby, vitamin D may 
prevent exaggerated inflammatory responses and further damage to the mucosal 
tissue, qualities that are very relevant in the context of chronic inflammatory (lung) 
diseases (Figure 2). 
Effects of vitamin D on epithelial oxidative stress and aging  
COPD is considered to be a disease of accelerated ageing lungs, underscored by 
markers of aging being increased in these patients partly as a result of oxidative 
stress (121). Evidence that vitamin D may protect epithelial cells from oxidative 
stress was provided by Pfeffer et al., who demonstrated that vitamin D increased 
expression of the antioxidant gene G6PD in airway epithelial cells. Furthermore, 
vitamin D increased the ratio of reduced to oxidized glutathione and decreased the 
formation of 8-isoprostane after exposure to PM (55). The induction of klotho by 
vitamin D might be another vitamin D-mediated anti-ageing mechanism (122). 
Klotho is an anti-ageing protein that is mainly expressed in the kidney, brain and in 
the lung by airway epithelial cells and exerts its protective effects through the 
inhibition of inflammation, insulin/IGF-1 signaling and activation of forkhead 
transcription factor (FoxO) signaling, which enables removal of reactive oxygen 
species (ROS) (123-125). Expression of klotho is impaired in the airways of smokers 
and further decreased in the airways of COPD patients and in cultures of the 
bronchial epithelial cell line 16HBE after CSE exposure (125). These studies suggest 
that vitamin D may protect against ageing via inhibition of oxidative stress and 
possibly via its ability to restore klotho expression (Figure 2). However, direct 
evidence showing that vitamin D indeed increases expression of klotho in airway 
epithelial cells is currently lacking. 
Effects of vitamin D on epithelial autophagy and apoptosis 
In addition to providing protection against oxidative stress and ageing, data from 
studies using intestinal epithelial cells suggest that vitamin D may also promote 
cellular survival via the induction of autophagy and reduction of apoptosis (126, 
127). In chronic inflammatory lung diseases, aberrant activation of autophagy plays 
a role in disease pathogenesis (128). A recent study showed that club cells and 
autophagy-related proteins were both decreased in COPD patients and that these 
proteins were important for club cell structure and function in airways (129). 
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However, the effects of vitamin D on autophagy in the airway mucosa of chronic 
inflammatory lung diseases are still unclear and need to be further evaluated (128).   
 
Role of vitamin D in the treatment of chronic airway diseases  
 
Clearly vitamin D has pivotal actions in host defense that are relevant in the context 
of chronic inflammatory lung diseases, in which vitamin D deficiency may be 
prevalent. Strategies to promote local bioavailability of vitamin D or use it as a 
treatment itself could be therefore of interest. Here, we will discuss the latest 
clinical evidence accompanied with functional in vitro- and animal studies that may 
explain the effects of vitamin D treatment on typical hallmarks of chronic airway 
diseases.  
Effect of vitamin D on inhaled corticosteroid responsiveness in chronic 
airway diseases  
Currently, inhaled corticosteroid (ICS)-use with or without long acting 
bronchodilators is the most frequently used treatment for COPD and asthma 
patients (130). However, the response to corticosteroids is not always effective in 
many COPD patients and in patients with steroid resistant (SR)-asthma (131). There 
are several complex mechanisms that underlie the resistance to corticosteroids in 
both COPD and SR-asthma that include but are not limited to genetic background, 
impaired glucocorticoid receptor binding, T helper type 17 cell (Th17)-inflammation 
and oxidative stress (e.g. from air pollution or smoking) and decreased numbers of 
IL-10 secreting regulator T cells (Tregs), which normally prevent skewing towards 
Th17-inflammation (131). Direct evidence of the ability of vitamin D to reverse SR 
was provided by a study showing that ex-vivo stimulation with 25(OH)D promoted 
generation of IL-10–secreting Tregs which restored sensitivity towards 
corticosteroids in CD4+ T cells that were derived from SR-asthma patients (132). A 
further potential treatment role of vitamin D was elegantly illustrated by studies 
that showed that vitamin D deficiency is associated with decreased steroid 
responsiveness in asthmatics and by the fact that several potential underlying 
mechanisms of SR such as oxidative stress and Th17-mediated inflammatory 




the corticosteroid dexamethasone was shown to increase expression of the vitamin 
D degrading enzyme CYP24A1 in renal cells and osteoblasts (139), which suggests a 
bidirectional interaction between corticosteroids and vitamin D and could further 
limit its bioavailability for patients. Additional research is needed to determine if 
vitamin D may also improve corticosteroid responsiveness in COPD.   
Vitamin D and exacerbations in COPD 
Exacerbations are a major burden for COPD patients, they accelerate decline in lung 
function and frequently result into hospital admissions (140, 141). Exacerbations 
are often triggered by pollutants or by bacterial- and/or viral infections (80, 142, 
143). COPD patients generally have lower serum 25(OH)D-levels than age- and 
smoking-matched controls, which is associated with more and more severe 
exacerbations (8, 10). Several in vivo and in vitro studies have provided evidence 
that explain the protective effects of vitamin D on exacerbations in COPD patients 
and this will be discussed accordingly.  
Air pollution  
First of all, Pfeffer and colleagues showed that 25(OH)D and 1,25(OH)2D reduce the 
production of proinflammatory cytokines in part via the ability to enhance 
antioxidant responses in airway epithelial cells that were exposed to PM (55). This 
was also demonstrated in human DCs that were matured in presence of PM, where 
treatment with 1,25(OH)2D counteracted the expansion of proinflammatory IL-17A+ 
and IFN-γ+ Th17.1 cells (136). In line with this, Bolcas et al., showed that vitamin D 
supplementation counteracted the development of airway hyperresponsiveness 
and accumulation of Th2/Th17 cells in mice that had been repeatedly exposed to 
both diesel exhaust and house dust mite allergens (144). Vitamin D could therefore 
exert a protective role in air pollution-triggered exacerbations.  
Respiratory viral infections 
In addition to its protective effects against pollutants, there is also increasing 
evidence that vitamin D may enhance clearance of respiratory viral infections that 
account for 30-50% as underlying cause of exacerbations in COPD patients (145). 
Infections with respiratory viruses such as HRV, coronaviruses and to a lesser 
extend respiratory syncytial virus (RSV) and (para)influenza virus are present during 
exacerbations and may predispose the host towards secondary bacterial infections 
that can eventually lead to uncontrolled bacterial outgrowth, more severe 
exacerbations and neutrophilic inflammation (145, 146). Two recent in vitro studies 
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showed that acute exposure to relatively high doses (100 - 1000 nM) of 1,25(OH)2D 
reduced HRV-infection in undifferentiated cultures of airway epithelial cells  (56, 
147). In those models, vitamin D most likely interfered with viral replication by 
increasing expression of interferon-stimulated genes and expression of hCAP18/LL-
37, which has been shown to have direct antiviral activity (56, 147, 148). In fully 
differentiated airway epithelial cells, treatment with lower concentrations of 
1,25(OH)2D (10 nM) during epithelial differentiation had no effect on acute HRV 
infection (149). As for other viruses than HRV, both Hansdottir et al. and Telcian et 
al. showed that vitamin D did not decrease RSV infection in airway epithelial cells, 
but did reduce virus-induced inflammatory responses  (56, 117). In addition, two 
other studies reported in influenza (H9N2 and H1N1)-infected A549 cells 
comparable findings (150, 151). Moreover, inhibitory effects of vitamin D on 
poly(I:C)-induced inflammatory responses were furthermore confirmed in primary 
airway epithelial cells Hansdottir et al. and by our group  (38, 83). Up to now, the 
afore mentioned studies suggest that higher doses of vitamin D might be protective 
against HRV-infections in undifferentiated airway epithelial cells only, whereas for 
other respiratory viral infections vitamin D mainly reduces inflammatory responses 
without affecting viral clearance. However, more studies are needed, especially in 
differentiated airway epithelial cells using multiple HRV-serotypes that use 
different receptors for infection to verify if vitamin D indeed is capable of promoting 
HRV-clearance. There is more consensus about vitamin D reducing virus-induced 
inflammatory responses and this may certainly help to alleviate the burden of 
exacerbations in COPD (38, 83).  
Bacterial infections  
In addition to viral infections, also bacterial infections are associated with COPD 
exacerbations and account for approximately 50% of all exacerbations (152). Due 
to improved study design and sampling techniques from the lower airways using 
bronchoscopy in recent decades, the causative role of bacteria in COPD-related 
exacerbations has become clear (152). This was additionally supported by Sethi et 
al., who found that acquisition of a new strain of pathogenic bacterial species into 
the airways was linked to COPD exacerbations (153). Recent developments in 
assessing the airway microbiota using 16S rRNA sequencing techniques further 
demonstrated that during exacerbations, the relative abundance of Haemophilus, 
Pseudomonas, and Moraxella was increased and the microbial composition was 
shifted towards the Proteobacteria phylum (143). The ability of vitamin D to 




epithelial cells. In differentiated airway epithelial cells, we have shown that vitamin 
D treatment enhances epithelial expression of hCAP18/LL-37 and antibacterial 
activity against NTHi, a Gram-negative bacterium, which is associated with COPD 
exacerbations (57, 154). In addition, Yim et al. demonstrated that vitamin D 
treatment increased expression of the AMP hCAP18/LL-37 and killing of 
Pseudomonas aeruginosa and Bordetella bronchiseptica, which are both Gram-
negative bacteria (155). These observed antibacterial effects of vitamin D on airway 
epithelium in vitro were recently confirmed in vivo by Vargas Buonfiglio et al.. The 
authors demonstrated that vitamin D supplementation increased antimicrobial 
activity against the Gram-positive Staphylococcus aureus in ASL in healthy non-
smokers and was dependent on presence of hCAP18/LL-37 (59). 
In murine airways, studies showed no effects of vitamin D on the expression of 
Defb4 or mCramp (the murine homologue for CAMP) (156). This can be explained 
by the fact that both the promotors of mCramp and Defb4 lack VDREs, suggesting 
that mice might not be suitable for studying the role of vitamin D in AMP-mediated 
host defense in infection (157). Indeed, Niederstrasser and colleagues showed no 
effects of vitamin D deficiency on the susceptibility of mice to pulmonary infection 
with Streptococcus pneumoniae or Pseudomonas aeruginosa (158). However, in a 
recently developed mouse model by Lowry et al., who transfected mCramp 
knockout mice with the human CAMP gene, topical vitamin D treatment increased 
expression of CAMP and promoted antibacterial effects on the mucosa of the skin 
(159). There are also multiple other murine studies that demonstrate protective 
effects of vitamin D on bacterial infections in the gut, indicating that vitamin D-
mediated antibacterial effects are additional modulated by other mechanisms such 
as via enhancement of epithelial barrier integrity (64, 160). In conclusion, these 
observations show that vitamin D promotes protection against pollutants and 
enhances clearance of viral– and bacterial infections (both Gram-positive and 
negative bacteria) in combination with a dampening effect on exaggerated immune 
responses and these features might explain why vitamin D (deficiency) is linked to 
COPD exacerbations.  
Modulation of microbiota by vitamin D 
There are strong indications that modulation of immune responses and 
antibacterial activities by vitamin D and/or vitamin D-regulated AMPs as well as 
autophagy have implications for the composition of the microbiota at the epithelial 
mucosa of the airways and the gut (161). Evidence for a role of AMPs in regulating 
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the composition of the microbiota in the gut came from a variety of studies, 
including those showing that Paneth cell-derived defensins may modulate the 
composition of the microbiome (162). This notion is further supported by 
observations showing that many commensal gut bacteria are protected from killing 
by AMPs such as the vitamin D-inducible hCAP18/LL-37 and hBD-2, whereas 
pathogens are in general more sensitive (163). Alterations in the gut microbiota 
have been linked to many diseases of the gut such as IBD but also with diseases 
affecting the lungs such as COPD and asthma, implicating an important role for the 
so-called gut–lung axis (164, 165). The mechanisms that explain how gut microbiota 
affect lung health and disease are complex and include the production of short 
chain fatty acids (SCFAs). SCFA have a wide range of effects on both immune and 
structural cells, and the effect of SCFA produced in the intestine on lung immunity 
may in part be explained by modulation of myeloid cells in the bone marrow, which 
subsequently migrate to the airways and modulate local immune responses (165). 
Microbiota that are diverse, rich and contain a higher abundance of SCFA-producing 
species within these populations are considered to be associated with health (166). 
In the gut there is strong evidence that both vitamin D deficiency and/or 
supplementation affect composition of the adult and infant microbiota (166, 167), 
specifically in relation to disease (168). However, due to the limited number of RCTs 
and small sample sizes, the precise effects on the microbiota and the mechanisms 
involved in this are still unclear (166). Alterations in the lung microbiota are also 
observed in COPD and asthma patients and are likely the result of environmental 
exposures, airway remodeling, infections and treatments such as the use of 
antibiotics. This may contribute to disease pathogenesis through altered epithelial 
innate and adaptive immune responses that damages the airway epithelial barrier 
and provokes further changes in the lung microbiome that accumulates with 
increasing disease severity (169, 170).  To date only 2 studies describe a possible 
influence of vitamin D on composition of the microbiota in the airways (171, 172). 
Toivonen et al. showed an association between low serum 25(OH)D-levels and 
reduced richness of the nasopharyngeal microbiota and bronchiolitis severity in 
patients with low 25(OH)D-levels (171), whereas in another study vitamin D 
supplementation decreased the abundance of Staphylococcus aureus, 
Staphylococcus epidermidis and Corynebacterium species in sputum samples in 
vitamin D-deficient CF patients compared to sufficient CF patients (172). In 
summary, there is evidence that alterations in the airway or gut microbiota can 




vitamin D deficiency and/or supplementation. However, due to the limited number 
of RCTs and small sample sizes more RCTs are needed in larger patient populations. 
 
Effect of vitamin D supplementation on chronic airway diseases 
COPD  
The above described protective and therapeutic possibilities of vitamin D, together 
with observations that many COPD patients are vitamin D deficient, suggest that 
COPD patients might benefit from vitamin D supplementation. As discussed 
elsewhere in this review, the link between circulating 25(OH)D-levels and the 
number of exacerbations has been extensively studied (8). So far however, only 4 
RCTs have investigated the effect of vitamin D supplementation in the context of 
COPD: only 2 out of 4 RCTs showed that vitamin D supplementation reduces the 
number of exacerbations (173-176). However, in a post-hoc analysis, selecting 
those patients that were vitamin D deficient, exacerbations were indeed reduced 
after vitamin D supplementation. Jolliffe et al. summarized these 4 RCTs and 
performed a recent individual participant data meta-analysis and concluded that 
vitamin D supplementation is only protective against exacerbations in COPD 
patients with baseline serum 25(OH)D levels < 25 nmol/L (177). These important 
findings suggest that exacerbations in this specific subset of COPD patients are 
connected to vitamin D deficiency and this part can be resolved with 
supplementation. In summary, the protective effects of vitamin D in patients 
suffering from COPD are most prominent in those with vitamin D deficiency and 
this would indicate that serum levels 25(OH)D in these patients should always be 
determined before considering using vitamin D supplementation. Since only 4 RCTs 
with relatively small patient populations have been conducted in both vitamin D-
sufficient and -deficient COPD patients, more RCTs are needed, especially in vitamin 
D-deficient patients. Currently, a multicenter RCT is being conducted by Rafiq and 
colleagues in a group of vitamin-deficient COPD patients (25(OH)D < 50 nmol/L), 
which may reveal whether vitamin D is indeed protective against exacerbations in 
this group (178).  
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Vitamin D supplementation in asthma, cystic fibrosis and acute respiratory 
tract infections 
In addition to the effects of vitamin D supplementation in COPD patients, the 
effects of vitamin D supplementation has also been extensively investigated in 
other lung diseases (which have associations with vitamin D deficiency) such as 
asthma, cystic fibrosis, upper respiratory tract infections. Most RCTs that 
investigated the effects of vitamin D supplementation were performed in acute 
respiratory tract infections (ARTIs) and asthma. A recent meta-analysis that 
assessed the effects of vitamin D supplementation in 25 RCTs (11 321 participants) 
showed that indeed vitamin D supplementation was protective against ATRIs and 
this effect was again more profound in patients with vitamin D deficiency 25(OH)D 
< 25 nmol/L at baseline (179). A recent meta-analysis in asthma that included a total 
of 14 randomized controlled trials (1421 participants), indicated that vitamin D 
supplementation reduced the rate of asthma exacerbations and increased lung 
function, especially in patients with vitamin D insufficiency (25(OH)D < 75 nmol/L) 
(180). Interestingly, in asthma patients that were supplemented with vitamin D, the 
frequency of respiratory infections was reduced, and this effect was related to the 
increase of hCAP18/LL-37 (181). CF patients with vitamin D deficiency had a higher 
rate of exacerbations as compared to patients with sufficient vitamin D levels (182). 
However  only one recent multicenter RCT was conducted and indicated that 
vitamin D supplementation did not affect the number of exacerbations in CF 
patients with serum 25(OH)D concentrations between 25 and 137.5 nmol/L (183). 
In summary, the protective effects of vitamin D supplementation in patients 
suffering from COPD, asthma or ARTIs are most prominent in those with vitamin D 
deficiency and this would indicate the importance of establishing  serum levels 
25(OH)D in these patients as supplementation could reduce unnecessary 






Conclusion and Perspectives 
 
Many drivers of COPD pathogenesis such as chronic exposure to noxious particles 
and gases, which are present in CS and air pollution, proteolytic enzymes, cytokines 
and chemokines that are released by infiltrating inflammatory cells, are known to 
harm the epithelial barrier and cause aberrant remodeling of the airway epithelium 
with important functional consequences for e.g. host defense. A dysfunctional 
epithelial barrier increases the susceptibility towards bacterial and viral infections, 
which are important triggers of COPD exacerbations and these exacerbations 
contribute importantly to disease progression. Sufficient levels of vitamin D may 
provide partial protection against these effects by reducing the effects of oxidative 
stress induced by exposure to inhaled oxidants or those derived from recruited 
inflammatory cells. Vitamin D furthermore protects against impairment of 
epithelial barrier function by promoting the integrity of the epithelial barrier, and 
by modulating both innate and adaptive immune responses. Protection against the 
detrimental effects of both bacterial and viral infections is provided by the ability 
of vitamin D to promote of antiviral responses, induce expression of AMPs and 
modulate of inflammatory responses. Taken together, these activities suggest that 
vitamin D may provide protection against development and progression of COPD, 
and against disease exacerbations. 
In addition, the local inflammatory milieu as well as the chronic exposure to noxious 
particles and gases, which are present in CS and air pollution, may negatively affect 
vitamin D bioavailability and signaling. Here we discussed the recent in vitro studies 
that demonstrated that disease-associated factors such as inflammation and 
exposure to CS and air pollution could interfere with vitamin D signaling and its 
degradation and activation by affecting expression of VDR, CYP24A1 and CYP27B1 
respectively. These findings indicate that vitamin D bioavailability and the 
protective effects of vitamin D on the airway mucosa might be impaired especially 
in patients with COPD with elevated exposures to cigarette smoke and cytokines 
such as TNF-α, IL-1β, IL-17A and TGF-β1. This suggests that even in patients with 
sufficient vitamin D serum levels the local activity of vitamin D in the lungs can be 
improved. We have to start generating more information on both systemic and 
local bioavailability of vitamin D and gene expression signatures related to vitamin 
D metabolism or vitamin D responses in COPD (and other chronic inflammatory 
diseases that are related to vitamin D deficiency), both at baseline and after vitamin 
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D supplementation. This information could lead to improved treatment strategies 
that enhance local efficacy of vitamin D, using e.g. specific CYP24A1-inhibitors such 
as VID400 (184). Alternatively, degradation by CYP24A1 could be prevented by 
using 1,25(OH)2D analogs that are insensitive to CYP24A1-mediated degradation, 
such as sulfone and sulfoximine derivatives, that also act as a VDR agonist (185). A 
third option is to entail the use of combination treatment with vitamin D and anti-
inflammatory or certain anti-fibrotic drugs that target cytokines/proteins that are 
known to potentially decrease bioavailability of vitamin D by inducing expression 
of CYP24A1 (48, 186, 187). When considering such strategies, it should be noted 
that these may enhance the calcemic side effects and lead to unwanted inhibition 
of the immune system. We therefore need to carefully analyze the preclinical in 
vivo and in vitro studies and balance the pros and cons of the different strategies. 
In conclusion, future studies in COPD and but also in other chronic inflammatory 
diseases that are related to vitamin D deficiency, should be designed with more 
focus on assessing and improving local bioavailability of vitamin D. These new 
insights may lead to the development of new treatment strategies, such as those 
targeting CYP24A1 to enhance local bioavailability of vitamin D resulting in 
improved homeostasis and protection of the airway mucosa in patients with 
chronic inflammatory lung diseases. 
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In this thesis, a collection of in vitro studies is presented that describe the role of 
vitamin D (biologically inactive 25-hydroxy-vitamin D [25(OH)D] and active 1,25-
dihydroxy-vitamin D [1,25(OH)2D]) and inflammatory mediators on respiratory host 
defense responses and exacerbations, specifically focused on chronic obstructive 
pulmonary disease (COPD). These in vitro studies are followed by a description of a 
clinical randomized controlled trail [RCT], that aims to investigate in COPD patients 
whether vitamin D supplementation would indeed be helpful in preventing 
exacerbations. This thesis is concluded by a review that discusses the latest studies 
on the effects of disease-associated factors on mucosal vitamin D metabolism and 
signaling in chronic airway diseases.  
The main aim of this thesis is to examine if vitamin D supplementation could be one 
of the possible strategies to restore the affected host defense responses and could 
therefore protect against exacerbations in chronic inflammatory lung diseases such 
as COPD. Before examining the protective role of 1,25(OH)2D in respiratory host 
defense responses, we first aimed to investigate why respiratory host defense 
responses are impaired in COPD, by investigating the role of cigarette smoke (CS) 
and airway epithelial remodeling herein. Furthermore, the presence of disease-
associated factors such as inflammation might affect 1,25(OH)2D mediated host 
defense responses in the lung. We therefore aimed to study the effects of 
inflammation on the protective role of 1,25(OH)2D in respiratory host defense 
responses. The aim here was to obtain a better understanding of 1,25(OH)2D 
signaling and its possible impairment in the lungs of COPD patients, in order to 
contribute to the discussion on whether (and which) new strategies are needed to 
enhance local levels of 1,25(OH)2D and protection against exacerbations in COPD. 
 
Overview of the Main Findings in this Thesis  
 
Bacterial- and viral infections are important triggers of COPD exacerbations and the 
airway epithelium plays a central role in orchestrating immune responses towards 




and immunological barrier function of the airway epithelium in COPD patients is 
defective (reviewed in (1, 5)). As a consequence of this airway epithelial 
dysfunction, the susceptibility towards bacterial- and viral infections is increased 
and this could further increase exacerbation rate and thereby contribute to disease 
progression in COPD patients (1, 6, 7). We therefore used in vitro culture models of 
primary airway epithelial cells to study the effects of cigarette smoking and 
inflammatory mediators on airway epithelial host defense mechanisms, with a 
specific focus on 1,25(OH)2D-mediated epithelial host defense mechanisms. In 
Chapter 2, we first investigated the effects of cigarette smoke (CS) on airway 
epithelial host defense mechanisms (8). In the studies described in this chapter, we 
daily exposed airway epithelial cells to whole CS during their differentiation phase 
to investigate its effects on the expression of constitutively expressed antimicrobial 
peptides (AMPs) and other host defense mediators such as the polymeric Ig 
receptor (pIgR). We found that CS exposure reduced the levels of the constitutive 
expressed host defense mediators SLPI, s/lPLUNC and pIgR and linked this to the 
inhibitory effects of CS on end-stage epithelial differentiation, i.e. formation of 
ciliated-, club- and goblet cells. As a result of these inhibitory effects, epithelial 
antibacterial defenses against M. catarrhalis and K. pneumoniae were impaired, 
and also polymeric IgA transport across the airway epithelium was lower after CS 
exposure. This indicates that CS may have a marked impact on humoral airway 
epithelial host defense mechanisms through its effect on epithelial remodeling.  
In Chapter 3, we further explored effects of airway epithelial remodeling on airway 
epithelial host defense mechanisms, and showed that TGF-β1 caused similar effects 
as chronic CS exposure on epithelial host defense. Short exposures to TGF-β1 were 
found to be sufficient to decrease expression levels of the constitutively expressed 
host defense molecules SLPI, s/lPLUNC and pIgR, as well as numbers of secretory 
club- and goblet cells (9). We additionally showed that TGF-β1 reduced baseline as 
well as 1,25(OH)2D3-mediated expression of the AMP hCAP18/LL-37. This inhibitory 
effect on 1,25(OH)2D3-inducible gene expression could be explained by the 
observation that TGF-β1 increases degradation of 25(OH)D3 and 1,25(OH)2D3 by 
increasing the expression of the 25(OH)D and 1,25(OH)2D-degrading enzyme 
CYP24A1. 
In Chapter 4, we further described that long-term exposure of differentiating 
airway epithelial cells to proinflammatory mediators such as TNF-α, IL-1β and IL-
17A, which are elevated in the airways of COPD and refractory asthma patients 
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(asthma patients, who do not respond to current standard therapy), increased 
25(OH)D and 1,25(OH)2D metabolism by enhancing expression of CYP24A1 (10). As 
a result, the ability of 25(OH)D3 to induce expression of hCAP18/LL-37 and to 
enhance killing of nontypeable Haemophilus influenzae (NTHi) was reduced.  
In contrast to Chapter 3 and 4, where we showed that 25(OH)D3 and 1,25(OH)2D3 
catabolism was induced and host defense responses in airway epithelial cells were 
impaired by TGF-β1, TNF-α, IL-1β and IL-17A, in Chapter 5 we demonstrated that 
presence of a Th2-inflammatory environment does in fact the opposite (11). We 
showed that exposure of airway epithelial cells to the Th2 cytokines IL-13 and IL-4 
enhanced the expression of CYP27B1, which in turn promoted conversion of the 
circulating -yet inactive- 25(OH)D3 into the active 1,25(OH)2D3, thereby inducing 
expression of hCAP18/LL-37. 1,25(OH)2D treatment was furthermore capable of 
dampening viral dsRNA-induced inflammatory responses in airway epithelial cells, 
which was illustrated by a reduction of cytokine- and chemokine release upon 
Poly(I:C) (a synthetic analog of [viral] dsRNA) stimulation.  
To assess whether the afore mentioned protective effects of vitamin D 
supplementation will indeed reduce exacerbation rate in COPD, a multicenter RCT 
is designed to study the effects of vitamin D supplementation in a study population 
that, in contrast to previous RCTs, specifically focusses on vitamin D-deficient 
patients (serum [25(OH)D] 15 - 50 nmol/L). Study design, protocol and read-outs 
are described in Chapter 6 (12). 
Finally, in Chapter 7 we have summarized the current knowledge of the effects of 
disease-associated factors such as inflammation and cigarette smoke exposure on 
availability and signaling of vitamin D in the lungs of patients with COPD and other 
chronic lung diseases. We further aimed to link the possible consequences of an 
altered 1,25(OH)2D status in the lung to the protective effects of 1,25(OH)2D on 
mucosal host defense mechanisms, inflammation and exacerbations and explore 
possible strategies to improve local levels of 1,25(OH)2D.  
To answer the question whether vitamin D supplementation could be one of the 
possible strategies to restore the affected respiratory host defense responses in 





Role of Cigarette Smoke and Airway Epithelial Remodeling on 
Host Defense Responses in COPD  
Physical barrier function 
Cigarette smoking is an important risk factor for COPD pathogenesis and already in 
1957 histological changes in the bronchial epithelium of smokers were described 
by Chang (13). He described that the bronchial epithelial cell layer was thicker with 
more stratification and increased numbers of basal and goblet cells, whereas 
ciliated cell numbers were reduced or had shorter cilia. Our observations in Chapter 
2 showed a marked reduction of cilia development during airway epithelial 
differentiation when cells were daily exposed to CS (8), and are therefore in line 
with those of Chang, and the many reports that followed this original observation 
(14). Moreover, several other studies demonstrated that cilia motility was also 
impaired in smokers with COPD (14). Expression and function of the cystic fibrosis 
transmembrane conductance regulator (CFTR) (which maintains optimal apical 
surface liquid (ASL)- and mucus hydration, volume and pH), is also affected in 
smokers and in COPD (15). This combination of goblet cell hyperplasia, aberrant 
expression and function of CFTR and cilia, collectively impairs mucociliary clearance 
and contributes to airway obstruction and increased susceptibility towards 
infections (14). Whereas goblet cell hyperplasia is known to be present in smokers 
and COPD patients, in Chapter 2 we observed that CS exposure inhibited the 
formation of goblet cells during epithelial differentiation at the air-liquid interface 
(ALI) (8). Interestingly, short-term exposure to TGF-β1 was already sufficient to 
decrease the number of goblet cells in fully differentiated airway epithelial cell 
cultures (Chapter 3) (9). This might indicate that the effect of CS exposure on the 
expression of mucins and formation of goblet cells could be mediated in part by 
TGF-β1, which is known to be increased by CS exposure (16). Also, the level of 
cigarette smoke exposure and the missing immune component could contribute to 
a lack of goblet cell hyperplasia.  
CS exposure furthermore reduces epithelial barrier integrity by causing degradation 
of its tight and adherens junctions, favoring trans-epithelial invasion of pathogens 
(7). The loss of expression of tight and adherens junction proteins such as zona 
occludens (ZO)-1 and E-cadherin, combined with gain of mesenchymal markers, is 
a hallmark of epithelial-to-mesenchymal transition (EMT) and is present especially 
in the small airways of (ex-) smokers with and without COPD (17, 18). The effects 
of chronic CS exposure on airway epithelial barrier integrity were also assessed in 
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Chapter 2, where only  a minor delay was observed in epithelial barrier 
development during the first week of differentiation, compared to air-exposed cells 
(8). This was however not significant and could be explained by the fact that 
decreases in epithelial barrier function (by measuring trans epithelial electrical 
resistance [TEER]) by CS are transient and normalized at the time of measurement 
(18-20 h after the previous CS exposure) (19). Altogether, these studies further 
support the notion that structural epithelial changes may affect physical barrier 
function in COPD patients and in smokers. Since studies have shown that 
1,25(OH)2D may increase epithelial barrier function (see review Chapter 7), it would 
therefore be of interest to investigate if the loss of epithelial junction proteins or 
epithelial barrier function could be restored by 1,25(OH)2D treatment in vitro in CS-
exposed airway epithelial cells or by vitamin D supplementation in vivo in smokers 
or COPD patients. 
Cellular remodeling 
More recent studies have highlighted the importance of club cells in respiratory 
host defense. Club cells are decreased in COPD patients and by CS exposure in vitro, 
this decrease could negatively impact epithelial barrier function, neutralization of 
toxins, immunomodulation and epithelial regeneration (20-23). CS furthermore 
increases production and activation of TGF-β1 in airway epithelial cells and elevated 
levels of TGF-β1 expression were found in the airways of COPD patients (17, 24-26), 
although this was not shown in all studies (27). In Chapters 2 and 3, we have indeed 
confirmed that exposure to both CS and TGF-β1 results in a reduction in levels of 
markers of club cells (8, 9). This could suggest that TGF-β1 might play an important 
role in the CS-mediated reduction of club cells and club cell-mediated functions in 
the airway epithelium of COPD patients and smokers. However, to fully determine 
the role of TGF-β1 in regulating club cell numbers and function (release of CC-10), 
further studies are needed. This could be achieved by using in vitro chronic CS 
exposure models of airway epithelial cells that are treated with TGF-β1-specific 
antibodies or TGF-β1-Smad signaling inhibitors followed by assessment of club cell 
markers. Furthermore, in Chapter 2 we showed that both ciliated and goblet cells 
strongly recovered upon cessation of CS exposure, except for club cells that 
remained absent after almost 1 week of recovery (8). This is in line with studies 
showing that club cells are more sensitive to damage by CS and other noxious gases 
than other airway epithelial cell types (28). Elevated TGF-β1-expression levels are 
known to persist in airway epithelial cell cultures derived from COPD patients, 




(29). Future studies could further explore the potential of selective TGF-β1 
inhibition in the reduction of club cells and its effects on host defense mediators to 
consider this as a future treatment strategy in COPD patients. 
Humoral respiratory host defense 
In addition to the physical barrier, humoral defenses of the airway epithelium are 
also affected in COPD, and this is at least in part attributable to CS-mediated 
changes in epithelial composition (30). The humoral barrier is provided by e.g. host 
defense mediators such as AMPs, reactive oxygen species (ROS), CFTR (which 
influences pH and therefore activity of AMPs), type I and III interferons and by 
production of cytokines, chemokines and lipid mediators (31-33). Many of these 
mediators are directly affected by cigarette smoking or indirectly by CS-induced 
inflammation or by epithelial remodeling (17, 18, 30, 34). For example, acute CS 
exposure directly decreases upregulation of inducible AMPs such as human β-
defensin-2 (hBD-2) upon triggering by a bacterial component (34), whereas other 
AMPs such as hCAP18/LL-37 and RNAse7 are increased upon CS exposure (19, 35). 
Moreover, expression and function of the CFTR is also negatively affected by CS and 
this process seems to be mediated by TGF-β1 (30, 36). In Chapter 3 and 4, we have 
demonstrated that both chronic CS and short-term TGF-β1 exposures decreased 
expression of constitutively expressed host defense mediators by affecting airway 
epithelial cell composition (8, 9). We additionally showed that in particular host 
defense mediators that are expressed by secretory luminal epithelial cells are 
reduced upon exposure to CS and TGF-β1 (8, 9). Recent developments in single cell-
RNA sequencing confirm that BPIFB1 (lPLUNC), SLPI and PIGR are indeed highly 
expressed by club cells (23, 37).  Our results indicate that specifically end-stage 
differentiation and expression of luminal cell expressed host defense mediators is 
impaired by chronic CS exposure and, when taking into account the results of 
chapter 3, new research endeavors should focus on investigating whether this is 
partly regulated by CS-induced expression of TGF-β1. In addition to its effects on 
airway epithelial antibacterial activity, SLPI and s/lPLUNC are furthermore known 
to promote respiratory host defense by dampening immune responses, inhibition 
of proteases and by maintaining apical surface liquid (ASL) hydration (38, 39).  
Future studies could use more complex culture models, such as an airway-on-chip 
model with the possibility to expose the cells to airflow and mechanical forces, is a 
better representation of the in vivo situation (40). This model further allows the use 
of immune cells in combination with well-differentiated airway epithelial cells and 
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could establish further consequences of both CS exposure and TGF-β1 on other 
aspects of respiratory host defense such as on immune responses (40, 41).  
Vitamin D-mediated host defense responses 
Vitamin D (1,25(OH)2D) displays protective effects on host defense responses in the 
airways, e.g. by maintenance of the of the mucosal barrier integrity, modulation of 
stress, damage and immune responses and by the promotion of killing of pathogens 
(e.g. via the induction of the AMP hCAP18/LL-37) (42-44). The VDR is expressed in 
all epithelial cell types of the lungs with higher expression levels in alveolar 
epithelial cells and lower expression levels in club cells, compared to other 
pulmonary epithelial cell types. CYP27B1 is also expressed in all epithelial cell types 
and higher expression levels are again present in alveolar cells, but lower 
expression levels are found in both goblet- and ciliated cells. This  indicates that all 
lung epithelial cells, but especially alveolar cells, should be responsive to 25-
hydroxy-vitamin D [25(OH)D], the main circulating, yet inactive form of vitamin D 
(45). Interestingly, expression of CYP24A1 (that converts both 25(OH)D and 
1,25(OH)2D into inactive metabolites) is absent in alveolar epithelial cells, but 
expressed at low levels in club cells and is highly expressed in basal-, ciliated- and 
goblet cells (45). This suggests that an increase in basal- and goblet cells, as present 
in the peripheral airways of COPD patients, might increase expression levels of 
CYP24A1, which degrades 1,25(OH)2D that mitigates its effects on epithelial host 
defense. Further studies in COPD patients showed that the expression of VDR 
mRNA and protein in alveolar tissue was gradually reduced in COPD patients with 
increasing disease severity (46). It would be of interest to determine if changes in 
expression of genes related to vitamin D metabolism are the result of destruction 
of alveolar tissue and remodeling of the airway epithelial cell layer, as seen in COPD 
patients.  
In Chapter 6 we have demonstrated that a pro-inflammatory environment, created 
by chronic exposure to proinflammatory cytokines such as TNF-α/IL-1β and IL-17A 
during the differentiation of airway epithelial cells, increased the expression of the 
25(OH)2D and 1,25(OH)2D-degrading enzyme CYP24A1 without affecting expression 
of CYP27B1 and VDR (10). We additionally assessed if the changes in CYP24A1 were 
the result of an altered epithelial differentiation by assessing the effects of TNF-
α/IL-1β on the expression of epithelial cell basal, club-, goblet-  and ciliated cell 
markers, and found that expression of these markers was not affected (10). This 




changes in the composition of the epithelial cell layer. Conversely, in Chapter 4 we 
found that the TGF-β1-mediated induction of CYP24A1 occurred in concert with a 
reduction in both club- and goblet cells (47). Despite the fact that similar effects 
were observed in submerged cultures of undifferentiated airway epithelial cells, we 
cannot fully exclude that TGF-β1-induced effects on CYP24A1 expression were the 
result of an altered composition of the epithelial cell layer. To fully elucidate this, 
airway epithelial cells can be differentiated in presence of stimuli that for example 
affect end-stage epithelial differentiation, such as CS. Another way is to 
differentiate cells in presence of a Notch-signaling inhibitor (DAPT), that skews 
differentiation towards ciliated cells or in presence of IL-13 to increase goblet cell 
formation. During these processes expression of VDR, CYP27B1 and CYP24A1, and 
1,25(OH)2D responses could be monitored at an early/acute phase (after 1 day) and 
at an later phase of epithelial differentiation (after 3 weeks). In fact, we have 
already tried this with CS exposure in a pilot study and found that CS inhibited end-
stage airway epithelial differentiation as expected and also increased CYP24A1 
expression (unpublished observations). Compared to the effects of TNF-α/IL-1β, IL-
17A and TGF-β1, the increase in CYP24A1 expression was much less prominent and 
this might explain why 1,25(OH)2D-mediated expression of hCAP18/LL-37 was not 
affected by CS. In conclusion, both chronic CS exposure and TGF-β1 cause aberrant 
epithelial remodeling in the conducting airways, thereby disrupting both physical 
and humoral airway epithelial host defense functions. This might help to explain 
why smokers with and without COPD have increased susceptibility towards 
respiratory infections, and how the local environment may determine vitamin D 
metabolism and action. 
 
Targeting Epithelial Remodeling in COPD 
 
Dysfunctional basal progenitor cells within the airway epithelium are considered to 
play a fundamental role in the observed aberrant remodeling of the airway 
epithelium in COPD patients and in smokers and could therefore be a target to 
reverse this process in COPD (48). Several studies have identified a subset of 
keratinocyte 5 (KT5)-positive basal cells as basal progenitor cells, and showed that 
these are characterized by the ability to self-renew and to differentiate into basal-, 
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secretory-, and ciliated cells (48). COPD patients and smokers with a reduced lung 
function have lower numbers of KT5+ clone-forming basal progenitor cells than 
healthy controls, and those cells display signs of exhaustion (49). One of the 
possible explanations for the observed exhaustion of the basal progenitor cells 
might be cellular senescence. Senescence is prevalent in both airway- and alveolar 
epithelial cells in COPD patients and recent studies showed that induction of airway 
epithelial basal cell senescence results in reduced basal cell proliferation (50-52). 
Other studies have shown that basal progenitor cells, derived from smokers and 
COPD patients, have aberrant Notch, TGF-β1, BMP-4 and/or EGFR signaling that 
also may additionally explain the dysfunctional properties of these progenitor cells 
(53-56). In our chronic CS-exposure model in Chapter 3, we have indeed observed 
decreases in expression of the Notch-target genes HEY1 and HEY2 (but not others) 
after chronic CS-exposure. In addition, when cells were differentiated in presence 
of the Notch-signaling inhibitor DAPT, expression of secretory goblet- and club cell 
markers as well as luminal constitutive host defense mediators was reduced (8), 
further supporting a role of these pathways in aberrant airway epithelial 
differentiation. Intervention strategies to treat dysfunctional basal progenitor cells, 
e.g. by combined targeting of Notch, TGF-β1, BMP-4 or EGFR-signaling pathways, 
may have the potential to stop or even reverse disease progression. For example, 
CS-mediated loss of ciliated cells was counteracted through inhibition of EGFR-
signaling by Gefinitib during in vitro airway epithelial cell differentiation (54). In 
addition, inhibition of BMP-4 by DMH-1 was able to (partially) reverse CS extract-
mediated induction of squamous cell markers and reduction of both ciliated- and 
secretory cell markers (55), whereas TGF-β1-inhibition during differentiation at the 
air-liquid interface was able to reverse signs of EMT that were still present in airway 
epithelial cells, derived from COPD patients (29). It would be interesting to also 
study effects of such strategies on key enzymes involved in vitamin D metabolism. 
In Chapter 3, we observed that inhibition of TGF-β1-Smad signaling by using 
SB431542 was sufficient to reverse TGF-β1-mediated reduction of the 1,25(OH)2D-
inducible hCAP18/LL-37 and this compound also prevented induction of CYP24A1 
(9). Perhaps reducing the inflammatory state of the local environment and reducing 
exposure to inhaled toxicants by smoking cessation could already reverse some 
features of EMT and other detrimental effects of TGF-β1. It seems that elevated 
expression levels of EMT-markers could return back to control levels, when COPD-
derived airway epithelial cells were cultured at the air-liquid interface for an 




with vitamin D-supplementation could serve to reduce the inflammatory state of 
the local environment without affecting respiratory host defense responses, which 
is a well-known side-effect of steroid use (Chapter 7, (57)). In conclusion, new 
approaches to specifically target dysfunctional basal progenitor cells together with 
improving the local environment could be considered to counteract aberrant 
airway epithelial remodeling. These new approaches are needed, since remodeling 
especially of the small airways is currently considered to be a crucial process that 
precedes further airway obstruction, destruction of alveolar walls and/or 
development of lung cancer (18, 58).  
 
Modulating of Vitamin D Metabolism in Chronic Inflammatory 
Lung Diseases 
 
Local availability and action of 1,25(OH)2D depends on expression of VDR and an 
equilibrium between the vitamin D metabolic enzymes CYP27B1 and CYP24A1, and 
this can be affected by several inflammatory mediators and exposure to inhaled 
toxicants, which is discussed in Chapter 7. The presence of these inflammatory 
mediators in chronic inflammatory lung diseases  could therefore interfere with 
expression of VDR, CYP24A1 and CYP27B1, which as a consequence may affect the 
local levels of 1,25(OH)2D. In Chapter 5 we observed that exposure to Th2 cytokines 
enhances expression of CYP27B1, thereby promoting 25(OH)D-metabolism in 
airway epithelial cells, whereas others have shown this effect after exposure to 
poly(I:C) (11, 60). We have indeed  demonstrated in Chapter 3,  4 and 5 that 
cytokines that are known to be elevated in both COPD and (refractory) asthma 
patients, such as IL-4, IL-13, TGF-β1, IL-1β, TNFα and IL-17A, have the ability to alter 
the expression of genes related to vitamin D metabolism, such as CYP27B1 and 
CYP24A1 in airway epithelial cells (9, 10, 61). These in vitro data suggest that 
(chronic) airway inflammation can have a large impact on local levels of 1,25(OH)2D 
through enhanced conversion into 1,25(OH)2D in presence of a Th2-inflammatory 
environment or enhanced degradation of both 25(OH)D and 1,25(OH)2D in 
presence of a TGF-β1, Th1-/Th17-inflammatory environment. Nonetheless, airway 
inflammation in COPD in vivo is far more complex and heterogeneous than we have 
tested so far in vitro using monocultures of airway epithelial cells, or using only 
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immune cells. For that reason, animal models or preferably more complex cell 
culture models such as organs-on-chips technology in combination with co-cultures 
of epithelial cells and immune cells that are derived from COPD patients could be 
used in future studies to fully understand the impact of airway inflammation on 
1,25(OH)2D responses and  discrepancies between systemic levels of 25(OH)D and 
local levels of 25(OH)D and 1,25(OH)2D. In addition to the demonstrated effects of 
viruses and cytokines on expression of genes related to airway epithelial vitamin D 
metabolism (CYP27B1 and CYP24A1), other studies have shown that exposure to 
inhaled toxicants such as CS and particulate matter (PM) may alter expression or 
activity of VDR and CYP27B1 (62, 63). This was in contrast to what was observed in 
most immune cells, such as monocytes and macrophages. In monocytes and 
macrophages, the effects of 1,25(OH)2D were even enhanced by exposure to most 
proinflammatory stimuli, apart from Benzo[a]pyrene (BaP), a polycyclic aromatic 
hydrocarbon produced by cigarette combustion, which increased the expression of 
CYP24A1 (64-69).  
A recent study in COPD patients that assessed both VDR and CYP24A1 expression 
in parenchymal lung tissue, observed lower expression of both VDR and CYP24A1 
compared to non-COPD controls, indicating that also in the lower airways the 
effects of 1,25(OH)2D might be impaired (70). Importantly, another recent study 
that investigated vitamin D metabolism in both serum and in lung tissues of both 
COPD and asthma patients, found evidence to suggest that the conversion of 
vitamin D3 into 25(OH)D3 was impaired (71). Furthermore, locally in lung tissue 
and/or in airway epithelial cells derived from both asthma and COPD patients, 
expression of 25-hydroxylase (CYP27A1), which converts vitamin D3 into 25(OH)D3, 
was reduced compared to healthy controls, while the opposite was true for VDR. 
The authors also showed no differences in CYP27B1 expression between groups, 
which is not in line with our observations in vitro of increases in CYP27B1 in 
presence of Th2 cytokines in Chapter 5 (11). Furthermore, expression of CYP24A1 
was decreased in asthma patients, whereas in lung tissue from COPD patients there 
was a trend towards a significant increase (log fold change 0.36; p = 0.06), which 
was more in line with our in vitro observations in Chapters 3 and 4 (9, 10).  More 
importantly, another study showed that expression of epithelial 1,25(OH)2D-
responsive genes was increased in sputum and nasal brushings from asthma 
patients, whereas this was decreased in lung tissue from COPD patients (72). This 
study indicates that especially in COPD patients, local levels of 1,25(OH)2D and 




of CYP27A1 might play an important role. Collectively, these studies imply that local 
inflammatory conditions in most cases negatively affect both local levels and 
activity of 1,25(OH)2D on the airway epithelium.  
To enhance local efficacy of 1,25(OH)2D, alternative strategies might be considered, 
such as inhalation with active 1,25(OH)2D or supplementation with 25(OH)D3 
instead of vitamin D3, to circumvent the impaired metabolism of vitamin D3 into 
25(OH)D3 which is seen in both asthma and COPD patients (71). Also specific 
CYP24A1 inhibitors, 1,25(OH)2D analogs that are resistant to degradation by 
CYP24A1, and other VDR agonists can be used, or a combination treatment of 
vitamin D with anti-inflammatory or certain anti-fibrotic drugs that target TGF-β1 
to prevent increases in CYP24A1 (73, 74). It should however be considered that 
these compounds may enhance the calcemic side effects or impair the immune 
system. Altogether, we need to fully establish the impact of local inflammation on 
local 1,25(OH)2D levels and responses by using advanced in vitro systems and to 
some extent animal models, and test these different strategies that may enhance 
local levels of 1,25(OH)2D. 
 
Role of Vitamin D in Airway Epithelial Host Defense Responses 
Exacerbations 
Exacerbations are a major burden in COPD patients, accelerate decline in lung 
function and frequently result into hospital admissions and are often triggered by 
pollutants or by bacterial- and/or viral infections (2-4, 75, 76). COPD patients 
generally have lower serum 25(OH)D-levels and this is associated with more 
exacerbations, suggesting that COPD patients might benefit from vitamin D 
supplementation (77-79). To date, the effects of vitamin D supplementation in the 
context of COPD exacerbations has been investigated in only 4 RCTs with mixed 
results: 2 RCTs showed that vitamin D-supplementation reduces the number of 
exacerbations (80, 81), whereas 2 other RCTs did not find this effect (82, 83). When 
these 4 RCTs were combined and summarized by using an individual participant 
data meta-analysis, vitamin D supplementation was shown to be protective against 
exacerbations in vitamin D deficient COPD patients (baseline serum 25(OH)D levels 
< 25 nmol/L)  (84). This suggests that exacerbations in this group of COPD patients 
were mainly driven by vitamin D deficiency. To investigate the effects of vitamin D 
supplementation in vitamin D deficient COPD patients and to gain more insight into 
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the mechanisms behind the protective effects of vitamin D, the following study was 
designed: a multicenter RCT that aims to study the effects of vitamin D-
supplementation of 6800 IU vitamin D or placebo orally once a week for 1 year on 
exacerbation rate, systemic and local inflammation, physical performance and 
quality of life in a study population of vitamin D-deficient patients only (serum 
[25(OH)D] 15 - 50 nmol/L) (Chapter 6) (12). We hypothesize that vitamin D 
supplementation will improve respiratory host defense responses and will 
therefore reduce exacerbations and will further improve quality of life in this 
particular group of COPD patients.   
Antibacterial activity 
In this thesis, we have identified mechanisms that may underlie the protective 
effects of vitamin D supplementation in vitro in the context of COPD exacerbations, 
thereby additionally confirming that the airway epithelium is a major target for the 
effects of locally synthesized 1,25(OH)2D. hCAP18/LL-37 is likely to be the most 
prominent AMP that is induced by 1,25(OH)2D in several types of mucosal epithelial 
cells and in immune cells, including monocytes and neutrophils (60, 65, 85, 86). The 
in vitro demonstration of 1,25(OH)2D-mediated induction of AMPs suggests that 
vitamin D supplementation could reduce the susceptibility to (respiratory) 
infections in vivo. This was indeed confirmed by several clinical studies, including a 
recent meta-analysis that showed a protective effect of vitamin D supplementation 
against acute respiratory tract infections (ARTI) (87). In Chapter 4, we have 
confirmed this ability of 1,25(OH)2D to promote antibacterial activity in 
differentiated cultures of airway epithelial cells by demonstrating that both 
25(OH)D and 1,25(OH)2D increased antibacterial activity against NTHi, a Gram-
negative bacterium which is associated with COPD exacerbations (10, 88). We 
additionally showed that exposure to TNF-α/IL-1β inhibited 25(OH)D and 
1,25(OH)2D-induced antibacterial effects as well as expression of hCAP18/LL-37, 
indicating that the 25(OH)D and 1,25(OH)2D-mediated antibacterial effects were 
most likely mediated through the induction of hCAP18/LL-37 (10). Moreover, also 
other studies have now demonstrated that 1,25(OH)2D treatment increased 
antibacterial effects against other bacteria such as E. coli, P. aeruginosa and B. 
bronchiseptica (89, 90). The specific role of hCAP18/LL-37 in the observed 
antibacterial effects of 1,25(OH)2D on airway epithelium in vitro was recently 
confirmed in vivo by Vargas Buonfiglio et al., who demonstrated that the increased 
antimicrobial activity against the Gram-positive S. aureus in ASL after vitamin D 




vitamin D, also other strategies of using AMP-inducers such as essential amino 
acids, sodium butyrate and other (natural) compounds show great potential in their 
capacity to reduce bacterial infections, especially when some of these compounds 
are combined (91-93). For example in human colonic epithelial cells (Caco-2), a 
combination treatment with natural compounds such as andrographolide and 
isoliquiritigenin synergistically enhanced the AMP human β-defensin-3 (hBD-3) 
expression and antimicrobial activity, especially against pathogenic bacteria (91). In 
conclusion, the ability of 1,25(OH)2D to promote bacterial clearance by increasing 
expression of hCAP18/LL-37 may help to explain why vitamin D deficiency is 
associated with chronic airway diseases such as asthma and COPD (77, 94). 
Inflammation 
We have furthermore demonstrated in Chapter 5 that 1,25(OH)2D3 dampens 
epithelial release of proinflammatory cytokines and chemokines such as IP-10, 
RANTES (with a trend towards a decrease in IL-8 and IL-6) that were triggered by 
stimulation with poly(I:C), a synthetic analog of double-stranded RNA, which is used 
to mimic viral infections (11). The release of these proinflammatory cytokines and 
chemokines may further recruit immune cells such as monocytes, eosinophils and 
neutrophils that secrete proteases and cytotoxic and proinflammatory mediators, 
which amplifies inflammation, causes alveolar destruction, airway mucus 
hypersecretion and airway obstruction (95-98). The dampening effect of 
1,25(OH)2D3 on the release of cytokines and chemokines in airway epithelial cells 
was also shown by other studies using other known triggers for COPD exacerbations 
such as PM, respiratory syncytial virus (RSV), and human rhinovirus (HRV) (99-101). 
Altogether, these studies indicate that vitamin D supplementation may reduce the 
severity of exacerbations in COPD by promoting the expression of hCAP18/LL-37 





Many drivers of COPD pathogenesis such as chronic exposure to noxious particles 
and gases (including those present in cigarette smoke, biomass fuels or air 
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pollution), proteolytic enzymes, cytokines and chemokines that are released by 
inflammatory cells, are known to destruct the epithelial barrier and cause aberrant 
remodeling of the airway epithelium and as a consequence affect secretion of host 
defense molecules (7, 102). Therefore, protection and restoration of the epithelial 
barrier may be a fruitful strategy to halt further disease progression. Firstly, we 
should consider targeting pathways that restore basal progenitor cell function. 
Secondly, the local environment should be improved by micronutrients such as 
vitamin D that protects the airway epithelium from epithelial injury and 
remodeling. However, we have demonstrated in the studies presented in this thesis 
that certain airway inflammatory mediators could possibly interfere with vitamin D 
metabolism by promoting expression of CYP24A1, thereby reducing local levels of 
1,25(OH)2D and accompanying protective antimicrobial and anti-inflammatory 
actions (Figure 1). Therefore, future studies in COPD and but also in other chronic 
inflammatory diseases that are related to vitamin D deficiency, should be designed 
with more focus on increasing local levels of 1,25(OH)2D and expression of genes 
related to vitamin D metabolism, especially CYP24A1. These new insights may yield 
possible new strategies to target CYP24A1 that enhance local levels and signaling 
of 1,25(OH)2D to increase protection against exacerbations in COPD patients. 
 
Figure 1. Effects of inflammation on vitamin D-metabolism and epithelial host defense in the 
airways. Vitamin D receptor, VDR; biologically active vitamin D, 1,25(OH)2D; 25-hydroxyvitamin D-1α-
hydroxylase, CYP27B1; circulating inactive vitamin D, 25(OH)D; 25-hydroxyvitamin D-24-hydroxylase, 
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Vitamine D staat van oudsher bekend om zijn regulerende rol bij de opname van 
kalk (calcium) en fosfaat in de darmen en draagt op die manier bij aan het behoud 
van sterke botten. Vitamine D wordt onder invloed van zonlicht (UV-B straling) in 
de huid aangemaakt of wordt uit ons voedsel opgenomen. Helaas is de zon in 
gebieden met hogere breedtegraden, waarin ook Nederland ligt, niet het hele jaar 
(november – maart) sterk genoeg om ons lichaam van voldoende vitamine D te 
voorzien. Mede daardoor hebben veel mensen in deze gebieden last van een 
vitamine D tekort. Daarnaast komt een vitamine D tekort veel voor bij mensen met 
een donkere huidskleur, die niet veel buiten komen of die in gebieden wonen met 
veel smog. Een vitamine D tekort werd in het verleden geassocieerd met 
botaandoeningen zoals rachitis, totdat geleidelijk aan duidelijk werd dat ook 
meerdere andere aandoeningen geassocieerd zijn met een tekort aan vitamine D, 
waaronder kanker, diabetes type 2, cardiovasculaire aandoeningen, ziekte van 
Alzheimer, multiple sclerose, chronische darm ontstekingen, psoriasis en 
chronische long aandoeningen zoals astma en chronisch obstructieve longziekte 
(COPD).  
Het vitamine D dat in de huid wordt aangemaakt of uit voeding wordt verkregen, is 
nog niet biologisch actief. Eerst wordt deze inactieve vorm van vitamine D in de 
lever door de enzymen CYP2RI en CYP27A1 in 25-hydroxy-vitamine D (25(OH)D; ook 
wel calcidiol of calcifidiol genoemd) omgezet. 25(OH)D is de meest voorkomende 
vorm van vitamine D in het bloed en een maat voor vitamine D status in het 
lichaam. In de nieren wordt vervolgens het nog inactieve 25(OH)D door het enzym 
CYP27B1 omgezet in zijn actieve vorm: 1,25 dihydroxy-vitamine D (1,25(OH)2D; ook 
wel calcitriol genoemd). Recente onderzoeken hebben echter aangetoond dat ook 
andere weefsels en celtypen zoals luchtwegepitheelcellen, huidcellen, darmcellen 
en immuuncellen deze enzymen kunnen aanmaken en dus lokaal calcidiol kunnen 
omzetten naar de actieve vorm van vitamine D. Als reactie op de aanmaak van 
actief vitamine D, wordt CYP24A1 aangemaakt in cellen die door 1,25(OH)2D zijn 
geactiveerd via de vitamine D receptor (VDR). CYP24A1 breekt zowel actief 
1,25(OH)2D als inactief 25(OH)D af. Dit “feedback” mechanisme zorgt voor een 




hoge calcium waarden in het bloed zou kunnen leiden en schadelijk is voor organen 
en botten.  
 
Vitamine D en het luchtwegepitheel 
In de luchtwegen is vitamine D een belangrijke factor in de homeostase van het 
luchtwegepitheel en heeft invloed op zowel het aangeboren als het adaptieve of 
verworven immuunsysteem. Het luchtwegepitheel is onderdeel van het 
aangeboren immuunsysteem  en fungeert als de frontlinie van de afweer van de 
longen. Het luchtwegepitheel vormt een fysieke barrière tegen een invasie van 
pathogenen en inademing van schadelijke deeltjes en gassen afkomstig van 
sigarettenrook of luchtverontreiniging. Het luchtwegepitheel bestaat uit 
verschillende celtypen, zoals gobletcellen (slijmbekercellen), trilhaarcellen, 
clubcellen en basale cellen, die allemaal een unieke rol spelen in het in stand 
houden van deze barrière. De gobletcellen produceren slijm, die een gelvormige 
bekleding vormen, dat over de trilharen heen wordt getransporteerd. Onderweg 
vangt het slijm pathogenen en andere schadelijke deeltjes op, om deze vervolgens 
door de bewegende trilharen uit de luchtwegen naar de keel te transporteren. 
Wanneer pathogenen alsnog door de slijmlaag doordringen dan is het lastig om 
door de epitheliale laag te kunnen, omdat deze cellen sterk aan elkaar verankerd 
zitten door de aanwezigheid van “tight-“ en “adherens junctions”. Naast deze 
fysieke barrière, beschermt het epitheel zich ook tegen pathogenen door de 
uitscheiding van ontstekings- en andere afweermediatoren. Deze 
ontstekingsmediatoren trekken vervolgens immuuncellen aan en activeren deze 
om mee te helpen met het klaren van de infectie. Verder scheidt het 
luchtwegepitheel verschillende afweermediatoren zoals o.a. antimicrobiële 
peptiden en eiwitten (AMPs) uit. AMPs zijn een natuurlijke vorm van antibiotica en 
doden virussen, bacteriën en schimmels, maar moduleren ook de immuunrespons 
en kunnen eventuele weefselschade helpen herstellen. Clubcellen kenmerken zich 
door het produceren van het CC16 eiwit dat een ontstekingsremmende werking 
heeft en verder kunnen deze cellen ook bepaalde giftige stoffen neutraliseren. De 
basale cellen zijn de voorlopercellen van het luchtweg epitheel en spelen een 
belangrijke rol in het herstel van het epitheel na beschadiging. Deze cellen kunnen 
zich na beschadiging gaan delen om de wond te sluiten om vervolgens zichzelf te 
transformeren (differentiëren) tot nieuwe goblet-, trilhaar- en clubcellen. 
Omgevingsfactoren zoals langdurige blootstelling aan luchtvervuiling of 




hebben op beschermende epitheelcelfuncties. Dit kan de vatbaarheid voor 
infecties vergroten en uiteindelijk leiden tot chronische ontsteking en schade die 
niet meer volledig hersteld kan worden. Bovendien hebben onderzoeken 
aangetoond dat het luchtwegepitheel van patiënten met chronisch ontstoken 
luchtwegen verschilt van dat van gezonde mensen, en tekenen vertoont van een 
afwijkend herstellend vermogen. Deze bevindingen suggereren dat het 
luchtwegepitheel een centrale rol speelt in het ontstaan en verloop van chronisch 
inflammatoire longziekten zoals astma en COPD. Verschillende onderzoeken 
hebben aangetoond dat vitamine D het luchtwegepitheel zou kunnen beschermen 
tegen luchtweginfecties en schade, door o.a. de epitheliale barrière te versterken, 
de aanmaak van AMPs (hCAP18/LL-37) te stimuleren en excessieve ontsteking te 
dempen. Of vitamine D ook zo beschermend is in chronisch ontstoken longweefsel, 




COPD is een progressieve longziekte die wordt gekenmerkt door een chronische 
obstructie van de luchtwegen en afbraak van de longblaasjes die de normale 
ademhaling verstoort, hetgeen niet volledig omkeerbaar is. De belangrijkste 
oorzaak van COPD is langdurige blootstelling aan schadelijke deeltjes en gassen, 
door bijvoorbeeld het roken van sigaretten, maar ook door luchtvervuiling, wat 
leidt tot een abnormale ontstekingsreactie in de longen. Daarnaast dragen ook 
andere factoren, zoals genetische aanleg, abnormale longontwikkeling en 
veroudering, bij aan de ontwikkeling van COPD. COPD is een belangrijke oorzaak 
van chronische morbiditeit en is momenteel de derde doodsoorzaak ter wereld. 
Helaas is er nog geen medicijn dat genezing mogelijk maakt en zijn de huidige 
behandelingen voornamelijk gericht op het remmen van de ontsteking en het 
verlichten van benauwdheidsklachten. Een belangrijke oorzaak van morbiditeit en 
mortaliteit in COPD zijn longaanvallen oftewel exacerbaties. Dit zijn episodes van 
acute verergering van symptomen (benauwdheid, slijmproductie, hoesten), die 
aanvullende therapie en mogelijk ziekenhuisopname vereisen. Exacerbaties 
versnellen de progressie van de ziekte en vormen een aanzienlijke belasting voor 
gezondheidszorgsystemen wereldwijd, omdat deze patiënten vaak met 
benauwdheidsklachten in het ziekenhuis terecht komen. Exacerbaties worden 




door blootstelling aan luchtverontreiniging. Zoals eerder al besproken, verhoogt de 
verstoorde epitheliale afweer in de luchtwegen van COPD patiënten de kans op 
infecties, en daarbij dus ook de kans op COPD exacerbaties. Bovendien hebben 
meerdere studies nu aangetoond dat COPD patiënten over het algemeen lagere 
vitamine D waarden hebben ten opzichte van gezonde personen, en COPD 
patiënten met lagere vitamine D waarden hebben vaker en meer ernstigere 
exacerbaties. Het bestuderen van het beschermende effect van vitamine D op de 
barrière functie van het luchtwegepitheel en bij exacerbaties in COPD patiënten 
zou daarom aanvullend inzicht kunnen verschaffen in het belang van monitoren van 





Het doel van dit proefschrift is om het effect van ontsteking op de beschermende 
effecten van vitamine D bij chronische luchtwegaandoeningen te onderzoeken, met 
name bij COPD. In de experimentele studies die in dit proefschrift worden 
beschreven, worden de effecten van vitamine D (inactief 25(OH)D en actief 
1,25(OH)2D) en ontsteking bestudeerd met behulp van celkweek modellen van 
primaire bronchiale epitheelcellen (afkomstig uit de grotere luchtwegen van de 
long). In deze modellen worden de effecten bestudeerd van ontsteking en van 
toxische- en microbiële blootstellingen zoals sigarettenrook (Hoofdstuk 2), 
cytokinen (Hoofdstuk 3 en 4), bacteriën (Hoofdstuk 4) en virussen (Hoofdstuk 5) 









Effecten van sigarettenrook en TGF-β1 op afweermechanismen van het 
luchtwegepitheel 
Bacteriële en virale infecties zijn belangrijke veroorzakers van COPD exacerbaties 
en het luchtwegepitheel speelt een centrale rol bij het orkestreren van 
afweermechanismen tegen de pathogenen die deze infecties veroorzaken. Eerdere 
studies hebben echter aangetoond dat de barrièrefunctie van het luchtwegepitheel 
bij COPD patiënten bepaalde defecten vertoont, zoals een verlaagde 
doordringbaarheid van de epitheliale cellaag, verhoogde slijmproductie en een 
afname van de trilhaarfunctie. Als gevolg van deze defecten hoopt het slijm zich op 
in de luchtwegen en is de gevoeligheid voor bacteriële en virale infecties groter, 
wat de kans op exacerbaties en verdere ziekte progressie doet toenemen. Een 
belangrijke oorzaak van het ontstaan van deze defecten is het roken van sigaretten 
en vaak ziet men dat ook “gezonde” rokers in het algemeen vatbaarder zijn voor 
luchtweginfecties.  
In Hoofdstuk 2 onderzochten we daarom in een celkweekmodel hoe sigarettenrook 
de afweermechanismen van het luchtwegepitheel beïnvloedt. In de studie die in dit 
hoofdstuk wordt beschreven, hebben we luchtwegepitheelcellen dagelijks 
blootgesteld aan sigarettenrook tijdens de uitrijping (differentiatie) van basale 
cellen naar gespecialiseerde club-, goblet- of trilhaarepitheel cellen. We ontdekten 
dat blootstelling aan sigarettenrook de uitrijping van basale epitheliale cellen naar 
gespecialiseerde club-, goblet- en trilhaarepitheelcellen afremt. Hierdoor werd ook 
de productie van bepaalde afweermediatoren zoals AMPs, die met name door 
gespecialiseerde club- en gobletcellen worden aangemaakt, sterk gereduceerd. Als 
gevolg van de afgenomen specialistische cel populaties, was ook de afweer tegen 
bepaalde pathogene bacteriën lager. Dit geeft aan dat bloostelling aan 
sigarettenrook een duidelijke impact kan hebben op antibacteriële 
afweermechanismen van het luchtwegepitheel door de uitrijping van het epitheel 
te onderdrukken. Via welke mechanismen sigarettenrook de uitrijping van het 
luchtwegepitheel beïnvloedt is vooralsnog niet bekend.   
Een aanwijzing voor de betrokkenheid van TGF-β1 als een mogelijk mechanisme 
voor het remmende effect van sigarettenrook op de uitrijping van het 




geassocieerd is met fibrose en is ook in verhoogde mate aanwezig in de luchtwegen 
van zowel astma als COPD patiënten. Studies in gekweekt luchtwegepitheel hebben 
tevens laten zien dat de aanmaak van TGF-β1 verhoogd kan worden door 
blootstelling aan sigarettenrook. In dit hoofdstuk hebben we aangetoond dat TGF-
β1 vergelijkbare effecten heeft op de uitrijping en de afweermechanismen van het 
luchtwegepitheel als sigarettenrook. Korte blootstellingen aan TGF-β1 bleken al 
voldoende te zijn om niet alleen de aantallen gespecialiseerde club- en gobletcellen 
te verlagen, maar ook de aanmaak van AMPs en andere afweermediatoren.  
 
Effecten van TGF-β1 op vitamine D-afhankelijke afweermechanismen van 
het luchtwegepitheel 
Eerdere studies hebben aangetoond dat vitamine D effecten van TGF-β1, zoals 
inductie van fibrose, zou kunnen tegengaan. Om te onderzoeken of vitamine D ook 
de nadelige effecten van TGF-β1 op zowel uitrijping als aanmaak van 
afweermediatoren kan tegengaan, hebben we in Hoofdstuk 3 luchtwegepitheel 
blootgesteld aan zowel vitamine D als TGF-β1. Helaas kon vitamine D deze nadelige 
effecten van TGF-β1 op het luchtwegepitheel niet tegengaan. Verder laten we zien 
dat TGF-β1 de beschermende effecten van vitamine D op het luchtweg epitheel 
afremt, zoals de inductie van het AMP hCAP18/LL-37. Een verklaring hiervoor kan 
gevonden worden in de observatie dat TGF-β1 de productie van CYP24A1, het 
enzym dat vitamine D afbreekt, in het luchtwegepitheel sterk verhoogt. Kort 
samengevat hebben we in dit hoofdstuk laten zien dat TGF-β1 erg nadelig is voor 
zowel de vitamine D-afhankelijke als vitamine D-onafhankelijke 
afweermechanismen van het luchtwegepitheel.   
 
Effecten van ontstekingsmediatoren op vitamine D-metabolisme en 
vitamine D-afhankelijke afweermechanismen van het luchtwegepitheel 
Naast blootstellingen aan sigarettenrook en TGF-β1, zijn de luchtwegen van COPD 
en astma patiënten in een chronische staat van ontsteking. Dat betekent dat het 
luchtwegepitheel dus constant wordt blootgesteld aan ontstekingsmediatoren, 
zoals TNF-α, IL-1β en IL-17A, die vrijkomen uit o.a. immuuncellen. In Hoofdstuk 4 
wilden we daarom de effecten onderzoeken van deze ontstekingsmediatoren op 




Luchtwegepitheelcellen werden eerst twee weken lang blootgesteld aan 
ontstekingsbevorderende mediatoren zoals TNF-α, IL-1β en IL-17A, en vervolgens 
behandeld met inactief vitamine D (25(OH)D) of actief vitamine D (1,25(OH)2D). We 
vonden dat blootstelling aan ontstekingsbevorderende mediatoren, net als TGF-β1, 
de aanmaak van het enzym CYP24A1 verhoogt. Dit kan de afbraak van vitamine D 
verder verhogen met als gevolg dat het vermogen van vitamine D om de aanmaak 
van het AMP hCAP18/LL-37 te stimuleren in het luchtwegepitheel sterk wordt 
verlaagd. Vervolgens hebben we ook m.b.v. een “killing assay” laten zien dat als 
gevolg van blootstellingen aan ontstekingsbevorderende mediatoren ook de 
vitamine D-afhankelijke antimicrobiële activiteit tegen een bekend 
luchtwegpathogeen, het niet-typeerbare Haemophilus influenzae (NTHi), was 
verminderd. 
 
Effecten van type 2 ontsteking op de omzetting van vitamine D  
In tegenstelling tot de bevindingen in hoofdstukken 3 en 4, waarin we aantoonden 
dat TGF-β1 en ontstekingsbevorderende mediatoren de beschermende effecten 
van vitamine D nadelig beïnvloedden, laten we in Hoofdstuk 5 laten zien dat de 
aanwezigheid van een ander type ontsteking in feite het tegenovergestelde doet. 
Dit type ontsteking, ook wel bekend als type 2 ontsteking, kenmerkt zich door 
verhoogde waarden van eiwitten afkomstig van een specifieke groep van T cellen, 
de T-helpercel 2 (Th2), namelijk de cytokinen IL-4 en IL-13. Dit is typerend voor 
patiënten met allergisch astma, maar daarnaast kunnen ook COPD patiënten 
verhoogde IL-4 en IL-13 waarden hebben. We toonden in dit hoofdstuk aan dat 
blootstelling van luchtwegepitheelcellen aan de Th2 cytokinen IL-13 en IL-4, de 
aanmaak van het enzym CYP27B1 verhoogt. CYP27B1 bevordert de omzetting van 
het circulerende, maar nog inactieve vitamine D (25(OH)D) naar het actieve 
vitamine D (1,25(OH)2D). Door deze hogere expressie van CYP27B1 was dus het 
vermogen van het inactieve vitamine D om de aanmaak van hCAP18/LL-37 in het 





Dempende effecten van vitamine D op virus-afhankelijke 
ontstekingsreacties in het luchtwegepitheel 
COPD exacerbaties worden voornamelijk veroorzaakt door respiratoire virale 
infecties, bacteriële (secundaire) infecties en blootstelling aan luchtverontreiniging. 
Wanneer het luchtwegepitheel wordt geïnfecteerd, herkennen de receptoren van 
het luchtwegepitheel bepaalde pathogeen-karakteristieke moleculen, en scheidt 
het luchtwegepitheel vervolgens als reactie diverse ontstekings- en 
afweermediatoren uit. Deze mediatoren kunnen enerzijds pathogenen 
uitschakelen (AMPs, interferonen en vrije zuurstofradicalen) of anderzijds het 
herstel bevorderen (groeifactoren) of immuuncellen aantrekken vanuit de 
bloedbaan (cytokinen en chemokinen) om de infectie te helpen klaren. Als gevolg 
van zowel de infectie zelf en de immuunrespons als reactie op de infectie ontstaat 
schade aan de longen, die niet altijd meer voldoende kan worden hersteld. Om de 
gevolgen en de ernst van de exacerbaties in deze patiënten te verlagen, zijn er 
strategieën nodig die zowel de afweer tegen infecties verhogen en tegelijk de 
schadelijke immuunreactie dempen. We onderzochten daarom in Hoofdstuk 5 of 
vitamine D in het luchtwegepitheel in staat is om, naast het bevorderen van afweer 
tegen infecties, ook de ontsteking ten gevolge van een virusinfectie kan dempen. 
We hebben in dit hoofdstuk laten zien dat behandeling van gekweekt 
luchtwegepitheel met actief vitamine D een door Poly[I:C] (synthetisch 
dubbelstrengs RNA, wat een virusinfectie nabootst) getriggerde uitscheiding van 
ontstekingsbevorderende cytokinen en chemokinen kan remmen. Mogelijk remt 
vitamine D hierdoor ook de influx van immuuncellen, wat de schade na een virale 
infectie of exacerbatie kan beperken.  
 
Studie naar de effecten van vitamine D-suppletie op exacerbaties in COPD 
patiënten 
Eerdere gerandomiseerde klinische studies (randomized controlled trials; RCTs) in 
een populatie van zowel vitamine D- sufficiënte en deficiënte patiënten laten zien 
dat vitamine D suppletie de incidentie van acute luchtweginfecties alleen verlaagt 
bij patiënten met een vitamine D deficiëntie. Deze bevindingen suggereren dat 
vitamine D suppletie nuttig kan zijn om ook het aantal exacerbaties in COPD 
patiënten te verlagen, omdat dit frequent veroorzaakt wordt door zowel virale als 
bacteriële infecties. Om te beoordelen of suppletie van vitamine D inderdaad het 




vitamine D deficiënt zijn, is een multicenter RCT ontworpen. In deze studie worden 
de effecten van vitamine D suppletie onderzocht in een studiepopulatie die, in 
tegenstelling tot eerdere RCT's, bestaat uit vitamine D-deficiënte patiënten (serum 
[25(OH)D] 15 - 50 nmol/L). De opzet, het protocol en de uitleesparameters van de 
studie worden beschreven in Hoofdstuk 6. Ten slotte hebben we in Hoofdstuk 7 de 
huidige kennis over de effecten van o.a. COPD-gerelateerde factoren, zoals 
ontsteking en blootstelling aan schadelijke deeltjes en gassen (zoals aanwezig in 
sigarettenrook en luchtvervuiling) op de lokale werking van vitamine D in de 
luchtwegen gebundeld. Verder wordt in dit hoofdstuk dieper ingegaan op de 
mogelijke gevolgen van een beperkte beschikbaarheid of activatie van (lokaal) 
vitamine D in de longen en laat dit hoofdstuk zien dat dit mogelijk consequenties 





Van veel factoren die bijdragen aan de ontwikkeling en verergering van COPD, zoals 
chronische blootstelling aan sigarettenrook of luchtvervuiling en aanwezigheid van 
ontstekingsmediatoren (zuurstofradicalen, proteolytische enzymen, cytokinen en 
chemokinen), is bekend dat ze de epitheliale barrière kunnen verzwakken. Verder 
kan mede door het chronische karakter van deze blootstellingen ook de schade niet 
meer volledig worden hersteld. Het versterken van zowel de epitheliale afweer als 
het vermogen tot herstel van de epitheliale barrière kan daarom een goede 
strategie zijn om de achteruitgang in het ziektebeloop te stoppen. Ten eerste kan 
er verder onderzoek worden gedaan naar precieze defecten in de functie van het 
luchtwegepitheel bij COPD, en met name in de voorlopercellen, zodat deze 
defecten in de toekomst gerepareerd kunnen worden met medicijnen die daarop 
aangrijpen. Ten tweede kan verder onderzoek zich richten op een aanpak die het 
lokale milieu in de longen verbetert m.b.v. micronutriënten zoals vitamine D, zodat 
het luchtwegepitheel beter beschermd is tegen epitheliale schade als gevolg van 
ontsteking en infecties.  
In de studies die in dit proefschrift worden gepresenteerd, hebben we echter 




metabolisme zouden kunnen verstoren door de expressie van CYP24A1 te 
bevorderen, waardoor het vitamine D wordt afgebroken. Daarom moeten 
toekomstige studies naar COPD, en ook naar andere chronische ontstekingsziekten 
die verband houden met vitamine D tekort, worden ontworpen met meer aandacht 
voor het verhogen van lokale waarden van actief vitamine D door bijvoorbeeld de 
verhoogde expressie van CYP24A1 te verlagen. Een effectieve remming van 
ontsteking kan hier een belangrijke bijdrage aan leveren. Tot slot zullen deze 
nieuwe inzichten mogelijke nieuwe strategieën opleveren om de lokale activiteit 
van vitamine D te verbeteren om zo COPD patiënten beter te beschermen tegen 
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